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ABSTRACT 
 
ANNA LOBUE: Norovirus Immunobiology and Vaccine Design 
 
(Under the direction of Ralph S. Baric) 
 
Noroviruses are a genus of 40+ diverse positive polarity RNA viruses that cause 
approximately 23 million cases of gastroenteritis annually in the United States alone.  The 
lack of a cell culture system or small animal model in which to study these human pathogens 
has hindered development of norovirus vaccines since their discovery in 1972.  Because 
noroviruses have a very low infectious dose and high transmissibility, vaccines would be 
beneficial for employees and patrons of institutionalized settings such as hospitals, nursing 
homes, and schools, where outbreaks frequently occur.  To begin to unravel how norovirus 
exposure affects the adaptive immune response, we utilized Venezuelan equine encephalitis 
virus replicons as immune adjuvants and delivery vectors for norovirus antigens to 
demonstrate induction of B cell and T cell responses in protective immunity to noroviruses in 
mice.  Norovirus-like particle (VLP) vaccination induces robust IgG and IgA responses in 
serum, feces, and tissues that can block norovirus binding to ABH histo-blood group antigen 
receptors in a strain-specific manner but have little cross-reactivity to additional norovirus 
strains.  CD4+ T cells are also activated following vaccination to produce large amounts of 
the anti-viral compound IFN-γ upon stimulation with homologous norovirus VLPs or 
peptides in vitro. To effect a broader immune response, we vaccinated mice with a cocktail 
of VLPs from multiple norovirus strains simultaneously resulting in cross-reactive receptor-
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blocking antibody responses to heterologous strains not included in the vaccine composition.  
Furthermore, multivalent vaccination did not diminish specificity or quantity of antibody or 
T cell responses to individual vaccinating strains.  Studies with the newly discovered murine 
norovirus (MNV) revealed that MNV VLP vaccination protects against MNV infection, and 
both humoral and cellular immunity are involved in clearance of the virus.  Furthermore, 
adoptive transfer of serum but not CD4+ or CD8+ T cells from vaccinated mice completely 
protected immunodeficient mice from MNV infection, suggesting pre-existing antibodies can 
prevent establishment of acute infection.  Vaccination with multiple human VLPs also 
provided significant protection against MNV infection in mice, advocating the development 
of multivalent human norovirus vaccines for cumulative protection against norovirus 
challenge.
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Calicivirus electron micrograph  
(http://www.fli.bund.de/). 
 
  
 
 
 
CHAPTER I. 
Introduction 
The Caliciviridae constitute a family of small (27-40 nm), non-enveloped, icosahedral 
viruses that infect a broad range of host species.  These positive-sense single-stranded RNA 
viruses obtained their name from the Latin word calix, meaning chalice, due to the cup-
shaped structures on the surface of intact capsids of several Calicivirus species, as seen by 
electron miroscopy (Figure 1.1).  Caliciviruses are divided into four genera based on 
sequence homology of their ~7.5 kilobase genome (Figure 1.2).  Norovirus and sapovirus 
species predominantly infect humans causing epidemic gastroenteritis; vesiviruses and 
lagoviruses are animal pathogens 
characterized by unique disease states.  For 
example, feline calicivirus, a vesivirus, causes      
respiratory disease in cats, while rabbit 
hemorrhagic disease virus, a lagovirus, causes 
fatal symptoms per namesake in rabbits.  Of 
the Calicivirus members, human noroviruses 
have the greatest impact in the medical and 
research fields due to the high incidence of 
norovirus outbreaks in susceptible populations, morbidity, and economic toll.  First 
discovered in 1972 by Albert Kapikian and colleagues (122), noroviruses still remain largely 
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Figure 1.2. Phylogenetic tree of Calicivirus species 
based on capsid sequence (190). 
uncharacterized 35 years later due to the lack of an in vitro culture system or small animal 
model that has hindered in depth investigation into immune mechanisms, pathogenicity, 
replication, and vaccine development of these important pathogens. 
 
Noroviruses 
Genome, proteins, and replication 
The linear RNA norovirus genome (7.5 kb) is composed of three open reading frames 
(ORFs) encoding both structural and non-structural genes (Figure 1.3).  ORF1 comprises the 
first two-thirds (~5 kb) of the genome and encodes a polyprotein (200 kDa) that is  
proteolytically processed to yield the 
non-structural norovirus proteins required 
for viral replication.  ORF 2 (1.8 kb) 
encodes the major structural capsid protein 
(57 kDa), which forms the outer surface of 
the norovirus virion, and ORF 3 (0.6 kb) 
encodes a minor basic structural protein 
(22 kDa) that has been suggested to 
function in packaging the genome into 
virions (75).  ORF1 and ORF2 have a 17-
20 amino acid overlap containing both the stop codon of ORF1 and the start codon of ORF2, 
creating a -2 frameshift.  A single nucleotide overlap exists between the ORF2 stop and 
ORF3 start codons, which restores the reading frame of ORF3 to that of ORF1 (75).  
Genomic RNA is likely covalently linked at its 5’ end to the virally expressed VPg protein 
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and flanked at its 3’ end by a polyadenylated tail (26, 95, 283).  The polyprotein encoded by 
ORF1 is cleaved into six identified constituent replicase proteins by the self-expressed 3C-
like viral cysteine proteinase.  Cleavage products include, from N-terminus to C-terminus, an 
N-terminal  
  
protein (p48; 37-48 kDa), a 2C-like nucleoside triphosphatase (NTPase; 40 kDa), a 3A-like 
protein (p20; 20 kDa), a genome-linked viral protein (VPg; 16 kDa), a 3C-like proteinase 
(Pro; 19 kDa), and a 3D-like RNA-dependent RNA polymerase (Pol; 57 kDa) (232).  The 
absolute function of the N-terminal protein p48 is not known; however, p48 expressed in 
vitro has been shown to colocalize with the Golgi apparatus in transfected cells and to 
potentially play a role in membrane rearrangement and intracellular protein trafficking (54, 
59).  Further proteolytic cleavage of the N-terminal protein by Pro or cellular caspase 3 may 
also occur and may be essential for replication, as seen with other calicivirus species (89, 
147, 232, 238, 239).  Activity of the norovirus NTPase was recently discovered when 
bacterially expressed protein was shown to bind and hydrolyze NTPs, similar to the 
picornavirus 2C protein, although its function does not appear to support DNA unwinding 
(208).  VPg, which binds to the 5’ end of the norovirus genome, plays a role in priming 
transcription and translation initiation of RNA, as suggested by its function in replication and 
its binding to translation initiation factors in both in vitro expression assays and following 
infection of cultured cells (43, 44, 225).  Pro and pol have been more extensively studied than 
the aforementioned non-structural proteins, and their functions have been well characterized.  
     Figure 1.3.  Norovirus genome organization (49). 
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Pro resembles cellular chymotrypsin-like serine proteases (23) and contains amino acid 
sequence motifs resembling the picornavirus 3C protease.  Pro catalytically cleaves the 
norovirus ORF1 polyprotein into 6 individual non-structural proteins at QG, EG, or EA sites 
(147, 148, 231, 238) (Figure 1.4).  Stable precursors include a p20-VPg and Pro-Pol in 
addition to several less stable intermediates (17, 238), and the Pro-Pol precursor retains 
enzymatic activity (16).  Pro amino acids His30, Glu54, and Cys139 have been identified as 
residues in the active site, which is located at the center of a deep cleft between the N- and C-
terminal domains and is stabilized by hydrogen bonds between conserved residues (175, 237, 
238).  Furthermore, His157 is responsible for substrate binding (175).  Pro is also able to 
inhibit cellular translation by severing the domains of cellular poly-A binding protein that 
bind translation initiation factors and RNA, respectively, as evidenced by addition of Pro to 
cell translation extracts.  The Pol protein functions in viral genome replication by initiating 
and propagating RNA synthesis.  Pol contains the amino acid motif glycine-aspartic acid-
aspartic acid (GDD), which is common to many plus-strand RNA virus polymerase active 
sites, and has shown to be essential for Pol function in vitro (62, 132).  Pol activity uses a 
VPg-priming mechanism for RNA synthesis from the genomic template that is dependent on 
the presence of the poly(A) tail; however, RNA synthesis from negative strand genomic 
templates are primer- and poly(A)-independent (62, 225).  The presence of Mn2+ or Mg2+ 
cofactor is also required for Pol activity (62, 224). 
Figure 1.4.  Cleavage sites for proteolytic processing of ORF 1 polyprotein into 
individual functional proteins (17). 
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 Norovirus replication is currently poorly understood.  It is believed genomic RNA 
acts as a template for negative strand synthesis, which in turn acts as a template for 
transcription of full-length positive strand RNA for packaging and subgenomic RNA for 
protein synthesis.  A model for Pol activity in replication initiation of positive and negative 
strand RNA has been proposed by Rohayem et al (225).  In positive genomic and 
subgenomic strand replication, Pol uridylylates VPg in the presence of polyadenylated RNA.  
Poly(U)-VPg then acts as a primer for initiation of negative strand synthesis.  
Subgenomically expressed proteins retain the first four nucleotides of genomic RNA—
GTAA—indicating the transcription initiation site is conserved in subgenomic RNA as well 
(5).  In contrast, replication of negative strand RNA by Pol is primer-independent.  A poly(C) 
stretch is added to the 3’ end of negative strand RNA by terminal transferase activity of Pol 
to initiate RNA synthesis (225).  Studies with other animal caliciviruses suggest that N-
terminal protein, NTPase, and p20 may be responsible for the formation of the viral 
replication complex (74, 121, 276); however, no studies with norovirus have supported these 
findings.  While VPg may regulate transcription, this protein is not thought to be part of the 
replication complex in its mature form due to its strong basicity but could participate in a 
precursor form (43, 125).  The cellular proteins La, hnRNP L, PTB, and PCBP-2, which play 
a role in hepatitis C and poliovirus translation, have also been found to bind synthetic 
norovirus RNA and may be used for viral translation and/or replication (83).  Following 
replication, genomic RNA is packaged into viral particles from a signal suggested to 
originate from within ORF1 (5).  While human noroviruses have not been cultured to date, 
murine noroviruses have a tropism for replication in dendritic cells in vitro and macrophages 
in vivo and in vitro (277). 
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Phylogeny and nomenclature 
Noroviruses constitute a genus of more than forty diverse virus strains that are 
divided into five genogroups based on sequence homology (55, 76, 124, 192).  Genogroup I 
(GI), GII, and GIV viruses infect strictly human hosts, with the exception of porcine-specific 
virus within GII; GIII and GV viruses infect bovine and murine hosts, respectively.  Each 
genogroup is subdivided into genoclusters.  GI contains at least eight genoclusters, GII 
contains at least seventeen, GIII contains two, and GIV and GV contain one each, based on 
phylogenetic analysis proposed by Zheng et al (290).  Genoclusters are designated 
numerically following identification of the genogroup to which they belong (i.e. GII.3).  
Distinct strains are further subdivided within a genocluster (Figure 1.5).  Norovirus strains 
are commonly named for their location of initial identified outbreak (i.e. the Norwalk virus 
strain was first isolated from an outbreak in Norwalk, Ohio), and individual isolates routinely 
use strain/year/country nomenclature (i.e. NV/93/USA).   
Analysis of representative complete norovirus genomes revealed 69-97% nucleotide 
homology between strains within a genogroup and 51-56%  homology between strains in 
different genogroups (126), which is typified by highly conserved and highly variable 
regions.  The ORF1/2 junction is the most highly conserved sequence in the norovirus 
genome maintaining 86-100% identity within a genogroup in the subsets of strains tested 
(120).  ORF1 remains more conserved than ORF2 and 3, where specific cleavage sites within 
the polyprotein, as well as functional motifs within the Pol sequence, are nearly identical 
across norovirus species (17, 126, 228, 238).  The structural proteins, on the other hand, are 
highly variable.  Strains within a genogroup can differ by up to 40% in capsid amino acid 
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sequence while strains in different genogroups usually differ by >50% (75).  ORF3 was 
found to differ 
 
  
 
by up to 51% in nucleotide sequence within a genogroup, when just four strains were 
analyzed (230).  While many attempts have been made to phylogenetically characterize 
Figure 1.5.  Phylogenetic tree representing norovirus genogroup 
classifications (290). 
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existing norovirus strains, no consensus region or strategy has been reached to focus these 
efforts, leading to a plethora of confusing and contradictory literature.  Because ORF2 is the 
most highly variable genome segment distinguishing one strain from the next genetically and 
antigenically and because it is likely under the highest environmental pressure to evolve into 
new norovirus strains, we have chosen phylogenetic clustering based on the complete capsid 
sequence as a representative model for the purposes of this dissertation (Figure 1.5). 
 
Disease and epidemiology 
Norovirus infection in humans is characterized by vomiting (69%), diarrhea (66%), 
nausea (79%), low-grade fever (37%), and abdominal cramping (30%) (123).  The incubation 
period for infection ranges from 24-48 hours, and manifestation of clinical symptoms usually 
lasts 12-72 hours, although individual cases can be prolonged (179).  Viral shedding can last 
up to three weeks after resolution of symptoms resulting in enhanced opportunity for 
transmission.  Noroviruses are responsible for more than 96% of all viral gastroenteritis cases 
and account for at least 23 million infections annually in the United States alone, as reported 
by the Centers for Disease Control and Prevention (166).   Furthermore, noroviruses cause up 
to half of all outbreaks of gastroenteritis worldwide (6), as well as being the most common 
cause of sporadic diarrhea in community settings (220).  All populations are susceptible to 
infection; however, the elderly are more susceptible, and outbreaks are common in retirement 
communities (110, 115).  Furthermore, the very young, the elderly, and the 
immunocompromised have increased risk for severe disease (162, 172, 187).  Infections are 
commonly food- and water-borne, although person-to-person transmission by direct contact, 
exposure to aerosols, or fecal-oral routes is predominantly responsible for amplification of 
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outbreaks (199).  Many outbreaks occur in institutionalized settings such as schools, nursing 
homes, hospitals, and day care centers or in settings where human contact is unavoidable 
such as aboard cruise ships or in military barracks (Reviewed in (53) and (107).  Persistence 
and frequency of outbreaks is heavily influenced by the very low infectious doses required 
for infection (<10 virions), as well as the high transmissibility and extreme stability of these 
viruses.  Because of the characteristics highlighted above, noroviruses have been named class 
B select agents.   
Noroviruses are cyclic in nature, both in the predominance of circulating strains and 
frequency of outbreaks (134).  The GII.4 strains have been predominantly circulating since 
the 1990’s, and recent studies indicate that evolution is occurring within this genocluster (25, 
55, 84).  Defining characteristics of this genocluster that allow its continued predominance 
are unknown.  Outbreaks from other GII strains are also common albeit sporadic, while GI 
outbreaks occur even less frequently (55, 110, 272).  Fluctuations in annual norovirus 
outbreak frequencies are likely primarily dependent on environmental factors and the 
emergence of new strains (261).  The incidence of norovirus outbreaks during the winter of 
2002-03 is the highest on record, as reported in the United States and Europe (2, 110, 261).  
While surveillance of norovirus outbreaks in previous decades has been rudimentary due to 
lack of advanced molecular assays to identify the etiological agents of gastroenteritis 
outbreaks or strain specificity, increased sensitivity of RT-PCR reagents and increased 
surveillance now allow stringent tracking of norovirus activity.  These advances will allow 
identification of changing epidemiological trends in the future.  
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Capsid 
Recombinant expression systems 
Noroviruses cannot be cultured outside its human hosts, and native virus isolation is tedious 
and cumbersome.  Because the intact capsid is the major immunogenic and antigenic 
determinant of the norovirus virion, recombinant expression systems have been developed to 
allow in vitro production of norovirus capsid protein that will self-assemble into virus-like 
particles (VLPs) in sufficient quantities to be characterized and utilized as immunological 
reagents.  Baculovirus and Venezuelan equine encephalitis (VEE) replicon systems have 
been well characterized for production of VLPs (11, 116), which are morphologically and 
antigenically indistinguishable from native norovirus (11, 73).  Baculovirus expression 
systems are implemented by cotransfecting wild-type baculovirus DNA and transfer vector 
DNA containing a cDNA copy of a norovirus ORF2 isolate. Baculovirus successfully 
expressing norovirus ORF2 following screening and plaque purification are used to reinfect 
Sf9 cells, and the expressed 38 nm VLPs are harvested on a sucrose cushion (116).  The 
alternative VEE replicon system uses a methodology whereby norovirus ORF2 is directly 
cloned into the polyclonal site of the VEE plasmid under the control of an internal 26S 
promoter, replacing the structural genes of VEE.  Transcripts of the replicon, helper VEE 
capsid, and helper VEE envelope glycoprotein are coelectroporated into baby hamster kidney 
(BHK) cells resulting in the packaging of VEE replicon particles (VRPs) that will undergo a 
single round of replication and express high levels of norovirus capsid protein that self-
assembles into VLPs when infecting cells in vitro or in vivo (11) (Fig. 1.6).  Additional 
methods using E. coli and yeast to express VLPs are not currently widely implemented for 
VLP production and are described elsewhere (252, 284).  New methods using genetically 
 11 
engineered plants such as tomatoes, potatoes, and tobacco for VLP production have also been 
described for the purpose of delivering VLP vaccines (105, 160, 246, 289). 
 
 
 
Structure 
Recombinant norovirus VLPs have been characterized by electron cryomicroscopy, x-ray 
crystallography, and computer imaging to reveal the structure of the intact norovirus capsid 
(212, 213).  The capsid is composed of 180 capsid molecules organized into 90 dimers in a T 
= 3 icosahedral symmetry (213) (Figure 1.7).  Capsid proteins have two distinct domains, the 
shell (S) domain and the protruding (P) domain, that are linked by a flexible hinge (212) 
(Figure 1.7).  The S domain constitutes the first 125 residues of the capsid protein and forms  
 
7546                     11329 
transgene 
Figure 1.6.  Depiction of VEE genome, RNA, replicons, and helpers 
(adapted from (214)). 
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the structural core of the intact capsid, maintaining its integrity by interactions with adjacent 
S domains (20).  The P domain constitutes the remainder of the protein and is divided into 
two subdomains, P1 and P2.  The P1 domain consists of residues 226-278 and 406-520 and 
functions as a stem region between the S and P2 domains.  The P2 domain, consisting of 
residues 279-405, protrudes furthest from the capsid shell in an arch-like structure, forming 
the exterior of the intact capsid.  The sequence of this domain is more hypervariable and 
contains receptor binding sites and a motif resembling an RNA binding domain (30, 212, 
249, 263).  During infection, immune pressure is exerted upon the distal regions of P2 as well 
as some surface exposed P1 residues, which can lead to novel patterns of evolutionary and 
structural changes in the protein (179). 
 
Receptor binding 
Norovirus VLPs have recently been shown to bind the ABH histo-blood group antigens 
(HBGAs) as putative receptors by hemagglutination of human red blood cells and attachment 
Figure 1.7.  Cryo-electron microscopy and x-ray crystallography of NV VLPs 
(141). 
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to human saliva, gastroduodenal epithelial tissue, and synthetic HBGA carbohydrate chains 
(91, 92, 109, 159).  HBGAs are a family of complex glycans that are expressed on the 
surfaces of red blood cells, gut and respiratory epithelia, and biological secretions in humans 
(reviewed in (158)).  The ability of noroviruses to attach to HBGAs is dependent on specific 
residues in the distal P2 domain of capsid homodimers that have been identified by 
cocrystallization of recombinant P protein from the VA387 strain with synthetic A and B 
trisaccharides (30).  It is likely that both strain-specific and non-specific interactions occur 
between virus and carbohydrate to stabilize binding.  Strain-specific interactions include 
hydrogen bonding at residues corresponding to Thr344, Arg345, Asp374, and Gly442 of 
VA387 (30).  Furthermore, Cao et al. and Tan et al. shared findings that Thr338 is essential 
for receptor binding due to conformational hydrogen bonding (30, 249).  Additionally, the 
presence of Asp302 near the receptor binding site and a conserved C-terminal arginine 
cluster may also enhance the efficiency of receptor binding (249, 251). Long distance 
interactions between additional non-specific residues are likely necessary for further 
stabilization of virus-receptor interactions.  Arg345 and Asp374 as well as peripheral 
stabilization sites are also conserved in heterologous Snow Mountain, Hawaii, and MOH 
genogroup II viruses.  However, receptor binding interfaces for the Norwalk strain, a 
genogroup I virus that has also undergone crystallization of the P domain, are distinctly 
different from VA387.  Such differences may explain why different norovirus strains exhibit 
diverse binding profiles to members of HBGA family.   
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ABH histo-blood group antigens 
Biochemistry 
ABH histo-blood group antigens are carbohydrates moieties expressed on and secreted from 
mucosal tissues and red blood cells.  HBGA expression is controlled by multiple genes that 
influence three biosynthetic pathways which lead to polymorphic ABO, Lewis, and secretor 
phenotypes (Figure 1.8).  Synthesis begins with a disaccharide precursor (GalΒ1,3GlcNAc 
for the Type 1 pathway) to which monosaccharides are sequentially added by 
glycosyltransferases.  The FUT3 gene encodes a fucosyltransferase that adds fucose residues 
in α-1,3 or α-1,4 linkages to the precursor, leading to synthesis of a trisaccharide of the 
Lewis a (Lea) phenotype, also synonymous with the non-secretor phenotype.  A separate 
pathway, leading to the secretor phenotype, depends on the action of the FUT2 gene, 
encoding a fucosyltransferase that adds residues to the precursor in an α-1,2 linkage, creating 
the H type 1 antigen.  Further activity on the trisaccharide by FUT3 or the A and B enzymes 
lead to synthesis of tetrasaccharides Leb, A type 1, and B type 1, respectively.  The A and B 
enzymes add N-acetylgalactosamine or galactose in an α-1,3 linkage, respectively.  
Alternatively, the Type 2 pathway begins with the GalΒ1,4GlcNAc precursor and is also 
acted on by FUT2, FUT3, A and B enzymes in a parallel fashion, resulting in the production 
of H type 2, Lex, Ley, A type 2, and B type 2, respectively.  The Type 3 precursor 
GalB1,3GalNAc is catalyzed by FUT2, resulting in the H type 3 product that can be further 
modified by the A and B  
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Figure 1.8.  HBGA Type 1/3 (A) and Type 2 (B) synthesis pathways with enzymatic 
modifications by FUT2 and FUT3 genes (146). 
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enzymes. (Reviewed in (158))  The presence or absence of the FUT2 and FUT3 alleles in an 
individual can determine if that individual is susceptible to norovirus infection in a strain-
specific manner (141). 
 
Norovirus susceptibility 
Recent outbreak investigations and human challenge studies following norovirus infection 
have lent strong evidence for HBGAs as the natural receptor for norovirus infection (94, 108, 
146, 222).  Similarly, expression of HBGAs and human susceptibility to infection appear to 
be directly linked.  Early studies revealed that some individuals could not be infected with 
Norwalk virus upon challenge, that resistant individuals typically clustered in families, and 
that the presence of pre-existing antibody did not correlate with protection (119, 133, 203).  
Further studies indicated that individuals of the O blood type appeared to be more susceptible 
to Norwalk virus infection than other groups (108), and Norwalk VLPs bound to 
gastroduodenal epithelial cells from individuals who were positive for the FUT2 allele and 
therefore exhibit a secretor-positive phenotype, while no binding occurred to cells from 
secretor-negative individuals (159).  The FUT2 gene encodes a fucosyltranferase responsible 
for generating the H type 1 and H type 3 antigens from disaccharide precursors, which are 
expressed on mucosal surfaces and have been shown to bind Norwalk VLPs (159).  
Furthermore, H type 1 and H type 3 antigens are further modified in individuals of A and B 
blood types by the A and B enzymes, which lead to differential HBGA phenotypes that have 
not been found to bind Norwalk VLPs.  Inactivating mutations in the FUT2 gene have been 
identified that lead to the non-secretor phenotype (193), and approximately 20% of European 
populations are homozygous recessive for the predominant Gly428Ala inactivating mutation.  
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These individuals, therefore, do not produce H type 1 or H type 3 antigens and appear to be 
genetically resistant to infection with Norwalk virus (146, 157, 159).  A tiny subset of the 
population exhibits the Bombay phenotype, where HBGAs are entirely absent from cells and 
secretions (193).  Additional studies with other norovirus strains have revealed that 
susceptibility to norovirus infection is differential and increasingly complicated compared to 
the paradigm shown with the Norwalk strain.  For example, blood type and secretor status 
did not have any impact on susceptibility to infection with the GII.2 Snow Mountain 
norovirus strain (145).  A separate study showed that individuals of the non-secretor 
phenotype had significantly lower antibody titers to GII.4 norovirus strains than secretors, 
indicating that non-secretors likely have a lower prevalence of infection to the predominantly 
circulating norovirus strains than secretors, but blood type was irrelevant to infection status 
(140).  Additionally, Rockx et al. reported that individuals with blood type B appeared to 
have a lower incidence of infection with GI viruses (222).  Although individual norovirus 
strains may only be capable of infecting specific subsets of the human population, the unique 
binding profiles of each strain may collectively allow nearly all individuals to be susceptible 
to a norovirus infection. 
 
Norovirus binding profiles 
Distinct norovirus strains have highly variable HBGA binding patterns.  Carbohydrate 
binding specificities of norovirus strains have been reported (Figure 1.9), and the human 
infectivity spectrum based on polymorphism of ABO, FUT2, and FUT3 has been deduced 
(141) (Figure 1.10).  While genetically related strains can share binding  
 
 18 
 
patterns, indicating that evolution of virus strains may be influenced by HBGA binding, 
specific binding profiles are not genogroup exclusive (104).  Viruses can, however, be 
categorized into two binding profile groups:  Those that bind A/B and/or H epitopes and 
those that bind Lewis and/or H epitopes.  No strains have been shown to bind both A/B and 
Lewis epitopes simultaneously, although many strains from either group bind H epitopes.  
The H epitopes have been shown to be independent docking sites for virus attachment; 
however, due to their intermediate placement on the HBGA structure, they can act together 
Figure 1.9.  Norovirus VLP binding profiles to A/B, H, and Lewis 
carbohydrate chains (104).  Strength of binding is indicated by +. 
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with the A/B or Lewis epitopes depending on the capsid binding site (104).  Furthermore, 
supporting data from blockade studies with HBGA-typed saliva, synthetic HBGAs, and 
monoclonal anti-HBGA antibodies suggest H epitopes can cross-block binding of strains that 
also bind A/B or Lewis epitopes, but the latter two cannot cross-block each other (104).  
These data indicate that strains in the two binding profile groups have distinct binding sites 
on the viral capsid.  A third group should be noted for which no HBGA ligands have been 
identified, such as the Desert Shield, VA115, and mouse norovirus (MNV-1) strains, 
suggesting additional alternative viral receptors may exist or the appropriate carbohydrate 
variations are not represented in saliva or are not biochemically available. 
 
 
Figure 1.10.  Human infectivity spectrum from eight identified HBGA binding 
specificities of norovirus strains dependent on FUT2 and FUT3 polymorphism 
of the individual (A) that are reflected on the HBGA monosaccharide (B) (141). 
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Norovirus infection models 
Large animal models 
Because no small animal model is susceptible to infection with human norovirus, 
investigations using primate species have been undertaken.  Mangabey, rhesus, and pigtail 
macaques screened for naturally occurring anti-norovirus antibody yielded 53% and 58% 
seropositivity for GI and GII noroviruses, respectively (112).  Likewise, chimpanzees were 
92% seropositive for GI noroviruses, suggesting exposure and potential infections are 
occurring at substantial rates in non-human primates.  One challenge study using common 
marmosets, cynomolgus and rhesus macaques, cotton top tamarinds, and chimpanzees found 
that, following inoculation with Norwalk and Grimsby virus strains, no animals developed 
diarrheal symptoms, and viral shedding in the feces had cleared after day four, although one 
of four rhesus macaques shed virus in stool for 19 days and developed IgG and IgM serum 
antibody responses (221).  In two separate studies, however, newborn pigtail macaques and 
adult chimpanzees were able to be symptomatically and asymptomatically infected with 
Toronto and Norwalk virus, respectively, and both infections were transmissible to other 
primates (243, 282).  Recently norovirus particles were also seen by electron microscopy in 
the feces of monkeys with diarrhea (269).  Because primate infection studies thus far have 
yielded inconsistent findings and are very expensive to carry out, advanced norovirus 
infection studies are unlikely to occur using this model. 
 Noroviruses in genogroups II and III, have been shown to infect porcine and bovine 
species, respectively.  Like human noroviruses, no cell culture system exists for these non-
human strains.  While 9-11% of cattle with diarrhea consistently test positive for bovine 
norovirus (169, 200), and antibody cross-reactivity may exist between bovine and some 
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human norovirus strains (14, 191), no pathology or mechanisms of infection have been 
determined in the bovine model.  Porcine noroviruses have been detected in 0.4-2% of swine 
stools from large sampling groups (244, 262); however one study showed that 36% and 71% 
of pigs were seropositive for porcine norovirus in Japan and the United States, respectively 
(57).  More than half of swine tested were also seropositive for human noroviruses.  
Furthermore, human VLPs can effectively bind to porcine buccal and intestinal tissues, 
binding is dependent on A/H expression phenotypes, and swine gastric mucin can effectively 
block human norovirus VLP binding to HBGAs or to porcine tissues (31, 258).  Infection 
studies with a human GII.4 norovirus strain in gnotobiotic pigs revealed that animals 
developed mild diarrhea (48/65), were RT-PCR positive for human norovirus in rectal swabs 
(29/65), had infected duodenal and jejunal enterocytes by immunofluorescence and electron 
microscopy (18/31), and one animal developed intestinal lesions (1/7) (32).  These findings 
suggest human noroviruses can replicate in a swine model and raise the question of zoonotic 
reservoirs for human noroviruses.  However, large animal models are cumbersome and 
expensive, and researchers would benefit from a small animal model for study of norovirus 
infection and cultivation. 
 
Murine norovirus 
In 2003, the first murine norovirus, MNV-1, was discovered by Herbert W. Virgin’s group at 
Washington University (124).  The virus clusters in the unique murine norovirus-specific 
genogroup five (GV), and 15 distinct murine strains have been identified to date (98, 99, 124, 
255).  Furthermore, MNV appears to be the most common murine virus, infecting ~22.1% of 
laboratory mice tested (100).  While MNV-1 asymptomatically infects wild-type mice and is 
 22 
naturally cleared within one week of infection, other identified strains can cause persistent 
infections with prolonged viral shedding beyond eight weeks post-infection in some cases 
(99, 100, 124, 171, 255).  MNV has furthermore been shown to specifically infect 
macrophages and dendritic cells (277).  Kupffer cells, the resident macrophages of the liver, 
and cells primarily within the red pulp and marginal zone of the spleen in MNV-1 infected 
mice stained positively with MNV antisera, and bone marrow-derived macrophages and 
dendritic cells showed visible CPE when infected with MNV-1 in vitro (277).  These 
findings lead to the subsequent discovery of the first in vitro cell culture system for a 
norovirus, where murine macrophage cell lines Raw 264.7, J774A.1, and WBC264-9C were 
able to support MNV infection and replication.  Raw 264.7 cells have additionally been used 
to develop the first ever plaque assay for norovirus titer quantitation (277).   
 Using this information, questions about norovirus infection and pathology can now be 
readily answered.  Following infection of Raw 264.7 murine macrophage-like cells, MNV 
virions could be seen intracellularly within or in close proximity to membranous vesicles 
after 12 hours, and vast intracellular membrane rearrangement had occurred after 24 hours 
(277).  These findings suggest norovirus replication occurs in association with intracellular 
membranes.  In wild-type 129 mice, MNV-1 was detectable in the small intestine, spleens, 
livers, and lungs of mice following oral inoculation with the virus, indicating that the virus is 
able to disseminate from the gastrointestinal tract following primary infection of the gut 
(171).   No gastroenteritis or additional clinical symptoms were detectable; however, 
histopathological examination of tissues revealed an increased number of inflammatory 
granulocytes in the intestine and increased activation and hypertrophy of splenic white and 
red pulp cells, respectively (171).  Immunodeficient mice lacking signal transducer and 
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activator of transcription 1 (STAT1-/-) or receptors for interferons α, β, and γ (IFNαβγR-/-) 
exhibited more severe pathology and fatal disease following MNV-1 infection, and mice 
lacking recombination-activating gene (RAG-/-) exhibit persistent non-fatal infection 
following intracerebral inoculation (124, 171).  Disease in STAT1-/- mice included 
encephalitis, meningitis, hepatitis, and pneumonia with high levels of viral RNA in the small 
intestine, brain, liver, lung, spleen, blood, and feces (124).  Lethality was 100% in STAT1-/-
and IFNαβγR-/- mice following intracerebral challenge; however per oral and intranasal 
challenge had variable lethalities in these mouse groups.  Because wild-type mice do not 
show clinical signs of norovirus infection and because infection can be fatal in 
immunodeficient animals, the mouse is not a perfect representative model for studying 
human norovirus infection.  However, the mechanism of norovirus infection and pathology in 
the mouse may well relate to that exhibited in human norovirus infection, and with newly 
identified culture, small animal, and reverse genetic (271) models we can learn exponentially 
more about noroviruses and their disease.   
 
 
 
Norovirus immunology and vaccines 
Human challenge and outbreak studies  
Because no animal or cell culture model exists for human noroviruses, very little is known 
about the immune response elicited following infection.  Norovirus outbreaks and human 
challenge studies provide the only available samples with which to study norovirus immunity 
in humans.  Susceptibility studies have revealed that certain individuals are genetically 
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resistant to infection with specific norovirus strains (146); however, previous exposure 
history and the immune response likely play a central role in determining infection outcomes 
following norovirus challenge.  Early human challenge and outbreak studies revealed that 
individuals with high serum or fecal antibody titers to Norwalk virus prior to challenge were 
more likely to become infected with the virus than individuals with low pre-existing antibody 
titers (13, 70, 119, 188).  Most but not all individuals were resistant to subsequent infection 
with the same virus six months later; however, less than half maintained high antibody titers 
six months after secondary challenge (119).  In long term immunity studies, individuals who 
were infected with Norwalk virus were all symptomatically reinfected 27-42 months later 
(203).  However, some individuals without common pre-exposure factors who are genetically 
susceptible to Norwalk virus infection never became infected (119).  These findings are 
contradictory in detailing the role of antibodies in preventing norovirus infection.  Evidence 
for short-term but not long term immunity exists, but evidence for persisting long term 
immunity is much more controversial.   
 It is clear that the presence of preexisting serologic responses does not protect against 
norovirus challenge.  These ambiguous data may be explained by the large number of 
circulating norovirus strains and the frequency of human exposure.  Studies of 
seroprevalence to GI and GII strains have shown that at least 50% of children under age five 
are typically seropositive for norovirus exposure, which increases to 60-90% by age ten and 
reaches 100% by adulthood (42, 96, 97, 118, 176, 201).  A cross-challenge study where 
volunteers infected with Norwalk virus were still susceptible to subsequent infection with 
Hawaii virus indicates that immunity to one strain is unlikely to confer cross-genogroup 
protection against infection with another strain (281).  Cross-reactivity studies have revealed 
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that antibodies can recognize heterologous norovirus antigens, particularly within a 
genogroup (86, 145, 180, 219, 259).  However, while homotypic antibodies from human 
antisera following infection can completely block VLP binding to HBGA receptors, 
heterotypic antisera to strains within the same genogroup are less able to do so (91, 219).  
Together, these findings suggest that cross-reactive antibodies are not likely to protect 
against heterologous norovirus infection; however, low to moderate antibody cross-reactivity 
between strains in combination with multiple exposures disguise the true impact of humoral 
immunity on resistance to subsequent norovirus challenge in the face of unknown exposure 
histories. 
 Cross-reactive antibody and T-cell responses in humans remain largely 
uncharacterized.  A single study investigating the presence of T-cell activity following 
norovirus infection was described by Lisa Lindesmith and colleagues (145).  Human 
peripheral blood monocytes (PBMCs) were harvested pre- and post-challenge with Snow 
Mountain virus and tested for activation following stimulation with homologous and 
heterologous VLPs.  T helper 1 (TH1) CD4+ cells responded to homologous VLP stimulation 
with increased secretion of gamma-interferon (IFN-γ) and interleukin-2 (IL-2).  IL-6 and IL-
10 were not secreted above pre-challenge levels, indicating TH2 cells may not be involved in 
norovirus immunity.  PBMCs from both infected and uninfected volunteers could be 
stimulated with VLPs pre- and post-challenge suggesting previous norovirus exposure. 
Furthermore, cells from infected individuals post-challenge exhibited cross-stimulation by 
Hawaii VLPs but not Norwalk VLPs, indicating that T-cell cross-reactivity may be 
genogroup specific. (145)  T-cell studies following infection with additional norovirus strains 
need to be conducted and collective cross-reactivity to multiple genoclusters in GI and GII 
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addressed.  Antibody responses to noroviruses have been more thoroughly characterized, but 
only to a limited number of strains.  Following exposure, individuals have been shown to 
mount serum IgG, IgA, IgM and/or salivary IgA antibody responses to the infecting 
norovirus strain (52, 70, 86, 145, 259).  Individuals exhibiting symptoms following infection 
typically have elevated IgG and IgA antibody titers compared to asymptomatic individuals 
(70).  On the contrary, cross-reactive antibodies sometimes exist following infection with 
heterologous strains, although serum responses are usually restricted to the IgG subclass and 
lower in magnitude than homotypic IgG (86, 219, 259).  For example, following infection 
with Snow Mountain and Hawaii viruses, respectively, 6/15 and 2/12 individuals mounted 
mean cross-reactive IgG responses to Norwalk VLPs that increased 6.2-fold after infection; 
however, 15/20 individuals infected with the homologous Norwalk strain mounted responses 
almost 30-fold higher than pre-challenge titers (259).  Another study showed that 3/9 
volunteers challenged with Snow Mountain had a >4-fold increase in cross-reactive antibody 
to Hawaii VLPs (145).  These responses indicate cross-reactivity within and across 
genogroups, the latter of which is not always detectable (145, 180).  Furthermore, antibody 
cross-reactivity is usually detectable to strains within a genogroup (86) but can be highly 
variable depending on the antigenicity of distinct genoclusters.  While little is currently 
known about this subject, outbreak studies by Noel et al. revealed that GI viruses may be 
more antigenically related than GII viruses (180).  Antisera from four heterologous GI 
outbreaks retained cross-reactivity to Norwalk VLPs, with a 70% seroconversion rate, 
although viruses were ≤38% divergent in capsid amino acid sequence from the Norwalk 
strain.  Only 16-46% of sera following heterologous GII infection seroconverted to 
intragenogroup Toronto or Hawaii antigens, suggesting these viruses are antigenically 
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distinct.  All available literature on human antibody responses and cross-reactivity following 
norovirus infection are confined to human challenge studies comparing ≤3 strains or 
outbreaks.  Many outbreak studies measure heterotypic but not homotypic antibody 
responses due to the lack of a recombinant antigen panel spanning many norovirus 
genoclusters that include the outbreak strain.  Trends of increased antibody cross-reactivity 
within norovirus genogroups have emerged; however, confounding pre-exposure histories of 
infected individuals, increasing numbers of identified strains, and less-than-clear antigenic 
relationships between strains leave a muddled picture of homotypic and heterotypic 
norovirus antibody responses following human infection. 
 
Recombinant vaccine studies 
Norovirus VLPs have been used in vaccine trials for humans since 1996 with limited success.  
In Phase I clinical trials, VLPs are safe and immunogenic when administered orally but don’t 
induce antibody titers as high as those achieved following actual infection (8, 9).  Volunteers 
receiving two doses of 250 µg-2000 µg VLP mounted anti-VLP serum IgG responses in 70-
90% of samples tested, but only 40% and ~30% of volunteers produced salivary and fecal 
IgA, respectively, regardless of dosage (247).  Examination of cellular immune responses 
revealed that PBMCs proliferated and secreted IFN-γ when stimulated with homologous 
antigen 21 days after primary immunization; however, no proliferation or cytokine secretion 
was detectable by day 56 although volunteers received a booster between the two time points 
(247) . VLP vaccines have additionally been developed using transgenic potatoes, although 
overall immune responses were somewhat poor (246).  Together, these data suggest that VLP 
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vaccines alone may not induce robust immune responses.  Experiments examining the ability 
of VLP vaccines to protect individuals from norovirus infection have not been done. 
 Although no small model animal exists for norovirus infection, recombinant subunit 
vaccines can be used to induce norovirus immune responses in mice, providing an alternative 
model to study norovirus immunology.  Mice have been shown to mount systemic, mucosal, 
and cellular responses following VLP vaccination by oral, intranasal, and subcutaneous 
administration (10, 80, 93, 105, 178, 207, 284, 289).  While one study showed that oral 
immunization with as little as 5 µg of recombinant baculovirus-expressed NV VLP induced 
detectable, albeit very low, serum IgG responses, >200 µg VLP in up to four doses are 
required to consistently induce systemic and mucosal antibody responses (10).  To 
circumvent the low immunogenicity of orally administered VLPs, adjuvants including 
cholera toxin (CT), the reduced toxicity CT mutant CT-E29H,  heat-labile Escherichia coli 
toxin (LT), and the LT nontoxic mutant LT-R192G have been coadministered with norovirus 
subunit vaccines (8, 10, 178, 207).  Serum IgG and mucosal IgA consistently increase with 
increasing VLP dosage, and the presence of adjuvant improves specific antibody responses in 
a dose-dependent manner (8, 10) (Fig. 1.11).  In one vaccine study, three immunizations of 
10 µg CT-E29H coadministered with 200 µg NV VLP increased fecal IgA responses from 
~200 ng/ml to ~700 ng/ml specific IgA compared to mice immunized without adjuvant 
(207).  While oral administration of norovirus vaccines would seem an obvious choice for 
these enteric pathogens, intranasal and subcutaneous vaccines have proved highly 
immunogenic by comparison.  Intranasal administration of 10 µg NV VLP with or without 
LT-R192G adjuvant induced serum IgG geometric mean titers (GMT) of  90,447 and 9,123, 
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 C. 
 
respectively, after two 
immunizations (80).  Fecal and 
vaginal IgA responses exhibited 
parallel trends.  In contrast, oral 
administration of 200 µg NV VLP 
in the absence of adjuvant induced 
a serum IgG GMT of only 1,280, and no responses were detected in mice orally immunized 
with 10 µg VLP without adjuvant (80).  Mice immunized intranasally with NV VLP and CT-
E29H secreted high amounts of anti-NV IgA from lung, trachea, small intestine, and Peyer’s 
patches, demonstrating immune induction occurs even in tissues not located near the site of  
Figure 1.11.  Murine serum IgG (A-B) and intestinal IgA (C) responses to oral 
administration of different doses of NV VLP in the absence (A) or presence (B) of 
adjuvant (10). 
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immunization (207).  Furthermore, serum IgG and fecal IgA responses were still detectable 
more than a year after intranasal vaccination with adjuvant or oral vaccination with or 
without adjuvant (80) (Fig. 1.12 and   1.13).  Subcutaneous vaccination with VRPs that 
express norovirus VLPs in vivo and have inherent adjuvant activity also induced robust 
serum IgG and fecal IgA after two immunizations that remained strong 120 days post-
vaccination (93).     
 Studies into cellular immunity induced by VLP vaccination are limited.   Following 
three oral immunizations with 200 µg NV VLP and CT-E29H, CD4+ T cells but not CD8+ T 
cells in murine Peyer’s patches proliferated in response to in vitro restimulation with antigen; 
however, both T cell subsets responded to stimulation in the spleen (207).  IFN-γ and IL-4 
production were both detected by ELISpot assay of stimulated splenocytes from mice 
receiving adjuvant, but only IFN-γ was detected in mice immunized with VLP alone 
 
 
Figure 1.12.  Murine serum IgG responses to NV VLPs following intranasal or oral 
administration in the absence or presence of adjuvant 36 (A) or 417 (B) days post-
immunization (80). 
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Figure 1.13.  Murine fecal IgA responses 
following intranasal or oral administration of 
NV VLPs 36 (A) or 417 (B) days post-
inoculation (80). 
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suggesting TH1 responses are induced by VLP immunization.  A separate study showed that 
mice immunized twice intranasally with 10 µg Dijon171/96 VLPs and 10 µg LT adjuvant 
mounted mixed TH1/TH2 responses (178).  Spleen, cervical lymph node, and mesenteric 
lymph node secreted IFN-γ, IL-2, IL-4, and IL-5 following in vitro restimulation with VLPs.  
No VLP immunizations without adjuvant were performed in this study, so it is unclear if the 
cytokine profiles are a result of immunization with VLP or adjuvant.  Peyer’s patches and 
CLN from mice intranasally or orally immunized with LT or LT-R192G had similar cytokine 
profiles following restimulation, although IL-2 and IL-5 but not IFN-γ were higher following 
intranasal immunization (178).  While these mice exhibiting a mixed TH1/TH2 response had 
high levels of both IgG1 and IgG2a subtypes in sera, a third study showed that four oral 
immunizations with 200 µg NV VLP elicited a primarily IgG2b subclass response in serum, 
effective in complement activation and cell cytotoxicity (10).  When CT was included as an 
adjuvant, the subclass IgG1 predominated, indicating a TH2 response although low levels of 
IgG2a were also induced.  Together, data indicate that VLP alone may induce a TH1 biased 
CD4+ T cell response; however, the addition of adjuvant can change the predominating 
cytokines and IgG subclasses produced.   
 Alternative safe and cost-effective immunization methods currently being developed 
include recombinant VLP expression from yeast and transgenic foods.  Studies show that five 
administrations of raw yeast extract containing 1 mg each of yeast-expressed recombinant 
VA387 VLPs without adjuvant also resulted in high levels of anti-VA387 serum IgG and 
fecal IgA (284).  Oral immunization with 4 doses of tobacco extract or dried tomato 
expressing a transgene for NV capsid protein (80 µg VLP) and adjuvanted with CT elicited 
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systemic and mucosal antibody responses in 100% of mice tested, while freeze-dried potato 
tuber immunizations required more VLP to elicit detectable responses in mice, and VLPs 
were less stable likely due to the freeze-drying process (160, 289).  Such transgenic 
vaccination strategies appear to elicit lower antibody responses than direct VLP 
immunization, however.  The use of VLP will likely prove instrumental in the development 
of norovirus vaccines.  A report by Harrington et al. showed that immunization with NV 
capsid protein containing a defective particle formation mutation resulted in no detectable 
mucosal antibody response and lower systemic antibody responses exhibiting only partial 
blockade in receptor binding assays (93).  Together, these data suggest adjuvanted intact 
VLP or vectored expression systems will likely be most effective in eliciting strong immune 
responses to noroviruses. 
 For norovirus vaccines to be effective, they must augment immune responses that are 
cross-reactive to additional norovirus strains.  Very few recombinant vaccine studies have 
been undertaken to address this question.  A single study showed that serum from mice 
immunized with NV contained antibodies that cross-reacted with NCFL, another GI strain 
(93).  Hybridoma production with splenocytes or mesenteric lymphocytes following oral 
immunization with VLPs has resulted in isolation of monoclonal antibodies that can cross-
react within and across genogroups (129, 253, 287).  The CM54 monoclonal antibody that 
was generated by Southampton (SH) VLP immunization cross-reacted with other GI strains 
and bovine GIII strains, and an epitope within the shell domain was identified (14).  
Additional studies argue whether the placement of immunodominant epitopes are located 
primarily in the N- or C- terminus (90, 287).  While monoclonal antibodies can be helpful for 
antigenic characterization, a panel of antisera generated against VLPs representing each 
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genocluster is needed to truly realize antigenic relatedness among norovirus strains.  
Furthermore, understanding this relatedness will be crucial in effective vaccine formulation. 
 
Murine norovirus immunology 
Since its discovery in March 2003, 15 distinct MNV strains have been identified to date (98, 
99, 124, 255).  All strains are closely related with only 13% variance at the nucleotide level 
between the most divergent strains, and genetic and serological tests confirm that all 
identified strains comprise a single genocluster and serotype (255).  To understand the 
immunology of MNV resistance and clearance, studies with immunodeficient mouse strains 
have been undertaken.  The innate immune response has been shown to be critical for MNV 
resistance, and knockout mice lacking the gene for STAT-1 (STAT-1-/-) or Type I and Type 
II interferon receptors (IFNαβγR-/-) were highly susceptible to MNV-1 infection (124, 270).  
In studies directly comparing STAT-1-/- and wild-type 129 mice, STAT-1 deficiencies were 
directly related to increased viral titers in the proximal intestine as early as 3 hours post-
infection and dissemination to peripheral tissues by 24 hours post-infection (171).  Mice 
deficient for STAT-1-dependent IFN signaling responded nearly identically to STAT-1-/- 
mice.  However, RAG1-/- and RAG2-/-mice, which have B- and T-cell deficiencies due to 
developmental arrest, did not have increased pathogenicity following per oral, intranasal, or 
intracranial infection but remained persistently infected (124).  Combined, these data suggest 
that innate immunity may be required to control replication and dissemination of norovirus 
following infection, whereas adaptive immunity is required for viral clearance.   
 Norovirus immunology has been understudied in humans due to the lack of a small 
animal model in which to study human norovirus infection.  Likewise, human norovirus 
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vaccines remain to be developed due to ineffectual pre-clinical trial options.  Using the MNV 
infection model, new insight can be gained into the immune response following norovirus 
infection and innovative vaccine approaches tested. 
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Abstract 
 Noroviruses are important agents of human gastroenteritis characterized by extensive 
sequence variation in the major capsid structural protein that likely encodes critical antigenic 
determinants of protective immunity.  The lack of an infection model has limited detailed 
characterizations of viral antigenic relationships and identification of the essential 
components for protective immunity.  This information would contribute to efficacious 
vaccine design against a broad array of norovirus strains.   To understand the extent of 
heterotypic norovirus antibody specificity to inter- and intra-genogroup strains and its 
applicability to vaccine design, we collected sera from humans infected with different 
norovirus strains and from mice inoculated with alphavirus vectors expressing strain-specific 
recombinant norovirus-like particles (VLPs).  We used VLPs that were assembled from 
Norwalk virus (NV), Hawaii Virus (HV), Snow Mountain virus (SM) and Lordsdale virus 
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(LV) as antigens to define and compare heterotypic antibody responses in humans and mice.  
We also examined if these heterotypic antibodies could block specific binding of ABH histo-
blood group antigens, putative receptors for norovirus binding and entry, to norovirus VLPs.  
Furthermore, we examined the effect of multivalent inocula on the specificity, titer, and 
ligand blockade properties of systemic and mucosal norovirus-specific antibodies in mice.  
Our studies suggest that infection with one of several different genogroup I (GI) strains in 
humans induces heterotypic antibodies that block NV binding to ABH antigens, although 
comparable findings were not evident following infection with genogroup (GII) strains.  
Additionally, inoculating mice with vaccine cocktails encoding multiple norovirus VLPs 
enhances heterotypic and ligand attachment-blocking antibody responses against the LV 
strain not included in the cocktail.   These data suggest that multivalent vaccination may 
provide better protection from a broader range of noroviruses than monovalent vaccination.  
 
 38 
Introduction 
 Noroviruses, members of the Caliciviridae family, are a group of more than 40 
extremely heterogeneous viruses whose study has been hindered since their discovery in 
1972 due to the lack of an appropriate cell culture or animal model (122).  Infection is 
typically characterized by self-limited vomiting and diarrhea, with symptoms prevailing for 
12-60 hours (50).  An estimated 23 million norovirus infections occur annually in the U.S. 
leading to an estimated 310 deaths in susceptible populations such as infants and the elderly, 
according to studies conducted by the Centers for Disease Control and Prevention and others 
(166, 170).  Outbreaks commonly occur on cruise ships and in the military, nursing homes, 
child care centers, and schools due to the extreme stability, low infectious dose and high 
transmissibility of these viruses (3, 29, 68, 81, 111, 177).  Public health risks, however, are 
likely underestimated as most norovirus infections are unrecognized.  An effective vaccine 
would clearly benefit health care providers, food handlers, the military, the elderly, and 
additional personnel that work in institutionalized settings by decreasing the morbidity of the 
disease and transmission of the virus (4, 78, 153, 161, 198, 254). 
 Noroviruses have a single-stranded, positive-sense 7.5 kb RNA genome that is 
organized into three open reading frames (ORFs).  ORF1 consists of non-structural genes 
encoding RNA-dependent RNA polymerase, 3C-like proteinase, and helicase proteins.  The 
major and minor capsid proteins are expressed from ORF2 and ORF3, respectively.  
Noroviruses are divided into five distinguishable genogroups (GI-GV) based on genome 
sequence similarity; however, only virus strains from genogroups I-II are known to widely 
infect humans.  Additional strains in the newly identified genogroup IV have also been 
detected in human stools (55).  Noroviruses within a genogroup can differ by up to 40% in 
 39 
capsid amino acid sequence and >50% between genogroups (71).  Of the strains used in our 
studies, the Bristol-like GII.4 strains have been the predominant globally-circulating strains 
for the past decade (55, 84, 131), while the Hawaii-like GII.1 strains and the Snow 
Mountain-like GII.2 strains have variable reported disease prevalence and appear in sporadic 
outbreaks (63, 218, 279, 280).  Outbreaks from the GI strains Norwalk, Desert Shield, and 
Chiba-like viruses occur more infrequently (55).  While GII viruses cause person-to-person 
outbreaks, and GI viruses are more common in environmental transmission, endemic disease 
rates are unclear.  Research efforts for the development of a multivalent vaccine against 
noroviruses have not yet been described.  Although common epitopes of the antigenic capsid 
proteins may be shared both within and across genogroups, antibody responses in humans 
have not yet proven to be protective following successive exposures to multiple norovirus 
strains (58, 86, 87, 93, 119, 129, 173, 180, 202).   
 Specimens from human challenge studies and outbreak investigations have allowed 
characterization of strain-specific norovirus antibody responses in humans following viral 
challenge.  Early studies on heterotypic antibody responses showed that some GII infected 
individuals mounted antibody responses capable of cross-reacting with the GI Norwalk virus 
strain (259), while others revealed little antibody cross-reactivity between genogroups (180).  
Heterotypic antibody characterizations previously reported by our lab have shown that 
following Snow Mountain virus (SM) challenge, serum IgG cross-reacted with Hawaii virus 
(HV) but not with Norwalk virus (NV) (145).  However, the variable and unidentified pre-
challenge exposure histories of humans have unknown effects on norovirus immunity but 
have been suggested to influence disease susceptibility (119).  
 40 
 Recombinant systems using Venezuelan equine encephalitis virus (VEE) replicon 
particles (VRPs) (11) or baculovirus vectors (116) expressing norovirus ORF2 have been 
developed and are capable of generating capsid proteins that self-assemble into virus-like 
particles (VLPs).  While VLP reagents produced from baculovirus vectors expressing 
norovirus ORF2 + ORF3 have been reported to enhance the stability of VLPs (19), the ORF2 
VLP reagents prepared in our laboratory using VEE VRPs are likewise indistinguishable 
from wild-type virus in their morphology, antigenicity, and ligand-attachment properties by 
transmission electron microscopy and solid-phase assay (11, 91-93).  For these reasons, VEE 
VRPs are invaluable and relevant surrogates for wild-type virus in biochemical, 
immunogenicity, and vaccine design studies.  We previously demonstrated that mice 
inoculated with VRPs expressing norovirus VLPs are capable of mounting robust homotypic 
antibody responses (93); however, further characterization of heterotypic antibody induction 
and its application to vaccine development are needed. 
 Recently, several norovirus strains have been shown to bind ABH histo-blood group 
antigens (HBGAs) (91, 92, 103, 109, 159).  HBGAs are carbohydrate moieties expressed on 
red blood cells and mucosal surfaces such as the gut, the natural site of norovirus infection.  
While certain norovirus strains appear to require the presence of HBGAs to produce an active 
infection (145, 146), it is unclear whether these ligands serve as primary receptors or 
coreceptors for norovirus binding and entry.  Various norovirus strains are capable of binding 
several different members of the HBGA family, suggesting that HBGA binding is a 
conserved and likely required step in norovirus infection.  Furthermore, sera from both 
infected humans and inoculated mice block binding of norovirus VLPs to HBGAs in a strain-
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specific manner.  These results suggest that antigenic epitopes may be important in virus-
ligand binding and should be considered in norovirus vaccine development strategies (91). 
 In this manuscript, we describe the first multivalent candidate vaccine against 
noroviruses.  Using samples collected following both human infection with noroviruses and 
murine inoculation with VRPs expressing norovirus VLPs, we evaluated heterotypic 
antibody responses and assessed the ability of homotypic (against infecting strain) and 
heterotypic (cross-reactive to different strain) antibodies to block virus-ligand binding.  
Following murine inoculation with a cocktail of three or four VRPs expressing strain-specific 
VLPs, we demonstrate that sera not only contains antibodies specific for all components of 
the inoculum but also demonstrates enhanced heterotypic antibody titers and ligand blockade 
against novel strains.  Our data suggest that cocktail-based vaccines may provide a means of 
protecting against a broad panel of noroviruses, including those not included within the 
antigen mix. 
 
Materials & Methods 
Cloning of Lordsdale isolate, a GII.4 norovirus. 
The Lordsdale-like LV-NC1 ORF2 capsid clone was obtained by RT-PCR of RNA extracted 
from a fecal sample of an infected individual during a norovirus outbreak in North Carolina.  
A consensus cDNA was inserted into the multiple cloning site of the pVR21 VEE replicon 
vector (VRP), and its sequence was determined using external vector-specific primers.   The 
ORF2 coding sequence was aligned with Norovirus strain 004, a GII.4 Bristol-like norovirus 
(181).  
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VLPs and VRPs.  All VRPs were produced as described in Harrington et al. (93).  VRP titers 
and efficient expression of recombinant protein were determined by immunofluorescence 
assay using human or mouse sera following respective viral challenge, as previously 
described (93).  To produce VLPs, BHK cells grown in Opti-PRO serum-free medium 
(Gibco, Grand Island, NY) supplemented with gentamicin/kanamycin and 4mM L-glutamine 
(Gibco) were infected with VRPs at an MOI of at least 2 in phosphate-buffered saline (PBS; 
Sigma, St. Louis, MO) containing Ca2+ and Mg2+ and incubated at for 1 h at 37°C.  PBS was 
then replaced with complete serum-free medium for 24-30 h at which time cells were 
pelleted and lysed with Triton X-100 (Sigma) (working solution: 100 µl Triton X, 1 complete 
mini protease inhibitor tablet (Roche, Indianapolis, IN) in 10 ml PBS) on ice.  Lysates were 
applied to a filter-sterilized 40% sucrose cushion and ultracentrifuged at 100K x g for 1.25 h 
at 4°C.  Lysate supernatant was discarded, and the entire sucrose fraction containing putative 
VLPs was collected and aliquoted.  Production of full-length capsid protein was determined 
by SDS-PAGE and production of intact VLPs was confirmed by transmission electron 
microscopy.  Protein concentration was determined by Bio-Rad Protein Assay (Bio-rad, 
Hercules, CA).  
Murine vaccine regimen.  Five to seven week-old male BALB/c mice were obtained from 
Charles River Institute (Wilmington, MA).  Mice were allowed to acclimate for one week 
under constant conditions and were inoculated immediately thereafter by footpad injection 
(day 1) with 2.5 x 106 infectious units (IU) VRP in PBS (10 µl total) expressing NV (n=4), 
SM (n=4), HV (n=4) or LV (n=4) VLPs.  Two additional groups of mice were primed with 
trivalent or tetravalent inocula consisting of equal concentrations of NV, SM, and HV (n=5) 
or NV, SM, HV, and LV-expressing (n=5) VRPs (with total VRP concentrations of 2.5 x 106 
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IU or 8 x 106 IU, respectively).  Mice were boosted on day 23 with identical priming 
inoculum.   
Serum samples.  Serum samples were collected from both humans and mice.  Pre-challenge 
and convalescent sera were obtained from human volunteers prior to and 2-4 weeks 
following human challenge studies where adult individuals were symptomatically infected 
with either NV (n=10) (91), SM (n=7) (145), or HV (n=2) (C. Moe, unpublished).  We 
obtained informed consent from volunteers, and specimen collection and use is approved by 
the University of North Carolina Chapel Hill Institutional Review Board (IRB). Acute and 
convalescent human sera were also collected after the onset of symptoms and up to 5 weeks 
later, respectively, during outbreaks of Desert Shield-like virus (DS) (n=7) (C. Moe, 
unpublished), Chiba-like virus (DF) (n=4) (15), or Lordsdale-like virus (LV) (n=4) (C. Moe, 
unpublished) strains.  Murine serum samples were collected by tail bleed on days 0, 14, and 
35 days post-inoculation. 
Serum IgG titers.  Homotypic and heterotypic antibody titers were determined by standard 
indirect enzyme-linked immunosorbent assay (ELISA).  Ninety-six-well high-binding round-
bottom plates (Corning, Corning NY) were coated with 2 µg/ml VLPs expressed from VRPs 
encoding ORF2 derived from NV, SM, HV, or LV isolates for 4 h at RT and blocked 
overnight with 5% milk in PBS (Blotto) at 4°C.  Human or mouse sera, diluted 1:50 or 1:100 
in blotto, were added to wells in duplicate, and 2-fold serial dilutions were performed, 
followed by incubation for 2 h at 37°C.  Plates were then incubated for 1 h with goat anti-
mouse IgG or goat anti-human IgG with alkaline phosphatase (AP) conjugate (Sigma), 
developed with p-nitrophenyl phosphate (pNPP; Sigma), and the OD at 405 nm was 
measured (Bio-rad Model 680 microplate reader).  All serum samples were tested against a 
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panel of NV, SM, HV, and LV VLPs for VLP-specific IgG content, and the VLP-specific 
IgG concentration was determined against a standard curve produced with a known mouse 
IgG standard (Pierce, Rockford, IL).  
Lymphoid culture.  Mice receiving either trivalent or control inoculum were sacrificed at 21 
days post-boost, and spleen and gut tissues were harvested.  The entire small intestines were 
harvested, and mesenteric fat, Peyer’s patches, and gut contents were removed with forceps.  
Tissue was then dissected longitudinally and segmented.  Gut tissue was washed 3x in 
Hank’s balanced salt solution (HBSS; Gibco) containing 15mM Hepes (Gibco) and 
Ca2+/Mg2+ followed by 2 additional washes in an identical buffer solution supplemented with 
5mM EDTA, 10% fetal bovine serum (FBS; Gibco), and gentamicin (Gibco).  Gut segments 
and spleens from each mouse were then washed once in complete RPMI 1640 media (Gibco) 
containing 15mM Hepes, 10% FBS, penicillin-streptomycin (Gibco), gentamicin, 2mM L-
glutamine, and amphotericin B (Sigma) (modified from (39)) and placed individually in 
wells of 48-well flat-bottom plates.  Tissues were incubated for 1 week at 37°C at which time 
supernatant was collected.    
     Supernatants were clarified by centrifugation, followed by isolation of gut IgG using 
an IgG separation column (Pierce), according to the manufacturer’s directions.  IgG eluate 
and retentant supernatant were then concentrated to volumes of 300 µl and 600 µl, 
respectively, using Centriplus centrifugal filtration devices with 100,000 molecular weight 
cut-off (Millipore, Bedford, MA), according to manufacturer’s instructions.  Samples were 
then used in IgG and IgA titer and blockade analysis assays.  Spleen IgG was diluted 1:10 in 
blotto and gut IgG eluate at 1:4 for use in the IgG titer ELISA described above.  Retentant 
supernatant was diluted 1:2 in blotto and screened for the presence of specific IgA in IgA 
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titer ELISAs otherwise identical to that described above for IgG.  Total IgG and IgA were 
measured by sandwich ELISA where plates were coated with 2 µg/ml sheep anti-mouse Ig 
capture antibody (Chemicon, Temecula, CA) and blocked prior to addition of lymphoid 
culture supernatants (1:50) and standards otherwise identical to the ELISA described 
previously.  
Antibody blockade assays.  Serum antibody blockade of HBGA binding to VLPs was 
measured as described by Harrington et al.(91).  Briefly, wells were coated with 2 µg/ml 
VLPs for 4 h at RT and blocked overnight with blotto at 4°C.  Wells were then incubated 
with serial dilutions of 10% sera in blotto for 2 h; positive control wells received buffer 
alone.  Wells were then incubated with H type 1-biotin or H type 3-biotin (Glycotech, 
Gaithersburg, MD) at a dilution of 1:50 (original concentration 1 mg/ml) in blotto for 4 h at 
37°C.  Following a final incubation with streptavidin-AP for 1 h, wells were developed with 
pNPP and the OD at 405 nm determined.  Antibody blockade of HBGA binding in serum 
treated wells was determined as a percentage of the average HBGA binding value (OD405) 
from positive control wells.  For blockade assays performed using lymphoid culture-derived 
antibody from inoculated mice, an IgG concentration equal to that required for ligand 
blockade in corresponding sera samples was used (26 µg/ml), due to limited sample volumes, 
to determine efficient gut and spleen IgG binding blockade.  Culture samples from control 
mice were measured for antibody blockade by 2-fold serial dilutions starting from 1:1.6, as 
described above.  
Saliva binding assays.  Saliva samples from a panel of individuals representative of each 
blood type and secretor status were tested for the ability to bind LV VLPs in an in vitro solid-
phase binding assay, as described in (91).  Briefly, microwells were coated with boiled saliva 
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from respective individuals followed by addition of LV VLPs.  Binding of VLPs was 
detected with human anti-LV sera, goat anti-human IgG secondary antibody, and pNPP 
substrate.  Results are represented as OD at 405 nm.   
Statistics.  Percentage ligand blockade by human pre-challenge or acute and convalescent 
serum from each sampling group and lymphoid antibody titers in experimental and control 
mice were individually compared using the student’s t-test (P≤0.05).  Statistical comparisons 
of serum IgG titers and 50% blockade serum concentrations between multiple groups having 
measurable values were performed using the One-way ANOVA.  If groups were found to be 
statistically different, post-hoc analysis was performed using the Tukey HSD Test (P≤0.05).  
For 50% blockade analysis of groups containing samples not having a determinable endpoint 
value, categorical differences in the percentage of serum necessary to block (or not block) 
50% ligand binding were determined using the One-way ANCOVA. 
 
Results  
Cloning and Characterization of Lordsdale Virus VLPs. 
The LV-NC1 ORF 2 was cloned into the pVR21 VEE replicon vector, and the amino acid 
coding sequence exhibited 99.1% identity to the GII.4 Bristol-like LV004 strain (181).  Intact 
LV VLPs were expressed from LV VRPs following infection of BHK cells, as determined by 
electron microscopy (Fig. 2.1a).  The binding profile of LV VLPs to HBGAs was also 
determined by solid phase binding assay.  VLPs bound strongly to the H type 3 and H type 1 
antigens (net OD405 1.64 and 0.51, respectively) without significant binding (net OD405 <0.2) 
to H type 2, the Lewis antigens, or H type 1 and H type 3 precursors (Fig. 2.1b), a profile that 
included fewer antigens than the related VA387 strain (104).  LV VLPs were further tested 
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for the ability to bind saliva from individuals of all blood types and all secretor status.   VLPs 
strongly bound saliva from 7 of 9 secretor-positive individuals regardless of blood type and 
did not appear to bind saliva from secretor-negative individuals (Fig. 2.1c), resembling 
binding patterns previously shown for related LV strains (103, 104).   
 
Homotypic & heterotypic IgG responses in humans following norovirus infections.  
With the synthesis of the LV VLPs and our existing panel of NV, HV and SM VLPs (11, 91, 
93), we measured homotypic and heterotypic serum antibody responses to each antigen 
following human norovirus infection with the NV (GI.1), DS (GI.3), DF (GI.4), HV (GII.1), 
SM (GII.2) or LV (GII.4) strain.  Data are presented as median fold-increase in IgG in 
convalescent sera compared to that in matched acute or pre-challenge sera.  Not surprisingly, 
homotypic sera from NV-infected individuals exhibited the highest IgG response against NV 
VLPs with a median fold-increase in IgG titer of 71.7 when compared to pre-challenge sera 
(Fig. 2.2a), consistent with earlier reports in the literature (93, 145, 180).  Heterotypic serum 
antibody titers to NV VLPs were lower for all other infection groups; however, sera from 
infections caused by other GI noroviruses exhibited a trend of more robust heterotypic 
responses than sera obtained following GII infections.  Both heterologous GI infections 
induced median fold-increases of 5.3 in IgG titer; GII infections induced median fold-
increases from 1.8-2.9 (Fig. 2.2a).  Similar results were found for homotypic and heterotypic 
IgG titers following GII infections:  median homotypic titers to GII antigens increased 17.7-
71.3-fold in convalescent sera, and heterotypic titers to GII antigens increased 2.4-8.5-fold.  
Heterotypic titers from GI infection groups increased 1.2-5.2-fold against GII antigens (Fig. 
2.2b-d).  Sera from each infection group contained higher homotypic IgG titers than 
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heterotypic titers to other norovirus antigens, while heterotypic antibody responses appeared 
higher within a genogroup than across genogroups.  Neither observation was statistically 
significant, however, due to a high degree of heterotypic IgG variability between individuals 
in each infection group as well as between infecting strains (One-way ANOVA).  However, 
in support of these observations we calculated percent seroconversion, defined as a >4-fold 
increase in IgG titer in convalescent or post-challenge sera compared to acute or pre-
challenge sera, and found that 81% of GI infected individuals and 38.5% of GII infected 
individuals seroconverted to GI antigen.  Likewise, 35% of GI infected individuals and 59% 
of GII infected individuals seroconverted to GII antigens (specified below each panel in Fig. 
2.2).  
 
Homotypic & heterotypic IgG responses in mice following inoculation with VRPs 
expressing norovirus VLPs.  Given the complications in measuring heterotypic antibody 
responses in humans with unknown norovirus infection histories, we inoculated mice with 
VRPs expressing recombinant norovirus VLPs from either the NV, SM, HV, or LV strain to 
examine antigenic cross reactivity in a naïve host.  Anti-norovirus serum IgG was analyzed 
by indirect ELISA and is presented as mean titer of post-boost IgG (µg/ml) per inoculation 
group (n=4) (Fig. 2.3).  Pre-boost (day 14) IgG titers were consistently 10-28% of post-boost 
(day 35) titers.  As seen with human sera, anti-norovirus IgG in the mouse was highly 
specific for homotypic VLPs (Fig. 2.3a-d) with titers reaching geometric means of 1099 
µg/ml in VRP-NV inoculated mice, 1575 µg/ml in VRP-SM inoculated mice, 1463 µg/ml in 
VRP-HV-inoculated mice, and 658 µg/ml in LV VRP-inoculated mice on day 35.  
Heterotypic IgG responses were 10-40-fold less than the homotypic antibody responses.  
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Mean heterotypic responses, however, exhibited a trend of higher cross-reactivity within 
genogroups than across genogroups (Fig. 2.3a-d), with the individual heterotypic IgG 
response of SM VRP-inoculated mice being significantly more cross-reactive to HV VLPs 
than NV VLPs (One-way ANOVA, Tukey HSD, P<0.01). 
 
Antibody blockade of norovirus VLP binding to ABH histo-blood group antigens.   It 
has recently been shown that several norovirus strains from both GI and GII are capable of 
binding glycoconjugates of the ABH histo-blood group antigen family as putative ligands for 
cellular attachment (91, 92, 103, 109, 159).  An antibody blockade assay, recently developed 
by Harrington et al. (91), measures the ability of antibody to block VLP binding to HBGAs.  
Because NV, the prototype GI norovirus, has been shown to bind strongly to the H type 1 
antigen (91), and LV VLPs bind strongly to the H type 3 antigen (Fig. 2.1c), we investigated 
the ability of homotypic and heterotypic anti-norovirus serum IgG from humans and mice to 
block HBGA attachment to NV (Fig. 2.4) and LV VLPs (Fig. 2.5) 
     Pre-challenge or acute and convalescent serum samples collected from infected 
volunteers and outbreak cases were analyzed for blockade of NV VLP binding to synthetic H 
type 1 antigen (Glycotech) in blockade assays by serial dilution of 10% sera (Fig. 2.4a).  
While pre-challenge sera were unable to block H type 1 binding, convalescent sera from NV-
infected volunteers ablated >90% of H type 1 binding to NV VLPs at an average 
concentration of 0.42% serum per volume.  Interestingly, some samples from individuals 
infected with two GI strains, DS (GI.3) and DF (GI.4), which are distantly related to NV, 
were also able to completely ablate ligand attachment to NV VLPs, while other serum 
samples from the same outbreaks were unable to do so.  The average blockade of all samples, 
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indicated in Fig. 4a, shows the average ability of DS samples to block >50% H type 1 
binding at serum concentrations of 2.5% and DF samples to block 40% of binding at 5% 
serum concentrations.  When the ability of individual serum samples to block 50% of ligand 
binding was compared, the concentrations of serum from individuals with heterologous GI 
infections were not significantly different from the concentrations of serum from individuals 
with NV infections in their ability to generate a 50% blockade response (One-way 
ANCOVA).  Heterotypic antibodies following infection with GII strains, however, were 
entirely unable to block NV-H type 1 binding. 
     Previously, homotypic IgG blockade of VLP-ligand binding was demonstrated in 
mice following inoculation using the VEE-VRP system (91).  Our data also clearly 
demonstrate that homotypic murine IgG eliminates NV VLP-H type 1 attachment (Fig. 2.4b).  
In agreement with results from our studies with human sera, heterotypic IgG from mice 
inoculated with VRPs expressing GII-derived VLPs SM, HV, or LV was unable to block H 
type 1 binding to NV VLPs (Fig. 2.4b).   
 Mean IgG titers from human and murine samples necessary for 50% and 90% 
blockade of ligand attachment (BT50/90) are shown in Fig. 4c.  In humans, all NV serum 
samples exhibited BT50/90 values for H type 1 blockade, with <5.1 µg/ml NV IgG required 
for 50% blockade of H type 1 binding and <6.4 µg/ml required for 90% blockade.  Five of 
seven DS serum samples had BT50/90 IgG titers, with mean antibody requirements being at 
least 2-fold and 3-fold higher, respectively, than titers necessary for blockade by homotypic 
NV IgG. Three of four DF serum samples showed BT50 values that were 1.2-fold higher 
than homotypic antibody requirements, and two of four DF samples showed BT90 values 
that were 1.7-fold higher than for homotypic IgG.  Sera from GII-infected individuals, 
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however, were unable to block H type 1 attachment to NV VLPs in all samples tested.  In 
murine sera, NV samples required 11.7 µg/ml IgG for 50% blockade of H type 1 attachment 
and 23.5 µg/ml for 90% binding blockade.   
     Homotypic and heterotypic sera from humans and mice were also analyzed for the 
blockade of H type 3 attachment to LV VLPs (Fig. 2.5).  Convalescent human sera from LV-
infected individuals completely blocked LV-H type 3 binding (Fig. 2.5a).  However, 
convalescent human sera from all other infection groups, except HV, also partially ablated 
LV-H type 3 attachment (Fig. 2.5a).  Upon analysis of matched pre-challenge or acute sera, 
we found that corresponding samples also partially or completely blocked H type 3 
attachment (Fig. 2.5a) and were not significantly different from matched convalescent sera at 
any serum concentration tested (student’s t-test, P≤0.05). These results suggest that previous 
exposure to the predominant GII.4 viruses is a likely cause of antibody specificity for LV 
epitopes and specific blockade of ligand binding.  The LV and HV infection groups, 
however, did exhibit a significant change in blockade between pre-challenge or acute sera 
and convalescent samples.  Sera following LV infection ablated >90% of H type 3 binding in 
3 of 4 samples, whereas acute samples exhibited very minimal blockade (P<0.05 at all serum 
concentrations).  Hawaii-specific sera, however, appeared to enhance H type 3 binding at low 
serum concentrations, a phenomenon not seen with matched pre-challenge sera (P<0.05 at 
0.3-0.6% serum), in the two samples sets tested.  Blocking titers of convalescent LV sera for 
50% and 90% blockade of H type 3 binding were 2.4 µg/ml (4/4 samples) and 1.7 µg/ml (3/4 
samples), respectively (Fig. 2.5c).       
     Sera from mice inoculated with VRPs expressing LV VLPs completely ablated H 
type 3 attachment (BT50=2.4 µg/ml; BT90=6.9 µg/ml (Fig. 2.5c)), while sera from other 
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inoculation groups did not block ligand binding regardless of genogroup (Fig. 2.5b).  It is 
important to note here that, unlike human sera, sera from mice inoculated with replicons 
expressing Hawaii VLPs did not show antibody responses that enhanced LV VLP binding to 
H type 3.  Because mice have no pre-exposure histories, our murine data likely reflect natural 
IgG blockade responses following primary exposure to norovirus antigens; however, multiple 
norovirus exposures may influence antibody specificity.  To distinguish if multistrain 
exposure may be an alternative causative influence for the high blockade response by acute 
or pre-challenge sera to LV-ligand binding in humans, we tested for ablation of virus-ligand 
binding following multivalent inoculation in mice. 
 
Mice inoculated with multivalent VRP vaccines mount cumulative antibody responses.  
Our data support the hypothesis that norovirus vaccines will likely require multivalent 
antigenic components to provide protection against this antigenically diverse group of 
viruses.  To test the efficacy of such reagents, two groups of mice were vaccinated with a 
multivalent inoculum of VRPs expressing equivalent concentrations of three (NV, SM, HV) 
or four (NV, SM, HV, LV) heterologous VLPs but with varying total amounts of VRPs.  
Trivalent vaccines were composed of a total VRP amount equal to the total VRPs received 
by monovalently vaccinated mice.  In tetravalent vaccines, each strain-specific VRP was 
administered at a dose equivalent to that received by monovalently vaccinated mice to 
determine if total VRP insult would proportionately alter the immune response.  Sera were 
collected 12 days post-boost and analyzed for specific IgG to a panel of VLPs (NV, SM, HV, 
LV) (Fig. 2.6a).  Mice receiving trivalent inoculum produced a robust antibody response to 
all three VLPs; those receiving tetravalent inoculum produced a robust response to all four 
 53 
VLPs.  IgG titers were similar to those elicited following inoculation with each VRP alone, 
as indicated in Fig. 2.6a,  and total VRP amount per vaccination did not influence the 
intensity of the immune response, likely due to an already saturated immune insult with such 
large VRP quantities.  No significant differences in mean IgG titers between sera from mice 
receiving individual versus multivalent inocula were seen for all four antigens, with the 
exception of higher NV-specific and SM-specific IgG responses in monovalent-inoculated 
mice than in mice inoculated with all four antigens (One-way ANOVA; P<0.05).  
Interestingly, mice receiving a trivalent vaccine also mounted a robust immune response to 
the fourth VLP (LV) that was not included in the inoculum and was not significantly 
different from responses mounted by the inoculation groups receiving the LV antigen.  
Furthermore, this heterotypic antibody response to LV VLPs was significantly greater than 
the heterotypic responses of mice inoculated with individual SM (P≤0.01), NV (P≤0.05) or 
HV VRPs (P≤0.01; One-way ANOVA and Tukey HSD) and was also greater than the 
heterotypic responses from all three monovalently inoculated groups combined (Fig. 2.6b).      
 Blockade assays were also performed to measure antibody interference of HBGA 
attachment to NV and LV VLPs (Fig. 2.7), as described above.  Sera from both multivalent 
inoculation groups blocked H type 1 binding to NV VLPs (Fig. 2.7a), and sera concentrations 
required for 50% blockade were not statistically different among the monovalent or 
multivalent groups.  When sera were analyzed for blockade of H type 3 binding to LV VLPs, 
we found that sera from the multivalent inoculation group that received the LV antigen could 
efficiently block binding (Fig. 2.7b) and were likewise not statistically different from the 
monovalent LV inoculation group in sera concentration required for 50% binding blockade 
(One-way ANOVA).  Importantly, sera from mice that did not receive LV antigen as an 
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inoculum component but mounted a robust heterotypic antibody response against LV antigen 
also blocked H type 3 attachment at high serum concentrations (Fig. 2.7b). This phenomenon 
was not seen after inoculation with VRPs to a single norovirus strain (Fig. 2.7c).  Blockade 
ability was, however, significantly lower in the multivalent inoculation group not receiving 
LV antigen compared to groups that did (P≤0.05, One-way ANOVA and Tukey HSD).  
BT50 and BT90 values were calculated to further measure interference of ligand binding 
(Fig. 2.7d).  Multivalent titers for H type 1 blockade were nearly equivalent to those achieved 
following monovalent inoculation with NV VRPs.  BT50 values for interference of LV-H 
type 3 binding were 4-fold higher and BT90 values 3-fold higher in tetravalent-inoculated 
mice than monovalent-inoculated mice, although actual titers were similar to that seen for 
NV-H type 1 blockade.  Furthermore, the trivalent vaccine that did not include the LV 
antigen was still able to induce BT50 values in mice that were roughly twice that necessary 
for blockade following a multivalent challenge that did include the LV antigen.  Our data 
support the suggestion that potentially neutralizing heterotypic antibody responses can in fact 
be induced to novel antigenic strains.   
     
3.6 Multivalent inoculum induces specific antibody secretion in multiple tissues.   
To measure the level of heterotypic mucosal IgA and IgG responses at biologically relevant 
sites, whole gut and spleen tissues harvested and cultured from mice inoculated with a 
trivalent VRP inoculum expressing NV, SM, and HV VLPs were analyzed for antibody 
secretion (Table 2.1).  Total antigen-specific IgG titers secreted from gut and spleen tissue 
and IgA titers secreted from the gut were determined for specificity to NV, SM, and HV 
VLPs.  All mice demonstrated specific IgG secretion to all components of the inoculum in 
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the gut and spleen (P≤0.01) as well as IgA in the gut (P≤0.05 for 2/3 VLPs) compared to 
control mice that received parallel inoculation with VRPs expressing the influenza 
hemagglutinin gene or a PBS placebo (student’s t-test).  Control animals did not mount 
specific antibody responses to norovirus VLPs.  Furthermore, when screened for ligand 
binding blockade, gut and spleen IgG blocked 100% of H type 1 binding to NV VLPs at 
similar IgG concentrations required for 100% blockade with serum IgG (Table 2.1).  These 
results indicate that multivalent inoculation with VRPs expressing norovirus VLPs is capable 
of inducing an immune response that is evident at a relevant mucosal site in mice. 
 
Discussion 
 Norovirus infections are associated with a significant disease burden, but the 
components of protective immunity in humans are unknown.  The extensive antigenic 
diversity and complex serological relationships among strains challenge our understanding of 
strain variation on viral infection and pathogenesis. Unraveling the details of antigenic cross-
reactivity is essential for developing effective vaccines.  Following norovirus infection in 
humans, varying degrees of humoral and cellular immune cross-reactivity have been 
documented within and across genogroups (42, 129, 144, 145, 155, 180, 259, 286).  
However, human sera samples are limited to those collected from underrepresented outbreak 
samples and a limited number of human-challenge studies.  Consequently, the biological 
significance of heterotypic immune responses has not been evaluated in vitro.  In this study, 
we examined the impact of heterotypic immune responses on virus-ligand interactions in 
biochemical assays designed to measure ABH antigen binding using human and murine 
model systems and addressed the impact of multivalent vaccination. 
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 In agreement with earlier reports, our studies demonstrate that humans mount 
moderate heterotypic antibody responses following norovirus exposure. We observed that the 
heterotypic responses to other members of the same genogroup were typically stronger than 
those between genogroups, but overall, the heterotypic IgG response was only about 5-10% 
of the measured homotypic IgG responses.  Reports by Treanor et al. demonstrated that 6 of 
15 individuals infected in a human challenge study with the SM virus seroconverted against 
the NV antigen (259), while our findings suggested a slightly lower heterotypic response 
with 2 of 7 SM samples displaying seroconversion against NV.  Examining sera collected 
from norovirus outbreaks, Noel et al. noted very little cross-reactivity between genogroups 
but varying degrees of cross-reactivity within genogroups (180).  Most humans have 
antibodies against noroviruses (152), but norovirus exposure histories are uncertain and can 
fluctuate drastically between individuals, making it difficult to decipher the exact degree of 
heterotypic immunity between strains. 
 Because mice cannot be productively infected with human noroviruses, they do not 
have pre-existing antibodies that complicate serologic comparisons.  Mice can, however, 
mount robust immune responses to human norovirus antigens delivered by alphavirus 
replicon particles.  Our data show that while homotypic antibody responses were singularly 
the most robust, heterotypic antibody responses were also mounted against all the strains we 
analyzed and were typically more robust within a genogroup than between genogroups, 
mirroring our findings following infection in humans.  Furthermore, the murine footpad has 
proven to be a distinctly immunogenic site for VRP inoculation in comparative studies 
including subcutaneous, intradermal, and intramuscular inoculations (A. West, unpublished 
data).  Because the murine footpad is closely related to the dermis, intradermal vaccination in 
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humans may be a preferred route to induce a similar immune response with VRPs.  We are 
aware that inbred mouse strains likely recognize a subset of the total repertoire of norovirus 
epitopes recognized by human populations. Interestingly, norovirus VLPs supersaturated 
with hyperimmune murine sera were only able to bind 7-8% of corresponding human 
antibodies following NV, SM, or HV infection (data not shown), suggesting that many of the 
epitopes may be common in humans and mice.  Overall, our data indicate that murine 
inoculation using recombinant VEE vectors may allow us to further characterize heterotypic 
immunity to multiple norovirus strains and help inform vaccine design strategies for humans.    
     Although we cannot truly define neutralizing antibodies without an animal model or 
cell culture system, our demonstration that noroviruses bind HBGAs as putative receptors 
has allowed us to further characterize the specificity of heterotypic antibodies in humans and 
mice.  The HBGAs H type 1 and H type 3, glycoconjugates expressed on the surface of 
mucosal tissues, have been shown to strongly bind to NV and LV VLPs, respectively.  
Furthermore, antibodies generated against NV and LV following active infection in humans 
and generated against NV and LV VLPs following inoculation of mice completely block 
VLP binding to their HBGA ligands.  Based on the hypothesis that antibodies that block 
virus-ligand interactions may neutralize infectivity (41, 102), antibody blockade experiments 
provide an obvious biological parameter to compare the immunogenicity between strains.   
 Acute and convalescent sera were available from different GI norovirus outbreaks 
(GI.3-Chiba-like and GI.4 Desert Shield-like strains) and from volunteers challenged with 
the GI.1 Norwalk virus strain.  Our results showed that several human serum samples 
collected following infection with GI.3 and GI.4 strains were capable of completely blocking 
NV VLP binding to H type 1, while other corresponding samples were less able to do so.  
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Previous immunoprecipitation studies with sera from similar infections have indicated the 
presence of shared antigenic sites between capsid proteins as well as the retention of unique 
antigenic sites (144), which would explain our observation of varying degrees of antibody 
blockade even within the same infection groups.  However, no sera from GII-infected 
individuals blocked the binding of H Type 1 antigen to NV VLPs, although our studies and 
others (259) demonstrate limited amounts of antibody cross-reactivity between genogroups.  
Our findings following murine inoculation with GII-derived VLPs agree with our findings in 
humans, although our current panel of GI-expressing replicons limits the scope of our overall 
study.  Although our data suggest that GI infections in humans may induce antibody 
responses that can block attachment of heterotypic strains, additional studies are needed to 
confirm these findings.  Interestingly, if GI infections induce a heterotypic blockade 
response, this may explain in part the noted lower prevalence of outbreaks associated with GI 
noroviruses (204).   
 LV and closely related GII.4 strains have been responsible for the majority of 
reported norovirus outbreaks in the last decade and have a worldwide distribution (181).  
When we analyzed heterotypic antibody blockade of LV VLP binding to the H type 3 ligand, 
we encountered several discrepancies between humans and mice.  Following norovirus 
infection in humans, heterotypic antibodies appeared to partially block LV VLP-ligand 
binding regardless of the original infecting strain.  Blockade potential, however, was also 
uniformly high in pre-immune sera, suggesting that the observed heterotypic blockade 
activity was due to an exposure to LV before the outbreak when the sera was collected or 
from heterotypic responses associated with exposure to common GII strains (84).  Many pre-
challenge and acute human sera samples also contained high antibody titers to LV VLPs.  
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When we compared our findings in humans to that in mice, it was clear that in animals with 
no norovirus exposure history, antibody responses to SM and HV provided no heterotypic 
antibody that would ablate LV VLP-ligand binding at any sera concentration tested.  Our 
results suggest that antigenic epitopes of GII viruses vary greatly between strains, which may 
make it challenging to formulate a broadly protective vaccine.   
 Because heterotypic antibody responses did not block LV-H type 3 ligand 
interactions in mice, we tested the hypothesis that a cocktail of VLPs could provide a greater 
number of distinct cross-reactive epitopes in the mouse, providing for heterotypic blockade 
against novel strains.  Cocktail VRP vaccines using multiple homologous proteins derived 
from different strains have not been developed and tested previously.  One group of mice was 
inoculated with a cocktail of three VRPs derived from NV, SM, and HV, which likely 
represent a small subset of norovirus outbreaks.  A second inoculation group added a fourth 
component of LV VRPs, which may represent a combined total of >70% of all norovirus 
outbreaks (134), depending on year-to-year variation.  We found that, in both multivalent 
inoculation groups, robust antibody responses were induced to all components of the 
inoculum.  Surprisingly, in the inoculation group not receiving the LV antigen as an 
inoculum component, a robust heterotypic IgG response to LV VLPs was also induced that 
was 2.5-5-fold higher than heterotypic IgG responses seen in mice monovalently inoculated 
with each VRP component.  Importantly, antibody titers to LV in the inoculation group that 
did not include LV as a vaccine component were not significantly different compared to anti-
LV titers in inoculation groups that did receive LV, supporting the hypothesis that 
multivalent vaccines might induce robust immunity against additional noroviruses not 
included in the vaccine mix.  When serum samples were screened for blockade of NV and 
 60 
LV VLP binding to their respective HBGAs, we found that both multivalent inoculation 
groups contained antibody capable of blocking both H type 1 and H type 3 binding to their 
respective VLPs.  This finding experimentally supports the use of multivalent antigen 
cocktails as a plausible norovirus vaccine method.  Unfortunately, animal models are not 
readily available to test whether cross-blocking antibody responses are protective against 
norovirus infection, although successful inoculation of rhesus macaques and chimpanzees 
have been reported with NV (221, 282).  Our working hypothesis is that an increased amount 
of epitopes encountered by the immune system upon multivalent inoculation provides a 
broader set of cross-reactive epitopes, allowing for greater recognition of novel strains.   
    Throughout this study, we examined serum IgG responses in humans and mice 
because IgG is readily obtainable in high volumes from both species and because it contains 
high titers of specific antibody for further testing.  Although the components of protective 
immunity and immune induction sites for clearance of norovirus infection are not currently 
known, the natural site of norovirus infection is the gut mucosa (159, 244), suggesting that 
mucosal immunity is likely critical for controlling infection.  We found that trivalent VRP 
inoculation does indeed induce a multi-system immune response, as we were able to identify 
IgG specific for all three VLPs in the gut and spleen as well as IgA specific for all three 
antigens in the gut.  Antigen-specific IgA and IgG were produced by resident lymphocytes 
present in intestinal tissue, as Peyer’s patches were removed and intraepithelial lymphocytes 
disrupted prior to culture.  Both IgG and IgA have separately been implicated in the efficient 
clearance of other viral as well as bacterial pathogens from the gut mucosa (12, 168, 217, 
229), although the biological relevance of each antibody subtype in norovirus infection is not 
known.   
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 We also tested the ability of IgG isolated from gut and spleen culture supernatants to 
effectively block binding of NV VLPs to its HBGA ligand and found that IgG from both 
tissues was able to completely block ligand binding at the lowest concentrations necessary 
for 100% binding blockade with sera, indicating that a specific and possibly neutralizing 
antibody response is induced in multiple tissues, including the biologically relevant gut, 
following inoculation with VRPs expressing norovirus VLPs in mice.  Unfortunately, we 
were unable to isolate sufficient IgA to evaluate its VLP attachment blockade activity.  
Nevertheless, we have made substantial progress in the development of a candidate vaccine 
strategy that can induce broadly reactive and potentially neutralizing antibody responses at 
both the systemic and mucosal level to circumvent norovirus infections.   
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Characterization of LV-NC1 isolate.  ORF2 of a norovirus isolate obtained following an 
outbreak in North Carolina (LV-NC1) was cloned into the pVR21 vector. Transmission 
electron microscopy revealed that VRPs expressing LV-NC1 ORF2 were able to form intact 
VLPs that were harvested following VRP infection of BHK cells (A).  LV-NC1 VLPs 
exhibited a specific binding pattern to a panel of HBGAs, as determined by solid-phase 
binding assay (B).  The ability of LV-NC1 VLPs to bind saliva from a representative panel of 
individuals of each blood type and secretor status was determined by solid-phase assay (C).  
Positive (Se+) and negative (Se-) sample designations indicate secretor status. 
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Figure 2.2   
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               Strain:     NV          DS          DF                                SM          HV         LV 
       Genogroup:                      I                                                            II  
Seroconversion:   10/10        5/7          2/4                                  2/7          1/2         2/4 
               Range: 201-273    1-149       0-17                                1-5         1-4         1-5 
                              
 
                    Strain:     NV          DS          DF                               SM          HV        LV 
       Genogroup:                       I                                                                 II 
Seroconversion:    5/10          2/7          0/4                                7/7           2/2         1/4                   
               Range:    2-15         1-51         1-3                               4-129       5-13       1-10 
                                                          
SM VLPs 
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                 Range:   1-19          1-26         1-5                                1-9           1-3          9-40   
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Homotypic and heterotypic serum IgG responses in humans following norovirus 
infection.  Pre-challenge and convalescent serum samples were collected from volunteers 
that became infected following participation in norovirus challenge studies with either NV 
(n=10), SM (n=7), or HV (n=2).  Acute and convalescent serum samples were collected from 
individuals infected during a LV (n=4), DF (n=4), or DS (n=7) outbreak.  Infection groups 
(by strain) and respective norovirus genogroups are indicated below the x-axis.  IgG titers 
from each infection group were measured using indirect ELISA for specificity to NV (A), 
SM (B), HV (C), or LV (D) VLPs.  Antibody titers are represented as median fold-increase 
in convalescent serum IgG from pre-challenge IgG titers on a logarithmic scale.  Values were 
not significantly different between any infection groups (One-way ANOVA).  The number of 
samples per group that exhibited seroconversion to each antigen and the ranges of the fold-
increase in IgG within each infection group are indicated below. 
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Figure 2.3   
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Homotypic and heterotypic serum IgG responses in mice following inoculation with 
VRPs expressing norovirus VLPs.  6-week-old male BALB/c mice were primed and 
boosted with 2.5x106 IU VRPs expressing NV, SM, HV, or LV VLPs in the footpad on days 
1 and 23, respectively (n=4 per inoculation group).  Serum was collected on day 35.  IgG 
titers from inoculation groups VRP-NV (A), VRP-SM (B), VRP-HV (C), or VRP-LV (D) 
were measured using indirect ELISA for specificity to NV (GI), SM, HV, or LV (GII) VLPs, 
as indicated below the graph.  Antibody titers are represented as the geometric mean serum 
IgG (µg/ml) on a logarithmic scale.  All homotypic responses were significantly greater than 
heterotypic responses (*).  Heterotypic responses that were significantly greater (P≤0.05) 
within a genogroup than between genogroups are indicated with **.  Heterotypic responses 
that are significantly greater than others within a genogroup are indicated with † (One-way 
ANOVA, Tukey HSD).  Bars show SD in each sample group.  Average baseline (day 0) 
titers to each antigen are <1 ug/ml.   
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Figure 2.4 
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Homotypic and heterotypic serum IgG blockade of H type 1 antigen binding to NV 
VLPs in humans and mice.  All pre-challenge or acute and convalescent sera collected from 
humans infected with NV, DS, DF, SM, HV, or LV (A; left and right panels, respectively) 
and from mice inoculated with VRPs expressing NV, SM, HV, or LV VLPs (B) were used in 
antibody blockade assays.  Blockade of H type 1 binding was measured at OD405 and 
compared to control wells representing 100% H type 1 binding.  Differences in blockade 
between matched human samples pre- and post-infection were significant following infection 
with NV at all serum concentrations (P≤0.0001, student’s t-test)(A, right vs. left panels).  
Blockade of 50% binding by convalescent human NV sera was not significantly different 
from other GI infection groups (One-way ANCOVA; right panel A).  Mean IgG titers 
(µg/ml) for 50% and 90% blockade of H type 1 binding (BT50/90) in measurable human 
convalescent sera samples and murine inoculation groups are presented in panel C. 
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Figure 2.5   
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Homotypic and heterotypic serum IgG blockade of H type 3 antigen binding to LV 
VLPs in humans and mice.  All acute or pre-challenge and convalescent sera collected from 
humans infected with NV, DS, DF, SM, HV, or LV (A; left and right panel, respectively) and 
from mice inoculated with VRPs expressing NV, SM, HV, or LV VLPs (B) were used in 
antibody blockade assays.  Blockade of H type 3 binding was measured at OD405 and 
compared to control wells representing 100% H type 3 binding.  Differences in blockade 
between matched human samples pre- and post-infection were significant following infection 
with LV at all serum concentrations (P≤0.05) and significantly lower following infection 
with HV at serum concentrations ≤0.6% (P≤0.05).  Other sampling groups were not different 
(student’s t-test)(A, left vs. right panels).  Human convalescent LV sera and murine LV sera 
IgG titers (µg/ml) necessary for 50% and 90% blockade (BT50/90) of H type 3 binding are 
presented in panel C. 
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Figure 2.6   
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Serum IgG responses in mice following norovirus inoculation with a cocktail of VRPs 
expressing VLPs from multiple norovirus strains. 6-8 week-old BALB/c mice were 
primed and boosted with a total of 2.5x106 IU VRPs expressing equivalent concentrations of 
NV, SM, and HV VLPs (trivalent VRPs; n=5), with 2.5x106 IU each of NV, SM, HV, and 
LV VRPs (tetravalent VRPs; n=5), or with 2.5x106 IU of the indicated strain-specific VRP 
(monovalent VRPs; n=4) in the footpad on days 1 and 23, respectively.  Serum was collected 
on day 35.  IgG titers from each inoculation group were measured using indirect ELISA for 
specificity to NV, SM, HV, or LV VLPs as indicated along the x-axis (A).  Antibody titers 
are represented as µg/ml geometric mean serum IgG on a logarithmic scale.  IgG titers 
induced by monovalent and tetravalent inocula were statistically different from one another 
in the NV and SM groups (P≤0.05); all other titers were not different (One-way ANOVA and 
Tukey HSD) (A).  The heterotypic serum IgG titers to the LV antigen in mice receiving 
trivalent inoculum is significantly higher (*) than the heterotypic IgG titers induced by the 
individual components of the trivalent inoculum (P≤0.05, One-way ANOVA), as shown in 
panel B.  Bars represent SD for each sample group.  Average baseline (day 0) titers are <1 
ug/ml. 
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Figure 2.7  
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Serum IgG blockade of ABH histo-blood group antigen binding to VLPs in mice 
inoculated with a VRP cocktail.  Sera collected from mice following inoculation with VRPs 
expressing NV, SM, and HV (trivalent VRPs) or NV, SM, HV, and LV VLPs (tetravalent 
VRPs) were tested for blockade of H type 1 binding to NV VLPs (A) or H type 3 binding to 
LV VLPs (B) by antibody blockade assays.  Monovalent and tetravalent inocula containing 
the LV antigen could block 50% H type 3 binding at significantly lower serum 
concentrations than trivalent inocula not containing the LV antigen (P≤0.05)(B).  Blockade 
of H type 3 binding to LV VLPs by sera collected from mice receiving trivalent inoculum 
compared to mice receiving the individual components of the trivalent inoculum is 
represented in panel C.  Panel D shows serum IgG titers (µg/ml) required for 50% and 90% 
blockade (BT50/90) of VLP-ligand binding. 
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TABLE 2.1.  Norovirus-specific gut and spleen antibody 
secretion following lymphoid culture in mice inoculated  
with multivalent VRP vaccines. 
 
         Value [mean ± StD] 
        Parametera 
        Poolb     Controlc 
     Gut IgG (µg)   
            HV VLP 12.5 ± 5.1 0.10 ± 0.12  
            SM VLP 7.6 ± 1.7 0.04 ± 0.07 
            NV VLP 9.9 ± 1.9 0.04 ± 0.06 
         Blockaded ≥100%  0-5.4% 
     Gut IgA (ng) 
            HV VLP 726 ± 293 157 ± 89 
            SM VLP 1023 ± 214 338 ± 247 
            NV VLP 594 ± 497* 216 ± 149 
           Blockade nte  nt 
Spleen IgG (µg) 
            HV VLP 28.0 ± 12.7 0.57 ± 0.72 
            SM VLP 21.5 ± 7.8 0.26 ± 0.25 
            NV VLP 18.0 ± 11.3 0.29 ± 0.29 
           Blockade ≥100%  0% 
 
a
 Gut and spleen lymphoid samples screened against 
HV, SM, and NV VLPs for specific antibody content 
and blockade of H type 1 binding to NV VLPs. 
b
 Mice (n=3) inoculated with three VRPs (2.5 x 106 IU) 
expressing equivalent amounts HV, SM, and NV VLPs. 
c
 Mice (n=3) inoculated with 2.5 x 106 IU control VRPs 
expressing HA (flu). 
d
 See Materials and methods for protocol; control 
samples represent blockade at 30% serum 
concentrations 
e
 Not tested due to limited sample volume. 
*
 Not significant from control values. 
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Abstract 
 
Background: Noroviruses are the leading cause of viral acute gastroenteritis in humans, 
noted for causing epidemic outbreaks in communities, the military, cruise ships, hospitals, 
and assistednliving communities. Worldwide, the majority of Norovirus outbreaks are caused 
by the GII.4 genocluster which was first recognized in the mid-1990’s. The evolutionary 
mechanisms governing the persistence of the GII.4 viruses in human populations are 
unknown. Previous studies by our laboratory indicate that some Noroviruses readily infect 
individuals who encode a functional FUT2 gene and are secretor-positive because they 
express ABH histoblood group antigens (HBGAs), a highly heterogeneous group of related 
carbohydrates on mucosal surfaces.  Individuals who encode defects in the FUT2 gene, are 
secretor-negative, don’t express the appropriate ABH HBGA necessary for docking and entry 
and are resistant to Norwalk virus infection, These data argue that the FUT2 gene and other 
enzymes that regulate processing of the HBGA carbohydrates function as susceptibility 
alleles. However, secretor-negative individuals can be infected with other norovirus strains 
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and many secretor negative individuals have antibodies against human noroviruses. In this 
manuscript, we investigate the molecular mechanisms governing GII.4 susceptibility and 
persistence mechanisms in human populations. 
Methods and Findings: Phylogenetic analysis of the GII.4 capsid sequences suggested a 
linear evolution over the last twenty years with serial replacements occurring every ~3-5 
years. Five distinct evolutionary clusters were identified and representative ORF2 genes 
expressed as virus like particles (VLPs). Using salivary and carbohydrate binding assays, 
GII.4 VLP-carbohydrate ligand patterns changed over time and included carbohydrates 
regulated by human FUT1, FUT2 and FUT3 pathways, suggesting that strain sensitivity to 
human susceptibility alleles will vary.  Variation in residues in the second ligand interaction 
domain, which stabilize carbohydrate binding, regulated carbohydrate binding patterns over 
time. Sites of variation also decorated the surface of P2 in the recently solved structure GII.4 
capsid, suggesting that antigenic drift may occur over time. Antigenic relatedness of GII.4 
VLPs was measured using time ordered murine and human sera and time-sensitive specific 
serologic and carbohydrate binding blockade responses were evident. These data suggest that 
the GII.4 noroviruses persist by recognizing new HBGA carbohydrate binding targets over 
time, which not only allows for escape from highly penetrant host susceptibility alleles, but 
simultaneously allows for immune driven selection in the receptor binding region to facilitate 
escape from protective herd immunity. 
Conclusions: Our data suggest that the surface exposed carbohydrate ligand binding domain 
in the norovirus capsid is under heavy immune selection and likely evolves by antigenic drift 
in the face of human herd immunity. Variation in the capsid carbohydrate binding domain is 
tolerated because of the large repertoire of similar, yet distinct HBGA carbohydrate receptors 
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that are available on mucosal surfaces that could interface with the remodeled architecture of 
the capsid ligand binding pocket. The continuing evolution of new replacement strains 
suggests that, like influenza virus, vaccines can be targeted that protect against norovirus 
infections and that continued surveillance and reformulations of norovirus vaccines will be 
necessary every 3-5 years. 
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Introduction 
 The majority of norovirus outbreaks are caused by the GII.4 genotypes and pandemic 
spread was first recognized in the mid-1990’s (181). During 1995-96, US95/96 was 
responsible for ~55% of the norovirus outbreaks in the USA and 85% of the outbreaks in the 
Netherlands (264). Between 2000 and 2004, US95/96 was replaced by two new GII.4 
variants. In the USA, Farmington Hills (FH) (274) was ultimately associated with ~80% of 
norovirus acute gastroenteritis outbreaks (55).  Simultaneously in Europe, a new GII.4 
variant, GII.4b, emerged and caused outbreaks during the winter, spring and summer (151, 
167, 209). In 2004, the Hunter GII.4 variant was detected in Australia, Europe and Asia (25, 
138, 209), and may represent the next pandemic strain as explosive outbreaks of disease have 
recently been associated with this GII.4 genotype worldwide (25). Sakai represents a neoteric 
GII.4 outbreak strain associated with outbreaks in healthcare facilities in Southeast Asia 
(187) and may represent a unique geographically confined cluster.  The evolutionary 
mechanisms governing the persistence and epidemic spread of the GII.4 viruses in human 
populations are unknown. 
 Expression of the Norovirus ORF2 protein produces virus-like particles (VLPs) 
and the Norwalk virus (NV) X-ray crystal structure indicates that dimer formation is required 
to form the higher order structure comprised of 180 subunits (212). The monomer has two 
domains known as the shell domain (S) which forms the inner core and the protruding 
domain (P), linked by a flexible hinge. P domain forms prominent protrusions that extend 
away from the structure (212) and is subdivided into P1 subdomains (residues 226-278 and 
406-520) which functionally flank the P2 mostly surface exposed region (residues 279-405) 
(212). 
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 Mutational analysis of the surface exposed P2 domain supports its role in HBGA 
binding (150, 248, 250), suggesting that it contains the determinants of strain specificity, 
receptor binding (34, 212, 249, 251, 263) and potential neutralizing antibody recognition 
sites (33, 150). More recently, the complex structures of the P-domain of a GII.4 virus, 
VA387, in complex with HBGA trisaccharide A- and B- antigens revealed a ligand 
interaction site in the P2 subdomain where specific capsid residues form a strong hydrogen 
bond network with the α-fucose group of the trisaccharide (30). A second interaction site on 
the VA387 P domain was predicted to stabilize binding and enhance ligand affinity by weak, 
long distance interactions with the β-Gal ring of the trisaccharide (30). 
 In this manuscript, we show that the GII.4 noroviruses are evolving linearly over 
time and map the antigenic variation onto the capsid structure. Using a time-ordered 
panel of GII.4 VLPs from 1987-2005, we demonstrate that specific changes in the 2nd 
interaction domain regulate carbohydrate binding patterns, which change over the 20 year 
interval. Using serum from human outbreaks in 1988 and 2000 and murine antisera, we 
use ELISAs and an in vitro carbohydrate blockade as a surrogate neutralization assay to 
demonstrate that the noted variation alters the serologic and blockade responses 
consistent with a model of antigenic drift. Our data suggest a model of molecular evolution in 
which norovirus GII.4 strains persist by evolving novel carbohydrate binding 
domains over time in response to immune driven selection and antigenic drift in the 
receptor binding regions of the P2 subdomain. The data suggest that vaccines are 
feasible but must be reformulated every few years as epidemic replacement strains 
emerge and sweep through human populations. 
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Materials and methods 
Sequences and Sequence Analysis.  Eighty-eight full-length GII.4 capsid amino acid 
sequences were downloaded from GenBank and aligned by ClustalXv1.83 (35) using the 
PAM distance matrix and default parameters. The alignment was refined manually, and 
variable sites were exported in table format and ordered by time. Columns that contained a 
single amino acid difference were removed as potential sequence errors. Five distinct clusters 
were identified and associated with outbreak years, and representative viruses from each 
cluster were selected, and analyzed by Bayesian inference of phylogeny using Mr. Bayesv3.1 
under default settings (226). Trees were viewed using TreeViewPPC version 1.6.6 (195). The 
nucleotide sequences were aligned as codons using the program PAL2NAL (245) which 
aligned the corresponding nucleotide sequences based on the amino acid alignment. Positive 
selection analysis was conducted using HyPhy with the Fixed Effects Likelihood parameter 
(135, 211) under the TrN model. 
VEE Replicon Particles (VRPs) and norovirus Virus-like Particles (VLPs).  Capsid gene 
constructs for each of the representative strains were designed and synthesized as reported 
previously (46). Briefly, the ORF 2 genes of GII.4-1997 (LVNC1) (149) and GII.4-2002 
were derived from RT-PCR products from outbreak stool samples collected in 1997 and 
2004 (265) while the ORF2 genes of GII.4-1987, GII.4-2004 and GII.4-2005 were 
synthesized commercially by BioBasic (https://www.biobasic.com/index.php), and then 
inserted directly into the VEE replicon vector for the production of VRPs (VRP-GII.4-1987, 
VRP-GII.4-1997, VRP-GII.4-2002, VRP-GII.4-2002a, VRP-GII.4-2004, VRP-GII.4-2005) 
(11, 149). The VLPs were expressed in VRP-infected BHK cells, purified and visualized by 
negative staining EM (11, 149). 
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Carbohydrate Binding Assays.  VLP binding to synthetic HBGAs was determined 
using Neutri-avidin coated plates (Pierce, Rockford, IL) treated with 10µg/ml 
biotinylated carbohydrate (Glycotech, Gaithersberg, MD) for one hour and washed with 
PBS-0.05% Tween 20 before the addition of 1-2µg/ml VLP for 1.5 hours at 37 oC. VLP 
binding was detected as described above. Blockade assays included serum pretreatment 
of the VLP for 1 hour at 37oC before addition to the carbohydrate-bound plate. Assays 
using mouse antisera for blockade used rabbit polyclonal anti-GII VLP antisera followed 
by anti-rabbit IgG-AP (Sigma) for VLP binding detection. BT50 titers were defined as 
the lowest percentage of sera tested that blocked 50% of binding compared to levels 
determined in the absence of antibody pretreatment. Serum samples that did not reach a 
BT50 by the maximum % sera tested were assigned a BT50 value equal to 2X the 
maximum % sera tested for statistical analysis. 
Serology.  Samples from archived GII.4 outbreaks occurring in 1988 and 2000 were obtained 
from the Gastroenteritis & Respiratory Virus Laboratory Branch of the CDC, (Atlanta, 
GA). Any serum pair with a norovirus-positive stool sample or a ≥4-fold increase in anti-
LV87 or LV97 IgG response between acute and convalescent samples (seroconversion) was 
further studied for cross reactivity and blockade ability. Mice were immunized with VRP 
constructs as described (149). Both human and murine VLP-reactive serum IgG was 
measured by ELISA (145, 146, 149) using VLP-binding detection methods as described. 
Human and mouse anti-VLP serum IgG was compared to a purified IgG of known 
concentration for quantitation. 
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Statistical Analysis.  The Mann-Whitney 2-tail test was used to compare the median 
responses between groups for human samples. The One-way ANOVA was used to compare 
responses between murine immunization groups. 
 
Results 
Sequence Analysis and Bayesian Inference of Phylogeny 
An amino acid multiple alignment of 88 full length GII.4 capsid sequences was 
generated and columns of heterogeneity were exported as a table, and ordered by time. 
Five distinct evolutionary clusters were identified in these analyses and representative 
strains were selected from each cluster and associated with outbreak dates such that the 
Camberwell cluster which ranges from 1987-1992 is represented by GII.4-1987, the 
Grimsby cluster from 1994 to 2001 is represented by GII.4-1997, the Farmington Hills 
cluster from 2002 to 2004 is represented by GII.4-2002, the newly recognized Hunter 
cluster (2004-2006) is represented by GII.4-2004, and the most recent Sakai cluster 
(2004-2006) is represented by GII.4-2005 (Figure 3.1A). 
 The extent of diversity among the clusters of GII.4 viruses is approximately 2%, 
with a total sequence identity of 92% occurring between the earliest cluster, Camberwell, 
and the extant clusters, Hunter and Sakai. While variation was noted in the S, P1, and P2 
domains of the capsid, the majority of heterogeneity occurred within the P2 subdomain 
(Figure 3.1A). Of the two receptor interaction sites recently reported, site 1 is strictly 
conserved in all clusters, while the second site is highly variable at positions 393 through 
395 (VA387 numbering) (Figure 3.1A). Of note, strains occurring after the GII.4-1997 
cluster encode an inserted amino acid between positions 393 and 394 of VA387 (Figure 
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3.1A). 
 Four sites in P2 at positions 298, 372, 376, and 394/395 (site 394 in viruses of the 
GII.4-1987 and GII.4-1997 clusters and position 395 of all later clusters) were 
determined by HyPhy to be operating under positive selection. A second Farmington 
Hills isolate (GII.4-2002a) which differs from GII.4-2002 by a single amino acid 
difference in the P2 subdomain at positively selected residue 395 (Ala395 in GII.4-2002 
and Thr395 in GII.4.2002a) was identified for further evaluation (Figure 3.1A).  Analyses of 
the Bayesian phylogenetic tree in conjunction with the evolutionary profiles suggests that 
the GII.4 capsids evolved linearly over the last twenty years in a similar fashion as 
influenza (28). Bayesian inference confirmed that the evolution of each cluster was 
correlated with time, with the Camberwell cluster being near the root of the tree and the 
Hunter and Sakai clusters shown to have evolved linearly from the earlier clusters (Figure 
3.1B). While some clusters persisted for ~8 years, new clusters appear to have evolved 
from subsequent populations every 3-5 years (Figure 3.1C), with the new strain eventually 
becoming the predominant strain. Taken together, these analyses suggest that the GII.4 
viruses evolved linearly over the last twenty years, with intense heterogeneity within the 
P2 region of the capsid sequence facilitating the emergence of new predominant strains. 
 Evolutionary analyses showed that the ligand binding residues reported for site 
1 (30) were strictly conserved in the GII.4 viruses, while one amino acid position in the 
second interaction site at position 393 was highly variable among the representative 
viruses. Further, three of the four P2 sites operating under positive selection occur near 
the two interaction sites, with position 395 being an important residue adjacent to the 
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second interaction site.  We hypothesize that microevolution in site 2 alters receptor 
specificity, and we predict that GII.4-2002 and GII.4-2002a will have different binding 
characteristics, facilitated by a single amino acid difference in the P2 subdomain.   
 To further characterize the binding characteristics of the GII.4-2002 viruses as well as 
the other representative viruses, the Camberwell GII.4-1987, Grimsby GII.4-1997, 
Farmington Hills GII.4 2002 and 2002a, Hunter GII.4-2004 and Sakai GII.4-2005 ORF 2 
sequences were inserted directly into the VEE replicon vector and all six replicons produced 
abundant 40nm VLPs following visualization by negative strain EM techniques (data not 
shown).  Synthetic HBGA binding assays revealed differences in the patterns of carbohydrate 
binding for the five VLPs, where GII.4-1987 VLPs bound strongly to H type 3 and less well 
to LeY. Concordant with these findings, GII.4-1997 bound H type 3, but also bound 
efficiently to LeY, A and B. In contrast, GII.4-2002 bound strongly to LeY and less 
efficiently to H type 3, while GII.4-2002a, GII.4-2004 and GII.4-2005 did not bind any 
carbohydrate tested (data not shown). Concordant with the predicted remodeling of the 
receptor binding pocket, these data indicate that sequence variation in and around the 
second carbohydrate stabilizing domain of ORF 2 alters VLP structure and modulates 
HBGA binding patterns within a genotype, resulting in changes in VLP-carbohydrate 
ligand receptor binding over time. 
 
Serologic Relationships among the GII.4 VLPs 
Sera and stools were collected from infected subjects from GII.4 outbreaks during the 1988 
and 2000 norovirus outbreak seasons.  Both the acute and convalescent serum samples cross-
reacted with each of the time-ordered VLPs, regardless of outbreak date. 
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Within both outbreaks, the reactivity to GII.4-1987 and GII.4-1997 VLP was equivalent. 
However, the 1988 outbreak convalescent sera titer to GII.4-2002 (P=0.02), GII.4-2004 
(P<0.01) and GII.4-2005 (P<0.01) was significantly and proportionately reduced as 
compared to LV87 (Figure 3.2A). Comparison of the IgG titer across VLPS also 
demonstrated a significant negative trend in reactivity of 1988 outbreak convalescent sera 
and VLPs circulating at later times (P<0.001). Sera collected in 2000 no longer differed in 
reactivity to GII.4-2002, GII.4-2004, or GII.4-2005 compared to GII.4-1987, consistent with 
exposure to progressively different strains over the lifetime of individuals (Figure 3.2B). 
 
Blockade Titer Varies Over Time 
As a robust cell culture system is not available, we utilized a surrogate 
neutralization assay exploiting the ability of serum IgG to block norovirus VLP 
interaction with putative HBGA receptors (91, 149). Figure 2.3 shows the median % 
control binding of VLP in the presence of sera compared to the binding of VLP in the 
absence of antibody pretreatment. Although the acute serum samples reacted with GII.4- 
1987, GII.4-1997 and GII.4-2002 in the IgG EIA, none of the acute samples collected 
blocked the VLP-HBGA interactions, even at high serum concentrations (data not 
shown). However, convalescent serum collected in 1988 completely blocked GII.4-1987 
and GII.4-1997 interaction with H type 3 but was significantly less able to block GII.4- 
2002 VLP interaction with LeY (P=.016) (Figure 3.3A). The median concentration of 
sera needed to block VLP-HBGA binding by 50% (BT50) was 0.13% for GII.4-1987 and 
GII.4-1997 interaction with H type 3 (Figure 3.3B). These titers were significantly 
different from the sera titer (>0.25%) needed to block GII.4-2002-LeY interaction 
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(P=0.03). Convalescent serum collected in the 2000 GII.4 outbreak completely and 
equivalently blocked GII.4-1987 and GII.4-1997-H type 3, and GII.4-2002-LeY 
interactions (data not shown). BT50 titers were 0.06%, 0.04% and 0.07% for each VLP 
respectively, indicating, no significant differences between any of the GII.4 VLPs (Figure 
3.3B). 
 
GII.4 Serologic Relationships Using Murine Sera 
Analyzing human serum samples is complex as norovirus exposure histories are 
unknown and serologic relationships between strains are not well defined (149). Our data 
suggested a varying ability of serum collected from infected individuals to block the 
GII.4-2002 strain binding to LeY or H type 3, indicating that exposure history may affect 
antibody response to a current norovirus challenge, making it more complex to decode 
the antigenic relationship between the time-ordered GII.4 strains in humans. Further, our 
previous work demonstrated that animals immunized with a cocktail of norovirus VRPs 
developed blockade-competent IgG that not only blocked immunizing strains, but also 
weakly blocked HBGA-binding of unrelated strains that were not included in the 
immunizing cocktail (149). As mice are not susceptible to human norovirus infection, they 
provide a clean background in which to study antigenic relatedness between unique 
timeordered norovirus VLPs. Therefore, we immunized naive mice with VRPs encoding the 
variant ORF2 of each of the GII.4 strains and collected sera for testing IgG cross reactivity 
and blockade ability. As seen with human outbreak sera, antisera from mice immunized with 
VRP- GII.4-1987 or GII.4-1997 reacted equivalently to GII.4-1987 and GII.4-1997 VLPs 
and to a significantly lesser degree to GII.4-2002, GII.4-2004 and GII.4-2005 VLPs 
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(P<0.05), indicating that antigenic sites are maintained more completely in early GII.4 strains 
while becoming variable in later emergent strains (Figure 3.4). Immunization with VRP- 
GII.4-2002 elicited a strong homotypic response with weaker cross-reactivity to all of the 
other strains tested (P<0.01)). Interestingly, antisera from GII.4-2004 and GII.4-2005 
immunized mice had uniformly low levels of heterotypic antibody to all strains tested 
compared to the homotypic response (P<0.01). Murine cross-reactive IgG data support the 
trend seen with human serum samples indicating clear serologic differences between the 
early and late GII.4 strains.  To further test this hypothesis, blockade experiments were 
performed using mouse sera. Blockade experiments provide a biological measure of the 
ability of antiserum to block the interaction of a specific VLP with a carbohydrate ligand 
partner, a surrogate assay for neutralization (91, 149). GII.4-1987 and GII.4-1997 interaction 
with H type 3 was blocked by sera from mice immunized with VRPs expressing GII.4-1987 
and GII.4-1997, weakly blocked by sera from GII.4-2004 and GII.4-2005, and minimally 
blocked by GII.4-2002 VRP-immunized mice (Figure 3.5A-C). GII.4-2002-LeY interaction 
was most completely blocked by antisera from mice immunized with VRPs expressing GII.4-
2002, efficiently blocked with GII.4-2004 and GII.4-2005 sera, but not blocked with antisera 
from VRP- GII.4-1987 or GII.4-1997 immunized mice. Our inability to identify 
carbohydrates that bound GII.4-2004 and GII.4-2005 precluded the testing of the ability 
of sera from historic strains to block their binding to ligands.  Median BT50 titers for 
blockade of GII.4-1987 and GII.4-1997 were equivalent for all immunization groups. 
Significantly more anti-GII.4-2002 sera (>5%) was needed to reach BT50 of GII.4-1987 
(P<0.05) and GII.4-1997 (P<0.01) (Figure 3.5D), as compared to all other strains. 
Correspondingly, BT50 of GII.4-2002 binding to LeY required significantly more anti-GII.4-
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1987 and GII.4-1997 sera (>5%) (P<0.01) compared to homotypic antibody BT50 at 0.31% 
serum (Figure 3.5D). None of the antisera generated to the GII.4 panel blocked NV-H type 3 
interactions at any of the serum concentrations tested (data not shown). These data support 
the hypothesis that not only does antigenic drift occur in the capsid region of GII.4 norovirus 
strains over time, but that the variation significantly influences the ability of pre-existing herd 
immunity to neutralize exigent strains. 
 
Discussion 
Globally, noroviruses are the 2nd most important cause of severe viral gastroenteritis in young 
children, cause 20% of endemic diarrheal disease in families, cause travelers diarrhea in all 
ages and are especially virulent in the elderly (53, 107, 134). Our phylogenetic and 
evolutionary analyses in ORF2 suggest that the GII.4 viruses have evolved linearly over the 
last twenty years in a similar fashion as influenza, with serial replacements occurring every 
~3-5 years, resulting in five distinct evolutionary clusters (Figure 3.1). Sites of heterogeneity 
predominantly occurred in the exposed P2 subdomain in and around the two carbohydrate 
interactions sites that form the receptor binding pocket (30, 150, 212). Site 2 was the most 
variable region in our model and changes in this region affected carbohydrate binding 
profiles. Our empirical studies suggest that escape from herd immunity may represent the 
selective force that drives antigenic variation within and around the receptor binding pocket 
on the surface of the GII.4 P2 domain of ORF2. Variation within the receptor binding 
domain in ORF2 variants is likely under strong co-selection to recognize variant HBGA 
carbohydrate receptors for docking and perhaps entry, allowing the GII.4 noroviruses to 
persist and simultaneously circumvent highly penetrant susceptibility alleles that are common 
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in human populations. Alternatively, as the current contemporary strains don’t bind any 
carbohydrates tested, the receptor binding pocket may evolve to recognize other fucosylated 
carbohydrates or proteins for docking and entry. 
 In influenza, herd immunity, mediated primarily by neutralizing IgG antibodies (37), 
positively selects for antigenic variation in HA, although the exact effect of individual 
mutations on antigenicity is complex. Mutations may occur in one or more of five 
neutralizing epitopes or in the sialic acid binding site in the HA glycoprotein, thus 
selecting for replacement strains that circumvent antibody neutralization (28). Among 
noroviruses, the concept of herd immunity is controversial.  Early human challenge 
studies suggested that strain-specific long-term immunity can be elicited following 
challenge, as 50% of volunteers did not become infected after multiple challenges with 
NV. However, this same study demonstrated that in some volunteers only short term 
immunity is evident (203, 281). In more recent studies, we and others have argued that 
long-term immunity is possible and that pre-exposure history may influence the duration 
of the immune response against individual strains (145, 146, 234). Although early mucosal 
IgA (146) and T cell (145) responses may include components of a long-term protective 
immune response in uninfected, challenged volunteers, the role of serum IgG in 
protective immunity remains controversial. Norovirus challenged volunteers or outbreak 
patients mount strong serum IgG antibody responses that block carbohydrate receptor- 
VLP interactions in a genogroup-specific manner in a surrogate neutralizing assay 
potentially representing a component of a long-term protective immunity (91, 149). 
However, IgG antibody levels are usually too low in pre-challenge sera, or in salivary or 
fecal samples for assaying by these methods. Importantly, the years following the 
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emergence of a new epidemic strain in Europe were characterized by decreased numbers 
of outbreaks, speculated to be associated with increased herd immunity (234). If herd 
immunity drives GII.4 norovirus evolution, these data predict that serologic relationships 
among temporal GII.4 epidemic strains should change over time. 
 Although GII.4-1987 and GII.4-1997 VLPs differed by seven amino acids, no 
significant differences in antibody reactivity were noted with sera derived from humans 
and experimentally immunized mice, suggesting that the few amino acid changes didn’t 
significantly alter variation between the two strains. We speculate that pre-1995 
Camberwell-like strains typically produced low level endemic disease and that these 
mutations promoted epidemic spread of the post 1996 Lordsdale/Grimsby strains in 
human populations, perhaps by allowing for more efficient binding with additional 
HBGA ligands on mucosal surfaces. The epidemic spread of the GII.4-1997-like strains 
in human populations may have subsequently allowed for higher levels of herd immunity 
and selected for more rapid antigenic changes in future strains. Influenza virus shows 
similar trends in that genetic variation oftentimes, but not always, tracks with antigenic 
variation, because some mutations result in disproportionately large antigenic changes 
(235). However, global serologic responses between GII.4-1987/1997 and GII.4-2002 
demonstrated significant antigenic differences, reflecting the increased number of variant 
residues in this later serotype. Concordant with these findings, GII.4-2004 and GII.4- 
2005 epidemic strains were also serologically quite distinct from GII.4-1987 and GII.4- 
1997 and to a lesser extent distinct from GII.4-2002. Thus, epidemic replacement strain 
ORF2 capsid sequences were antigenically related yet distinct due to antigenic drift. At 
this time, surveillance data is not sufficiently robust to determine whether the emergence 
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of replacement epidemic strains drives earlier isolates to extinction as seen with influenza 
viruses or whether these strains continue to persist at low levels and cause sporadic 
endemic disease in previously unexposed, susceptible individuals. 
 All outbreak sera blocked carbohydrate binding of GII.4-1987 and GII.4-1997 
VLPs, yet only 2000 sera could completely block binding of GII.4-2002 VLP. 
Interestingly, the mouse anti-GII.4-2004 and GII.4-2005 sera more efficiently blocked 
binding of GII.4-1987 and GII.4-1997 to H type 3 than GII.4-2002 sera. 
However, amino acids at positions 329, 355, and 365 in GII.4-2004 and GII.4-2005 are 
the same as GII.4-1987 and GII.4-1997, but not GII.4.2002, which implies that these sites 
may account for the cross blockade of anti-GII.4-2004 and anti-GII.4-2005 sera to GII.4- 
1987 and GII.4-1997 carbohydrate binding. These sites may also be important determinants 
of antigenic variation within the GII.4 genocluster.  The GII.4-2004 and GII.4-2005 strains 
didn’t bind any HBGA carbohydrates tested, suggesting that their carbohydrate ligands are 
either not represented within the panel of biotinylated HBGA carbohydrates available for 
testing or they utilize non-HBGA mediated pathways for entry. Thus, over time, it is 
reasonable to predict that noroviruses have the capacity to utilize the large number of related 
HBGAs as receptors. The potential plasticity in the carbohydrate binding site would likely 
accommodate sufficient amounts of antigenic drift to escape herd immunity, while 
simultaneously altering strain susceptibility to the many different human alleles that regulate 
HBGA expression. 
 Fucose ligand binding site 1 was strictly conserved in the GII.4 viruses, including 
paradoxically, exigent strains that do not bind saliva or any carbohydrate tested. In 
contrast, the secondary interaction site appears to facilitate receptor specificity as binding 
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characteristics of the time ordered VLP panel varied extensively. In the secondary 
interaction site, positions 390, 391, 392 and 443 were conserved throughout the GII.4 
strains while sites 393, 394 and 395 were variable. In two instances, binding characteristics 
could be directly correlated to residue changes within this region. First, based on our 
structural models, we predicted that carbohydrate binding would differ between the 
Camberwell cluster and the Grimsby cluster (including VA387) based primarily upon an Asp 
to Asn change at position 393 in site 2.  In agreement with our hypothesis, binding between 
GII.4-1987 and GII.4-1997 was different. The substitution of an Asp at position 393 appears 
to sterically hinder or otherwise alter binding of the larger tri-saccharide moieties of A- and 
B- antigens, as the Camberwell representative VLP binds H type 3 and Le Y, but not A or B. 
In contrast, both GII.4-1997 and VA387 bind H type 3, Le Y, A, and B (113, 149); and they 
encode Gly and Asn at the 393 position, respectively. Interestingly, our data suggest that the 
primary impact of the mutations that occurred between the Camberwell and Grimsby clusters 
led to an expansion of receptor specificity as representative strains GII.4-1987 and GII.4- 
1997 were indistinguishable antigenically. In the second case, a Thr at position 395, as 
exhibited by GII.4-2002a, renders this VLP refractory to binding of any tested carbohydrate. 
Alanine at this position facilitates binding of LeY and H type 3 in GII.4-2002. These results 
are also in agreement with our hypothesis that microevolution in site 2 alters receptor 
specificity. Of note, HBGAs used to determine binding in this study were biotinylated and 
attached to Neutri-avidin coated plates. These synthetic HBGAs, although a useful reagent 
for determining binding, lack the complex structures often found in vivo. Larger  
polysaccharide moieties likely play a crucial role in receptor affinity and avidity, by 
interacting directly with the second interaction site. 
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 The data presented in this manuscript provide support for the hypothesis that 
antigenic drift and receptor switching may function as one mechanism to maintain the 
GII.4 noroviruses in the presence of human herd immunity. Our data suggest that strain 
specific protective immunity is possible and that vaccines and immune prophylaxis must 
be formulated to protect against contemporary strains. As shown with influenza virus, 
new therapeutic formulations will be necessary every 3-5 years or so. Moreover, 
continued norovirus surveillance will be an essential component necessary for 
maintaining vaccine and drug effectiveness. At this time, it is unclear whether GII.4 
noroviruses will continue to predominate as the major cause of epidemic gastroenteritis 
worldwide, or like influenza virus, undergo an antigenic shift to a variant GI or GII 
genocluster that is currently circulating at low levels in human populations, or a new 
strain introduced from zoonotic pools. However, important caveats must be considered 
when evaluating this work. While it is clear that the mucosal compartment has high 
concentrations of IgG, carbohydrate-VLP blockade assays use serum IgG while mucosal 
IgA and IgG responses may be more important in protective immunity (146, 149). 
Unfortunately, the mucosal antibody concentrations are usually not only insufficient for 
blockade studies, but mucosal antibodies were not obtained during the time-ordered 
norovirus outbreaks, preventing the testing of this possibility. In the absence of a robust 
cell culture model, blockade studies themselves represent a surrogate assay for 
neutralization, and it is likely that antibodies might neutralize virus infectivity by binding 
to regions distinct from the carbohydrate binding pocket or even outside of P2 and inhibit 
other steps in entry as shown with West Nile virus among others (189).  Additional studies 
will be needed to prove these hypotheses and to determine if the evolutionary patterns are 
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unique to the GII.4 noroviruses or represent a general evolutionary pattern of the Norovirus 
family. Our study, however, clearly articulates a predictive model for future empirical studies 
investigating the relationship between antigenic change, norovirus pathogenesis, vaccine 
design, and human disease. 
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Figure 3.1  
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Evolutionary analysis of representative GII.4 strains from 1987 to present.  
Panel A. Five distinct evolutionary patterns were observed in the mutational 
profiles of the GII.4 sequences, and these are represented by: GII.4-1987, GII.4-1997, 
GII.4-2002, GII.4-2004, and GII.4-2005. Amino acids present in the late 1980s 
Camberwell cluster (GII.4-1987) are highlighted in yellow, changes that occurred to form 
the Grimsby (GII.4-1997) cluster are noted in red, changes associated with the 
Farmington Hills (GII.4-2002) cluster are blue, changes specific to the Hunter cluster 
(GII.4-2004) are green and substitutions important for the Sakai cluster (GII.4-2005) 
cluster are orange. The P2 region is highlighted in dark blue beneath the amino acids, 
with the N-terminal and C-terminal flanking regions of heterogeneity noted in black for 
the Shell domain and brown for P1. Lavender sites represent residues that hydrogen 
bond to the ligand at site 1, framed residues have been predicted to interact in a second 
stabilization domain. Amino acids operating under positive selection within P2 are shown 
with a plus sign in the dark blue row marking the P2 domain. Residues that are not 
colored represent single amino acid changes that were seen in other strains in the cluster. 
Strain VA387 is included for comparison, as it is a Grimsby-like virus with a solved 
crystal structure of the capsid. Bold residues represent amino acids which reverted to a 
residue from a previous cluster. Panel B. Phylogenic reconstruction of the GII.4 capsid 
sequence. Seventeen sequences selected to represent the five clusters were optimally 
aligned with ClustalX and the alignment was used to generate a phylogenetic by 
Bayesian Inference using Mr. Bayes3.12. Node confidence is presented as posterior 
probabilities. This tree shows a linear evolutionary relationship among the five clusters 
indicated by the representative sequences (shown in white text on black background). 
This observation supports the hypothesis that the GII.4 strains are evolving via episodic 
antigenic drift. Panel C. Analysis of the representative clusters over time. Although the 
sequence information available from GenBank is sporadic and does not provide enough 
information to completely reconstruct the evolution and emergence of the GII.4 strains, 
our data suggest that episodic antigenic drift facilitates linear replacement of epidemic 
GII.4 strains every 3-5+ years. A comparison of the span of each cluster indicates that 
each ranges from 3-8 years, with overlap likely occurring between clusters. This suggests 
that epidemic strains emerge from one cluster and eventually out-compete with the extant 
strain to evolve a new cluster. There are not enough sequences to fully establish the 
cluster boundaries and the extant clusters are likely still evolving. Yellow, sequences 
from Camberwell (GII.4-1987) cluster; red, sequences from Grimsby cluster (GII.4- 
1997); blue, sequences from the Farmington Hills (GII.4-2002) cluster; green, sequences 
from the Hunter cluster (GII.4-2004); and orange, sequences from the Sakai cluster 
(GII.4-2005). 
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Figure 3.2 
 
A. 
 
B. 
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Anti-GII.4 VLP IgG titers. The median geometric mean titer of anti-VLP 
IgG (g/ml) for acute (dotted bars) and convalescent (solid bars) serum samples was 
assayed for the 1988 (Panel A), and 2000 (Panel B) GII.4 outbreaks and the percentage 
of subjects who seroconverted to each VLP determined. * Significant increase in titer 
between acute and convalescent samples. ^ Significant difference between convalescent 
titers compared to LV87. Error bars represent the range of the data. 
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Figure 3.3 
A. 
 
 
B. 
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Blockade of GII.4 VLPs binding to HBGA by outbreak sera. Convalescent 
serum collected from a GII.4 outbreak in 1988 (Panel A) were assayed for blockade of 
GII.4-1987 and GII.4-1997 interaction with H type 3, or GII.4-2002 interaction with LeY 
bound to avidin-coated plates and the median % control binding calculated compared to 
the no-serum control. Error bars represent SEM. The box plot (Panel B) shows the 
median % sera needed for BT50 for each outbreak and each VLP; the whiskers show the 
25-75 percentiles and the error bars represent the minimum and maximum. Outbreak 
sera BT50 responses significantly different from GII.4-1987 or GII.4-1997 are marked 
with an *. 
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Figure 3.4 
 
 
 
Murine antisera cross-reactivity to GII.4 VLPs. Mice were immunized by 
footpad inoculation on day 1 and day 21with 2.5 x 106 IU VRPs expressing GII.4-1987, 
GII.4-1997, GII.4-2002, GII.4-2004, GII.4-2005 ORF2 (N=4 per inoculation group). 
Antisera were collected on day 35 and analyzed for homotypic and heterotypic IgG 
responses to each VLP by ELISA. Antibody titers are represented as geometric mean 
µg/ml serum IgG. 
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Figure 3.5 
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D. 
 
 
 
Murine antisera blockade of GII.4 VLP binding to HBGAs. Antisera 
collected from mice immunized against each GII.4 ORF2 were assayed for blockade of 
GII.4-1987 (Panel A) and GII.4-1997 ( Panel B) interaction with H type 3, or GII.4-2002 
(Panel C) interaction with LeY bound to avidin-coated plates and the median % control 
binding calculated compared to the no-serum control. The box plot (Panel D) shows the 
median % sera needed for BT50 for each antisera and each VLP; the whiskers show the 
25-75 percentiles and the error bars represent the minimum and maximum. Antisera 
groups that did not block 50% VLP-HBGA binding at the highest serum concentration 
tested (5%) was assigned an arbitrary value of 10%. VLP requiring significantly less 
serum for BT50 compared homologous sera are designated with an *.
  
 
 
 
 
CHAPTER IV. 
 
Identification of unique norovirus CD4+ T cell epitopes in Norwalk virus and 
Farmington Hills virus capsid sequences 
 
Abstract 
 
 The mechanisms governing norovirus immunity in humans are unknown.   
Homotypic antibody responses following norovirus infection have been characterized; 
however, T cell responses remain largely undefined.  We immunized mice with alphavirus 
vectors expressing Norwalk virus or Farmington Hills virus-like particles to examine T cell 
responses following norovirus antigen exposure.  Depletion of splenic CD4+ or CD8+ T cells 
followed by stimulation with norovirus VLPs revealed a predominantly CD4+ T cell 
response.  CD4+ T helper 1 (TH1) and TH2 cell-specific cytokine profiles were examined, and 
splenocytes secreted high amounts of interferon-γ (IFN-γ) following stimulation, indicating a 
TH1-mediated response.  Surprisingly, stimulation with norovirus VLPs from heterologous 
strains also resulted in high IFN-γ secretion, suggesting T cell responses may be cross-
reactive between norovirus strains.  Stimulation of splenocytes with overlapping peptides 
from complete libraries of the NV or FH capsid proteins further revealed specific amino acid 
sequences containing T cell epitopes that were conserved within genoclusters and/or 
genogroups.  Identification of unique strain-specific epitopes will allow detailed studies into 
the cross-reactive responses elicited by genetically related and unrelated norovirus strains 
and provide insight into T cell mediated norovirus immunity. 
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Introduction 
 Norovirus infection is characterized by the induction of both humoral and cellular 
immune responses.  Humoral immunity in humans following norovirus infection has been 
described in detail to a limited number of norovirus strains (52, 70, 86, 145, 259).  Humans 
mount specific antibody responses to the infecting strain, which bears limited cross-reactive 
yet undefined epitopes to other strains within or across genogroups (180, 259).  Short-term 
immunity following homologous norovirus challenge has been documented, but long term 
immunity remains controversial (119, 203).   Furthermore, no studies have demonstrated 
cross-protection following heterologous norovirus challenge to date (281).  While susceptible 
individuals can become reinfected with multiple norovirus strains throughout their lifetime, 
the mechanism of short-term protection and the impact of previous exposures on 
susceptibility to reinfection remain unknown.   
 The role of T cells in controlling norovirus infection also remains largely undefined 
and unexplored.  A single comprehensive study detailing immune responses in Snow 
Mountain virus-infected individuals revealed that CD4+ TH1 cells can be stimulated by VLPs 
to secrete IFN-γ and IL-2 (145).  Furthermore, heterologous stimulation from VLPs derived 
from different norovirus strains within but not across genogroups also induced significant 
IFN-γ production compared to uninfected individuals (145).  Vaccination of humans with 
VLPs also results in short-term induction of IFN-γ (247).   
 Because norovirus infection studies in humans are confounded by previous exposure 
histories, the use of inbred mice maintained in pathogen-free environments allow for the 
study of norovirus immune responses on a naive background.  While mice cannot be infected 
with human norovirus strains, VLP vaccines induce comparable immune responses that can 
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be measured and studied.  Mice immunized orally or intranasally with VLP vaccines in the 
presence of adjuvant similarly induced CD4+ IFN-γ responses in Peyer’s patches and spleen 
(178, 207).  Induction of CD8+ T cells and secretion of the TH2 cytokine IL-4 were separately 
noted; however, it is unclear if these responses were influenced by the presence of VLPs or 
coadministered vaccine adjuvants (178, 207).   
 To advance our understanding of the scope of the cellular immune response, we 
immunized mice with VEE replicon particles (VRPs) expressing norovirus VLPs derived 
from the Norwalk (GI.1) or Farmington Hills (GII.4) strains and analyzed splenocytes for T 
cell subset activation, cytokine secretion, heterologous VLP stimulation and epitope 
identification.   
 
Materials and methods. 
VRP immunization.  VRPs were produced as described in Harrington et al. (93).  6 week old 
BALB/c mice (N=4/experiment) were immunized with 2.5 x 106 VRP expressing Norwalk 
virus (NV) VLPs, Farmington Hills virus (FH) VLPs, influenza hemagglutinin (HA) or a 
short noncoding sequence (null VRP) at day 0 and 21.  Sera and tissue were harvested on day 
42.   
Splenocyte stimulation.  Spleens were harvested three weeks post-boost.  Individual 
splenocytes were obtained by manual separation, filtration, and lysis of red blood cells.  
CD4+ and CD8+ T cells depletions were performed using QuadroMACS magnetic bead 
separation (Miltenyi) per manufacturer’s instructions.  Cells were cultured at 1 x 106 
cells/well in 96 well cell culture treated plates in 100 µl complete RPMI media containing 
one of the following:  VLP (1 µg/ml), inactivated MNV or VRP (1 µg/ml), individual NV or 
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FH peptides or peptide pools (1 µg/ml each), Concanavalin A (5 µg/ml), or no stimulant.  
Splenocytes were cultured for 48 h at which time supernatants were harvested and stored at -
80° C.  VLPs were produced as described in LoBue et al. (149).  Complete overlapping 
15mer (+5) peptide libraries spanning the entire NV and FH capsids were synthesized at the 
UNC peptide synthesis core facility.  Lyophilized peptides were resuspended in PBS; 
insoluble peptides were further dissolved in 1:1 acetonitrile:PBS. 
ELISA and cytometric bead array.  Sera samples were tested for IgG subtype reactivity to 
NV or FH VLPs by indirect ELISA as previously described (149).  Purified IgG1 (Sigma) or 
IgG2a (Sigma) were used as assay standards.  IFN-γ concentrations in splenocyte culture 
supernatants were determined by EIA (BD Pharmingen); TNF-α, IL-2, IL-4, and IL-5 
concentrations were determined using the TH1/TH2 cytokine cytometric bead array (BD 
Pharmingen) per manufacturer’s instructions.  T-tests were performed to measure statistical 
differences between sample groups of two.  All other statistics were performed using One-
way ANOVA and Tukey post-test. 
Sequence alignments.  Stimulatory sequences identified using 15-mer peptides within the NV 
and FH capsids were aligned with sequences representing the entire VLP panel using Vector 
NTI software. 
 
Results 
CD4+ T cells exhibit heterologous VLP stimulation. 
 Comprehensive T cell cross-reactivity analyses have not been reported across 
norovirus strains, which can differ genetically by >50% in the capsid amino acid sequence 
(75).  Because human samples from heterologous outbreaks with which to conduct these 
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studies are scarce, we have cloned the antigenic ORF2 capsid gene from multiple 
heterologous strains into alphavirus vectors that, when expressed, form VLPs that can be 
simultaneously used as antigenic reagents and to induce immune responses in mice.  Cellular 
immune responses following norovirus immunization with VRP are also unknown. 
 Previous reports describe CD4+ TH1-like immune induction following norovirus 
infection in humans and VLP immunization in mice (145, 178). To determine if CD4+ or 
CD8+ T cells are responsible for IFN-γ secretion following immunization with VRP-NV, 
splenocytes were depleted of CD4+ or CD8+ T cells.   Depleted cell suspensions were 
stimulated with NV VLPs, and unstimulated cells were cultured in parallel.  Supernatant was 
then collected, IFN-γ secretion measured by EIA, and background IFN-γ levels from 
unstimulated cultures subtracted.  Splenocytes depleted of CD8+ T cells secreted significantly 
higher amounts of IFN-γ than CD4+ depleted splenocytes (P<0.001; Fig. 4.1), suggesting 
IFN-γ secretion following VRP immunization are mediated by CD4+ cells. 
 To determine if T cell responses could be induced by heterologous VLP stimulation, 
splenocytes from VRP-NV immunized mice were harvested and cultured with homologous 
NV VLPs or GI VLPs derived from Southampton (SH), Chiba (CV), or Desert Shield (DS) 
strains, GII VLPs derived from Snow Mountain (SM), Hawaii (HV), Lordsdale (LV), 
Toronto (TV), or M7 strains.  Unstimulated cells were used as negative controls.  
Supernatants were harvested after 48 h and tested for IFN-γ levels by EIA.  All GI VLPs and 
the one GII VLP induced significantly more IFN-γ secretion than unstimulated controls 
(P<0.01; Fig. 4.2).  Stimulation with other GII VLP did not induce IFN-γ levels different 
from stimulation with GI VLPs or negative controls.  Interestingly, heterologous GI 
stimulation was not different from homologous NV VLP stimulation.  These data suggest 
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that cross-reactive T cell responses to human norovirus strains can be induced following 
norovirus vaccination, with highest cross-reactivity to genetically related strains within a 
genogroup. 
 To determine if additional TH1 cytokines are also induced following VLP stimulation, 
supernatants from VRP-NV splenocyte cultures stimulated with NV VLP, heterologous GI 
VLPs (CV), heterologous GII VLPs (HV) were pooled and analyzed for secretion of 
TH1/TH2 cytokines TNF-α, IFN-γ, IL-2, IL-4, and IL-5 by CBA.  Homologous stimulation 
with NV VLPs resulted in secretion of the TH1 cytokines TNF-α (420 pg/ml), IFN-γ (1975 
pg/ml), and IL-2 (150 pg/ml) that were 2.7-, 8.4-, and 7.7-fold higher, respectively, than 
unstimulated controls (Table 4.1).  The TH2 cytokine IL-4 was induced to much lower levels 
(26.8 pg/ml) but was higher (3.4-fold) than unstimulated controls.  IL-5 secretion was not 
different between NV VLP and unstimulated cultures.  Fold-increase in cytokine levels 
following VLP stimulation compared to unstimulated controls closely mirrored those 
reported in human challenge studies from infected individuals compared to matched pre-
challenge controls (145).  Heterologous VLP stimulation induced cytokine profiles 
equivalent to homologous stimulation.  These data support previous findings that noroviruses 
induce TH1-type responses following antigen exposure. 
 To rule out non-specific stimulatory effects that may be induced by immunization 
with VRPs or stimulation with VLPs, mice were additionally immunized with VRP 
expressing the irrelevant hemagglutinin (HA) protein, and unimmunized mice were treated in 
parallel.  Splenocytes were stimulated with NV VLPs, UV-inactivated MNV (i-MNV), or i-
VRP and tested for IFN-γ secretion by EIA.    Splenocytes from VRP-NV immunized mice 
secreted significantly higher amounts of IFN-γ following VLP stimulation than VRP-HA or 
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unimmunized controls (P<0.001; Fig. 4.3).  However, control VRP-HA cultures also 
mounted a stimulatory response to NV VLPs compared to unimmunized mice (P<0.05), and 
both VRP immunized groups secreted equivalent and significant IFN-γ responses following 
stimulation with i-VRP (P<0.001), which acts as a non-replicating control for VEE-specific 
antigen stimulation, compared to unimmunized cultures.  These data suggest that VRP 
immunization results in specific IFN-γ responses to the VRP antigens and non-specific 
stimulation to VLPs. 
 
Stimulation with overlapping peptide libraries facilitates identification of T cell 
epitopes. 
 Because stimulation with VLPs did not reveal distinct cross-reactivity profiles to 
heterologous norovirus strains, we generated overlapping peptide libraries reconstituting the 
capsid protein of the Norwalk (GI.1) and Farmington Hills (GII.4) strains.  To determine if 
overlapping peptides could induce IFN-γ responses, we immunized mice with VRP-NV, 
VRP-FH, or null VRP and harvested splenocytes.  Splenocytes from unimmunized mice were 
treated in parallel.  Peptide libraries were sequentially divided into 5 overlapping pools, as 
shown in Table 4.2.  Splenocytes were stimulated with individual peptide pools composed of 
1 µg/ml each peptide and supernatants analyzed for IFN-γ by EIA or for additional TH1/TH2 
cytokines TNF-α, IL-2, IL-4, and IL-5 by CBA.  
 Splenocytes from VRP-NV immunized mice secreted significantly higher levels of 
IFN-γ following stimulation with NV peptide pool 1 (amino acids 1-105; Table 4.2) 
compared to other NV peptide pools or controls (P<0.001; Fig. 4.4a).  Immunization with 
null VRP, which does not express a transgene from its internal promoter, did not result in 
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splenocyte stimulation by NV peptides (Fig. 4.4a).  Sequential overlapping peptide pools 
consisting of two peptides each from NV peptide pool 1 were then used to stimulate 
splenocytes from VRP-NV immunized mice (Fig. 4.4b).  Pools containing NV peptide 9 
were positive for IFN-γ stimulation compared to all other overlapping peptides (P<0.01).  
Individual and sequentially overlapping peptides flanking peptide 9 were used to confirm this 
finding (Fig. 4.4c).  These data suggest a stimulatory CD4+ T cell epitope resides in the shell 
domain of the NV capsid within sequence FDLSLGPHLNPFLLH spanning amino acids 81-
95 (Fig. 4.4d). 
 Splenocytes from VRP-FH immunized mice secreted significantly higher levels of 
IFN-γ following stimulation with FH peptide pool 5 (amino acids 431-540; Table 4.2) 
compared to other FH peptide pools (P<0.001; Fig. 4.5a).  Cultures from mice immunized 
with null VRP or unimmunized controls were not stimulated by FH pool 5 (P<0.001; Fig. 
4.5a).  Sequentially overlapping pools and individual peptides within FH peptide pool 5 were 
then used to stimulate splenocytes from VRP-FH immunized mice as described above (Fig. 
4.5b-c).  Overlapping peptides 45-46 induced significantly higher levels of IFN-γ than 
peptides 46-47 (P<0.01) and all other overlapping groups (P<0.001; Fig. 4.5b).  Peptides 46-
47 and 47-48 also induced higher levels than all remaining overlapping groups (P<0.001).  
Upon closer evaluation, stimulation with individual or overlapping peptides containing 
peptide 46 induced significant IFN-γ responses compared to individual peptides 45 or 48 
(P<0.05) but not peptide 47 (Fig. 4.5c).  Stimulation with individual or overlapping peptides 
containing peptide 47 also induced IFN-γ secretion that was elevated above peptides 45 or 48 
stimulation but was not significant.  Together, these data suggest that peptides 46 and 47 
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spanning amino acids 461-485 of sequence CLLPQEWVQHFYQEAAPAQSDVALL in the 
P1 capsid domain contain 1-2 distinct T cell stimulatory epitopes (Fig. 4.5d).    
 Supernatants from original peptide pool stimulations analyzed by CBA also revealed 
elevated levels of TNF-α.  NV cultures stimulated with NV pool 1 and FH cultures 
stimulated with FH pool 5 secreted TNF-α 2-fold and 4-fold, respectively, over unstimulated 
pools, verifying a TH1-type response to peptide stimulation (Table 4.3).  Levels of IL-2 or the 
TH2 cytokines IL-4 and IL-5 were not elevated compared to unstimulated controls.  
Supernatants from null VRP and unimmunized control cultures were not stimulated by any 
norovirus peptide pools (data not shown).  Sera from VRP-NV and VRP-FH immunized 
mice were also tested for IgG subclass responses to NV or FH VLPs, respectively.  IgG1 and 
IgG2a titers were not different from one another in either immunization group (Figure 4.6).   
 
Stimulatory sequences are conserved within genoclusters and within genogroup I. 
 Stimulatory sequences identified within the NV and FH capsids by overlapping 
peptide stimulation were aligned with corresponding sequences representing our panel of 
VLPs.  Alignments revealed that sequences from the two NV-like strains tested within the 
GI.1 genocluster were completely conserved (Fig. 4.7A).  Furthermore, the stimulatory 
sequence was also highly conserved (86.7%) across all other GI sequences tested but was 
only 46.7% conserved among GII sequences.    
 Stimulatory FH sequences were highly conserved (88%) within the GII.4 genocluster 
among six strains tested, and the LV97, FH02, and FH04 sequences, representing three 
sequential evolutionary strains, were identical.  However, sequences to additional strains 
within GII (60%) or in GI (40%) were much less conserved (Fig. 4.7B). 
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 Not surprisingly, cross-stimulation of NV-immune splenocytes with stimulatory FH 
pool 5 and FH-immune splenocytes with stimulatory NV pool 1 did not result in IFN-γ 
secretion (Fig. 4.8), suggesting epitopes are not conserved across genogroups due to lack of 
sequence identity. 
 
Discussion 
 The components of protective immunity are unknown.  Understanding the 
mechanisms governing norovirus immunity is of utmost importance for development of 
norovirus vaccines and phophylactics.  Two vaccine strategies for norovirus immune 
induction are currently being evaluated: 1) Oral or intranasal administration of VLPs, and 2) 
VRP expression of VLP in vivo following subcutaneous administration.  Oral administration 
of VLP vaccines in humans, while safe and immunogenic, have been shown to induce very 
weak humoral and cellular immune responses to norovirus compared to norovirus infection 
(247).  In contrast, VRPs induce strong mucosal, cellular, and humoral immune responses to 
the expressed transgene, including norovirus VLP (45, 93, 256). 
 The emergence of literature documenting T cell responses following norovirus 
infection in humans or immunization in mice suggests that the cellular immune response is a 
potentially important component in noroviruses vaccine design.  Findings from our group 
and others support CD4+ TH1 T cells as likely candidates involved in the cellular immune 
response to norovirus challenge [(145, 178, 207, 247) and Table 4.1].  Our results did not 
show that VRP vaccination elevated serum IgG2a antibody subclass responses over IgG1 
levels (Fig. 4.6), which can be reflective of a TH1 response; however, TH1 cytokines IFN-γ 
and TNF-α but not TH2 cytokines were elevated in splenocyte culture supernatants following 
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stimulation with norovirus VLPs or peptides (Fig. 4.2, 4.4, 4.5, Table 4.1 and 4.3).  Previous 
work reported by our group also showed that VRPs induce IgA and IgG responses at mucosal 
surfaces that can block receptor binding (149).  Together these data suggest that norovirus 
vaccination by VRP may be a promising strategy for individuals in high exposure risk 
environments such as hospitals and primary care facilities.   
 To facilitate vaccine design, we have begun to characterize T cell responses to 
homologous and heterologous norovirus capsid peptides following VRP immunization in the 
mouse.  While we cannot predict if murine and human T cell epitopes are conserved across 
species, we can determine murine-specific epitopes and their relative conservation across 
genetically related norovirus strains.  This information will likely be useful in determining if 
previous exposure or vaccination to heterologous strains can confer T cell-mediated 
protection upon subsequent challenge.   
 Our results indicate that T cell responses following VRP vaccination to one norovirus 
strain are cross-reactive to heterologous norovirus VLPs, with highest cross-reactivity to 
genetically related strains within a genogroup (Fig. 4.1).  These data support previous 
findings by Lindesmith et al. showing that peripheral blood mononuclear cells (PBMCs) 
from humans infected with a GII strain cross-reacted to stimulation with VLPs from another 
GII strain but less so to GI VLPs (145).  Because unknown pre-exposure histories in humans 
can skew cross-reactivity profiles and are highly variable between individuals, we used 
norovirus-naïve mice to provide a clearer view of T cell cross-reactivity between strains.  We 
were surprised to discover, however, that intra-genogroup VLPs were able to stimulate IFN-γ 
secretion to the same degree as homologous VLPs from the immunizing strain, and cross-
reactivity by inter-genogroup VLPs was also present.  However, splenocyte cultures from 
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mice immunized with VRP expressing an irrelevant protein were also stimulated by 
norovirus VLP (Fig. 4.3).  UV-inactivated MNV (i-MNV), which consists of intact capsid 
particles not produced by the VRP expression system, were used as a control for VLP 
stimulation.  Because VRP-HA cultures were stimulated by VLP but not i-MNV and because 
cultures from all VRP immunized mice were stimulated with i-VRP, we believe background 
stimulation by VRP antigens, including VLPs produced using the VRP expression, may be 
skewing cross-reactivity results.  The impact of VRP immunization independent of norovirus 
antigen delivery is beyond the scope of our research; however, it has been documented that 
CD4+ T cells are activated and IFN-γ produced following alphavirus infection in mice (22, 
77, 227), suggesting residual VRP-induced IFN-γ secretion could also occur.  In addition, 
strains within norovirus genogroups can still differ by up to 40% in capsid amino acid 
sequence; therefore, we would not expect equivalent stimulation to heterologous GI VLPs in 
NV immune mice.   
 To circumvent the potential problem of background VLP cross-reactivity induced by 
the VRP vector, we turned to synthetically produced overlapping peptides reconstituting 
norovirus capsid sequences.  Peptides can be used not only to determine cross-reactivity 
between strains but also to identify specific T cell epitopes, making them particularly 
advantageous.  Stimulation with peptides resulted in robust IFN-γ secretion from identifiable 
pools (Fig. 4.4A and 4.5A); however, cross-reactivity was not evident between NV and FH 
strains (Fig. 4.8).  Stimulatory sequences were located in different domains of the capsid for 
NV and FH.  The amino sequence FDLSLGPHLNPFLLH located in the shell domain was 
found to be stimulatory to NV-immune splenocytes, and the sequence 
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CLLPQEWVQHFYQEAAPAQSDVALL located in the P1 domain was found to be 
stimulatory to FH-immune splenocytes.   
 Alignments of capsid sequences of additional GI.1 and GII.4 strains to the stimulatory 
sequences within NV and FH, respectively, revealed high homology to additional strains 
(100% and 88%, respectively), suggesting T cell epitopes are conserved within a genocluster 
and are likely to activate a memory T cell response upon subsequent challenge with 
genetically related strains.  In contrast, additional GI sequences outside the GI.1 genocluster 
were also highly conserved (86.7%) compared to the stimulatory NV sequence whereas 
heterologous GII sequences outside the GII.4 genocluster were not highly conserved (60%) 
to the stimulatory FH sequence.  These findings may explain why GII strains are more 
globally predominant than GI strains, assuming previous exposure lends some level of 
immunity upon subsequent challenge.  Alternatively, presumed higher variability within the 
GII.4 cluster and heterologous GII sequences may simply be the result of a higher number of 
strains included in the alignment compared to GI.  Likewise, the shell (S) domain, where the 
stimulatory NV sequence resides, is typically more highly conserved across strains than the 
latter part of the P1 domain (88), where the stimulatory FH sequence resides.  Sequences 
were not conserved across genogroups, which is supported by our findings that stimulatory 
NV peptides did not stimulate FH-immune splenocytes and vice versa (Fig. 4.8).  
Identification of the exact T cell epitopes within stimulatory peptide sequences and 
heterologous immunization followed by epitope stimulation of lymphocytes will determine 
the extent of true cross-reactive T cell responses.  Defining specific epitopes for T cell 
activation on distinct norovirus capsids will reveal unknown antigenic and immunogenic 
relationships among norovirus strains.  Epitopes for CD4+ T cell activation in mice may be 
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different than that in humans; however, the mechanism(s) of protection following infection 
are likely similar.  The newly developed mouse norovirus challenge model will allow 
continued investigation into the effect of the T cell response following homologous or 
heterologous norovirus exposure as well as a system in which to evaluate the efficacy of 
preventative therapies triggering T cell-specific responses.  These preliminary studies will 
provide previously unattainable answers to questions that can bridge to important issues in 
human medicine.   
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Figure 4.1 
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CD4+ and CD8+ depleted splenocyte stimulation.  CD4+ or CD8+ T cells were depleted 
from splenocyte preparations from mice immunized with VRP-NV using marker-specific 
depleting antibodies conjugated to magnetic beads (Miltenyi).  Depleted splenocytes were 
stimulated with NV VLP for 48 h and supernatants analyzed for IFN-γ by EIA.  CD8 
depleted cultures secreted significantly more IFN-γ than CD4 depleted cultures (P<0.001).  
CD8 depleted cultures secreted significantly more IFN-γ upon stimulation with NV VLPs 
than unstimulated controls (P<0.01).  Background IFN-γ secretion from unstimulated 
cultures was subtracted from total values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*** 
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Figure 4.2 
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Splenocyte stimulation with norovirus VLP panel.  Splenocytes from mice immunized 
with VRP-NV were stimulated with 5 µg/ml VLP from one of nine norovirus strains from GI 
or GII.  After incubation for 48 h, culture supernatants were analyzed for IFN-γ by EIA (BD 
Pharmingen).  GI strains NV, SH, CV, and DS and GII strain M7 stimulated IFN-γ secretion 
significantly more than unstimulated cultures (P<0.01). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
** 
** ** 
** 
  ** 
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Table 4.1.  NV immune stimulated splenocyte cytokine profile by cytometric bead 
array. 
 
 TNF-α  IFN-γ  IL-2  
 pg/ml fold- pg/ml fold- pg/ml fold- 
Stimulant 
  Increase*   increase   increase 
NV VLP 419.6 2.7 1974.9 8.4 149.2 7.7 
CV VLP 398.4 2.6 2172.1 9.3 219.4 11.3 
HV VLP 336.5 2.2 1263.7 5.4 144.7 7.4 
mock 155.8 1.0 233.9 1.0 19.5 1.0 
 
 
IL-4 
 
IL-5  
 pg/ml fold- pg/ml fold- 
Stimulant 
  increase   increase 
NV VLP 26.8 3.4 284.5 1.3 
CV VLP 26.5 3.3 315.3 1.4 
HV VLP 28.4 3.6 315.2 1.4 
mock 7.9 1.0 224.5 1.0 
*fold increase in cytokine levels over mock stimulation 
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Figure 4.3 
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Splenocyte stimulation controls.  Splenocytes harvested from unimmunized mice or mice 
immunized with VRP-NV or VRP-HA were stimulated with 5 µg/ml NV VLP, UV-
inactivated MNV (i-MNV), or i-VRP for 48 h. Culture supernatants were analyzed for IFN-γ 
by EIA.  Cultures from VRP-NV immunized mice secreted significantly more IFN-γ than 
VRP-HA immunized mice or mock controls upon stimulation with VLP (P<0.001).  IFN-γ 
levels from VLP stimulated cultures were also significantly higher than levels following i-
MNV stimulation or no stimulation in VRP-NV cultures. VLP stimulated cultures from HA 
immunized mice had significantly higher levels than mock immunized mice (P<0.05).  i-
VRP stimulated cultures were not different between HA and NV immunized mice and were 
significantly higher than mock immunized mice (P<0.001).  IFN-γ levels in NV cultures were 
not different following VLP or i-VRP stimulation, but levels in HA cultures were higher 
following i-VRP stimulation than VLP stimulation (P<0.001). 
 
* 
***  *** 
 *** 
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Table 4.2 
 
Norwalk virus and Farmington Hills virus capsid peptide library sequences. 
 
Capsid Amino acids NV peptide Amino acids FH peptide Amino acids
domains*    pools     pools
S 1-125 1 1-105 1 1-115
P1 226-278 2 91-215 2 101-235
406-520 3 201-305 3 221-345
P2 279-405 4 291-405 4 331-445
5 391-525 5 431-540
 
*As described in (20). 
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Figure 4.4 
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C. 
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Norwalk capsid peptide stimulation.  Splenocytes from mice immunized with VRP-NV, 
null VRP, or no immunogen were stimulated with overlapping peptide pools of 10-11 
peptides spanning the entire capsid and supernatants tested for IFN-γ (A).  Overlapping sets 
of peptides from stimulatory pools were used to stimulate splenocytes from VRP-NV 
immunized mice to identify stimulatory peptides (B).  Individual and overlapping peptides 
were then used to identify peptides containing stimulatory sequences (C).  Stimulatory 
peptide sequences are shown in (D).  Peptides in NV pool 1 (A) stimulated IFN-γ secretion 
significantly more than other pools (P<0.001).  Overlapping peptides 8-9 and 9-10 stimulated 
IFN-γ secretion significantly more than all other overlapping pairs (P<0.01; B) and more than 
peptide 8 or 10 alone (P<0.05; C). 
 
 
 
 
NV peptide Amino acids Sequence Domain
8 71-85 SPNNTPGDVLFDLSL S
9 81-95 FDLSLGPHLNPFLLH S
10 91-105 PFLLHLSQMYNGWVG S
 *   * 
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Figure 4.5 
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C. 
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D. 
 
FH peptide Amino acids Sequence Domain
45 451-465 CSGYPNMNLDCLLPQ P1
46 461-475 CLLPQEWVQHFYQEA P1
47 471-485 FYQEAAPAQSDVALL P1
48 481-495 DVALLRFVNPDTGRV P1
 
 
 
Farmington Hills capsid peptide stimulation.  Splenocytes from mice immunized with 
VRP-FH, null VRP, or no immunogen were stimulated with overlapping peptide pools of 10-
11 peptides spanning the entire capsid and supernatants tested for IFN-γ (A).  Overlapping 
sets of peptides from stimulatory pools were used to stimulate splenocytes from VRP-NV 
immunized mice to identify stimulatory peptides (B).  Individual and overlapping peptides 
were then used to identify peptides containing stimulatory sequences (C).  Stimulatory 
peptide sequences are shown in (D).  IFN-γ was significantly higher following stimulation 
with FH pool 5 than other pools (P<0.001; A).  Overlapping peptides 45-46 induced 
increased IFN-γ secretion compared to peptides 46-47 (P<0.01) and all other overlapping 
peptides (P<0.001; B).  Peptides 46-47 and 47-48 induced increased IFN-γ secretion to all 
other overlapping peptides (P<0.001; B).  Individual and overlapping peptide stimulations 
containing peptide 46 were significantly higher than peptide 45 or 48 stimulation alone 
(P<0.05; C). 
* 
* 
* 
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Table 4.3 
 
Cytometric bead array of pooled stimulated splenocyte supernatants from immunized 
mice for TH1 and TH2 cytokine secretion. 
 
  
Vaccine Stimulant Cytokine (pg/ml) 
  
VRP-NV 
 
TNF-a IL-2 IL-4 IL-5 
 N1 497 531 24 178 
 N2 248 636 19 183 
 N3 332 690 22 176 
 N4 315 673 22 166 
 N5 259 557 25 156 
 none 264 954 19 199 
VRP-FH F1 299 322 14 98 
 F2 256 252 14 93 
 F3 208 221 15 97 
 F4 227 245 15 94 
 F5 823 200 18 92 
 none 208 394 13 148 
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Figure 4.6 
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Serum IgG subtype response.  Sera from mice immunized with VRP-NV or VRP-FH were 
tested for specific IgG1 and IgG2a to NV or FH VLPs, respectively, by ELISA.  IgG1 and 
IgG2a levels were not different from one another within each immunization group.  
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Figure 4.7 
 
A. 
 
 
                  NV-68 F D L S L G P H L N P F L L H   
WC-02 F D L S L G P H L N P F L L H     
SoV F D L Q L G P H L N P F L S H  
DSV F D L Q L G P H L N P F L L H  
Chiba F D L Q L G P H L N P F L L H  
HV L N L E L G P E L N P F L A H  
SMV L N L E L G P E L N P Y L A H  
TV L N L E L G P E I N P Y L A H  
FH W S A P L G P D L N P Y L S H  
M7 L D L E L G P E L N P Y L A H  
 
GI.1 
  GI 
  GII 
 
13
9 
 
 
 
 FH-04 C L L P Q E W V Q H F Y Q E A A P A Q S D V A L L 
 FH-02 C L L P Q E W V Q H F Y Q E A A P A Q S D V A L L 
 LV-97 C L L P Q E W V Q H F Y Q E A A P A Q S D V A L L 
 LV-87 C L L P Q E W V L H F Y Q E A A P A Q S D V A L L 
 Hu-04 C L L P Q E W V Q H F Y Q E S A P A Q S D V A L L 
 Sak-05 C L L P Q E W V Q H F Y Q E A A P S Q S D V A L L 
 HV C L L P Q E W I Q H F Y Q E S A P S P T D V A L I 
 SMV C L L P Q E W V Q H F Y Q E A A P S M S E V A L V 
 TV  C L V P Q E W V Q H F Y Q E S A P A Q T Q V A L V 
 M7  C L L P Q E W I E H F Y Q E A A P S Q S D I A L V 
 NV C L L P Q E Y I S H L A S E Q A P T V G E A A L L 
 SoV C L L P Q E Y I T H F V S E Q A P T M G D A A L L 
 DSV C T I P Q E F V T H F V N E Q A P T R G E A A L L 
 Chiba C L L P Q E Y I T H F I S E Q A P I Q G E A A L L 
 
  GII.4 
  GII 
   GI 
Alignments of stimulatory NV and FH capsid peptide sequences.  Identified stimulatory sequences within the NV (A) and FH (B) 
capsids were aligned with corresponding sequences from other GI and GII strains.      =amino acid completely conserved across 
genogroups;     = amino acid completely conserved within genogroup;     =amino acid completely conserved within genocluster;     
=variable.
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Figure 4.8 
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Cross-stimulation of NV and FH immune splenocytes to stimulatory peptide pools.  NV-
immune splenocytes were stimulated with FH pool 5 and FH-immune splenocytes were 
stimulated with NV pool 1 and IFN-γ levels in supernatant measured by EIA. 
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Abstract 
 Human noroviruses cause greater than 90% of epidemic non-bacterial gastroenteritis 
worldwide.  Despite the importance of these pathogens, the nature of norovirus immunity and 
applicability of vaccination has not been demonstrated in part due to the lack of culture 
systems and small animal models for human noroviruses.  Using the murine norovirus 
system, we define both antibody- and T cell-mediated mechanisms responsible for efficient 
clearance of primary norovirus infection and demonstrate both short term and long term 
protective immunity generated by live virus vaccination.  Furthermore, vaccination with the 
capsid protein using the VEE replicon vector system is effective and tissue specific for the 
effects of CD4+ T cells, CD8+ T cells, and B cells.  Vaccination with the capsid protein of 
human Lordsdale virus (GII) provided partial protection against MNV challenge.  Perforin, 
but not interferon-γ, was required for the CD8+ T cell-mediated clearance of MNV infection. 
Adoptively transferred polyclonal anti-MNV sera or neutralizing anti-MNV monoclonal 
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antibodies (mAbs) were also sufficient to reduce the level of MNV infection both 
systemically and in the intestine. These studies prove the practicality of vaccination against 
mucosal norovirus infection, identify tissue-specific requirements for vaccination and 
clearance, and suggest that there may be conserved epitopes between human and murine 
noroviruses.  
 
Introduction 
More than 90% of epidemic nonbacterial gastroenteritis worldwide can be attributed 
to human noroviruses (56, 94, 196, 197, 285, 288).  Infection is most commonly transmitted 
by the fecal-oral route (75), and symptomatic infection is characterized by nausea, vomiting 
and/or diarrhea lasting 24-48 hours (281). Non-epidemic, community acquired infections 
may be more indolent than epidemic infections, with symptoms lasting longer than one week 
(220). There are reports that some infected individuals shed virus for longer periods after 
clearance of symptoms than others, but the basis for this is not known (51, 53, 69, 172, 188, 
220). 
Despite the significant costs and morbidity due to human norovirus infections, no 
vaccine is currently available. This is in part due to our incomplete understanding of the 
nature of norovirus immunity. Adaptive immunity is likely involved in control of primary 
infection as immunocompromised individuals have been documented to shed virus for 
prolonged periods (64, 128, 179).  The potential to vaccinate against these and related viruses 
has been demonstrated in gnotobiotic piglets and rabbits (18, 156, 242), and human challenge 
studies demonstrate short-term but not long term protection against homologous but not 
heterologous viral challenge (50, 203, 281).  Because human noroviruses are extremely 
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genetically heterogeneous, lack of cross-protection poses a challenge for vaccine 
development.  
In the absence of a cell culture system for human noroviruses, virus-like particles 
(VLPs) that assemble when the viral capsid protein is expressed have been important tools 
for evaluating norovirus immune responses (47, 49, 72, 85, 114, 116, 117, 129, 142, 182).  In 
VLP vaccination studies, high doses of VLPs administered intranasally (i.n.), or perorally 
(p.o.), with or without adjuvants, induced mucosal IgA and serum IgG in human volunteers, 
calves, pigs or experimental mice (9, 10, 80, 91, 109, 207, 240-242, 247).  Antisera from 
infected human volunteers and experimentally vaccinated mice are also able to block binding 
of Norwalk and Lordsdale VLPs to ABH Histo-blood group antigens (91, 109, 149). The 
presence of antibodies that block norovirus receptor binding suggests that antibodies may 
exert a protective effect against infection or promote resolution of symptoms. Additionally, 
inoculating mice with vaccine cocktails comprised of multiple norovirus VLPs enhances the 
production of heterotypic blocking antibodies against strains not included in the cocktail 
(149). However, no formal assessment of the physiologic importance of antibodies in 
norovirus infection has been undertaken to date.     
Studies into the cellular immune response have shown that peripheral blood 
mononuclear cells (PBMCs) from Snow Mountain virus (GII) infected individuals produce T 
cell effector cytokines IL-2 and interferon γ (IFN-γ) when stimulated with VLPs from viruses 
in the same genogroup in vitro (145).  Other studies in human volunteers, gnotobiotic pigs 
and calves, and mice using Norwalk Virus and HuNoV-HS66 VLPs show cytokine 
production as well as proliferation of CD4+ and CD8+ T cells from murine Peyer’s patches 
and spleens after in vitro restimulation (207, 240-242, 247). Together, these studies show that 
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norovirus infected individuals and VLP vaccinated mice develop B cell and T cell responses 
but do not define the importance of these responses for clearance of primary infection or 
resistance to re-challenge.  These studies in total reflect the potential for vaccination, but 
leave open important questions about vaccine efficacy, longevity of immune responses, 
mechanisms of adaptive immunity, and the potential for cross-protection between distantly-
related noroviruses.    
 The identification of the first murine norovirus (MNV) and its routine propagation in 
cultured cells provides a facile animal model for studies of norovirus immunity and 
pathogenesis (124, 277).  MNV is an efficient enteric virus that, like its human counterparts, 
is spread by fecal-oral transmission (278). The MNV genome encodes three open-reading 
frames with ORF1 encoding a polyprotein that is cleaved into individual non-structural 
proteins in a manner similar to the polyprotein of human noroviruses (238), demonstrating 
the conserved nature of norovirus replication mechanisms. The MNV capsid, like that of 
human strains, consists of 90 dimers of the capsid protein arranged in a spherical capsid 
(127).  Studies into MNV pathogenesis reveal an important role for IFN-mediated innate 
immunity and STAT-1 dependent immunity in resistance to acute infection (124, 171). In 
addition, the importance of adaptive immunity in control of MNV infection is suggested by 
the observation that RAG1-/- mice develop persistent MNV infection whereas wild type mice 
can clear infection (124, 171, 255).  
 MNV infected mice generate a significant neutralizing antibody response (99, 100, 
124, 206, 255, 270), and neutralizing mAbs have been identified (277).  Cellular immune 
responses, however, have not been investigated.  The MNV1.CW3 strain, which is cleared 
from intestine, spleen, liver, mesenteric lymph nodes (MLN) and feces within seven days of 
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infection (124, 171, 255), provides a challenge model to study vaccine efficacy and the 
adaptive immune mechanisms responsible for clearance of virus following primary infection.   
 We show here that vaccination with either live MNV or Venezuelan equine 
encephalitis (VEE) replicon particles (VRPs) expressing the MNV capsid protein protects 
against re-challenge for up to six months.  Both clearance of primary infection and effective 
vaccination require the concerted efforts of CD4+ T cells, CD8+ T cells, and B cells.  
However, the role of each cell type is tissue-specific, and requirements for immunity in the 
ileum differ from those in the lymphatic system.   
 
Materials and methods 
Viruses, viral stocks, VRPs, and plaque assays.  MNV strain MNV1.CW3 or MNV1.CW1 
were used in all virus infections (255, 277). Two non-synonymous mutations distinguish the 
genomes of MNV1.CW3 and MNV1.CW1 (277). To generate concentrated virus stocks, 
RAW 264.7 cells were infected in VP-SFM media (Gibco) for 2 days at a multiplicity of 
infection (MOI) of 0.05. Supernatants were clarified by low-speed centrifugation for 20 min 
at 3,000 rpm. Virus was concentrated by centrifugation at 4°C for 3 h at 27,000 rpm (90,000 
g) in a SW32 rotor. Viral pellets were resuspended in PBS and titered on RAW 264.7 cells as 
previously described (277). Type I Lang reovirus was kindly provided by Dr. Terrence S. 
Dermody (Vanderbilt University, Nashville, TN). Plaque assays were performed as 
previously described (277). Tissues were harvested into sterile, screw-top 2-ml tubes 
containing 500 mg of 1-mm zirconia/silica beads (BioSpec Products, Bartlesville, OK) and 
stored at −80 °C.  To determine viral titers,1 ml of complete DMEM was added to each 
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sample on ice and homogenized using a MagNA Lyser (Roche) prior to plaque assay. The 
limit of detection was 20 PFU/ml. 
 All VRPs were produced as previously described (93). Briefly, ORFs 1, 2 and 3 from 
MNV1.CW3 and ORF2 from Lordsdale virus (LV) and Chiba virus (CV) were individually 
cloned into VRP expression vectors.  Following infection of BHK cells with VRPs for 24 h, 
culture supernatants were harvested and cells lysed. Proteins were separated by SDS-PAGE 
and analyzed by western blot with polyclonal rabbit anti-MNV serum. VRP titers and 
efficient expression of recombinant protein were determined by immunofluorescence assay 
using mouse antisera following inoculation with respective antigens.  Cell lysates from MNV 
ORF2, CV, and LV VRP-infected cultures were further purified to obtain VLPs as described 
(149).   
Cell cultures and antibodies. RAW 264.7 cells (ATCC, Manassas, VA) were maintained as 
previously described (277). Monoclonal antibodies (MAbs) YTS191.1 specific to CD4 (38), 
H35 specific to CD8 (236), 9BG5 specific to the reovirus type 3 hemagglutinin (27), anti-
MNV mAbs A6.1, A6.2 and H6.1 and SFR3-DR5 (ATCC HB-151 (216)) were produced in 
INTEGRA Celline CL1000 flasks (Integra Biosciences, Ijamsville, MD) as previously 
described (163).  The titer of polyclonal anti-MNV antibody in serum was determined using 
ELISA (149).  
Mice, inoculations, and infections. All mice were bred and housed at Washington University 
School of Medicine or the University of North Carolina at Chapel Hill in accordance with all 
federal and university policies. Wild type C57BL6/J, B6 RAG1-/-, IFNγ -/-, perforin -/-, 
MHC Class II -/- and B-cell -/- (µMT) mice were purchased from The Jackson Laboratory 
(Bar Harbor, Maine). Kb−/−x Db−/−x β2-m−/− (MHC Class I x β2-m−/−) mice were a generous 
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gift of Dr. Ted Hansen (154). Senescent wild type C57BL6/J mice were purchased from 
Harlan Sprague Dawley (Indianapolis, IN) and aged to 14 months.  Wild type mice were 
tested by ELISA for the presence of MNV antibody prior to experiments.  All mice used in 
these studies were seronegative.  
 Mice used in vaccination studies were immunized with 3x107 plaque forming units 
(PFU) of MNV1.CW1, MNV1.CW3, or control Type I Lang reovirus p.o. in 25µl of DMEM 
containing 10% fetal bovine serum (Hyclone, Logan, UT) or with 2.5 x 106 infectious units 
(IU) of each VRP expressing MNV1.CW3 ORF1, ORF2, or ORF3 (individually or in groups 
of 2-3 VRPs), CV ORF2, LV ORF2, or HA VRP in 10µl or 50µl volume by footpad 
inoculation on day 0 and boosted on day 21.  Control mice were inoculated with PBS in 
parallel.  Mice were then challenged with MNV1.CW3 at specified times after boost and 
tissues harvested three days post-challenge.  RAG1-/- and all splenocyte donor mice were 
infected with 3x106 PFU of MNV1.CW3 p.o. in 25µl of cDMEM. All other mice were 
infected with 3x107 PFU MNV1.CW3 p.o. RAG1-/- mice were inoculated at 4-6 weeks of 
age, and aged wild type mice were inoculated at 14 months of age.  All other mice were 
inoculated at 6-10 weeks of age.  In RAG1-/- mice, a one inch section of the small intestine 
immediately distal to the pylorus of the stomach (duodenum/jejunum) and a one inch section 
of the small intestine immediately proximal to the cecum (distal ileum) were harvested. In all 
other mice the distal ileum and three mesenteric lymph nodes (MLN) were harvested. The 
duodenum/jejunum was not harvested from wild type mice since viral titers could not be 
detected at this site.  
Adoptive and passive transfer studies. Spleens were harvested from mice and single cell 
suspensions were generated. Cells were counted and diluted in RPMI-1640 media (Sigma, St. 
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Louis, MO) supplemented with 10% characterized fetal calf serum (HyClone), 100 U 
penicillin/ml, 100 µg/ml streptomycin, 10 mM HEPES (N-2-hydroxyethylpiperazine-N9-2-
ethanesulfonic acid), 1mM sodium pyruvate and 2 mM L-glutamine (cRPMI). Cells were 
injected into persistently infected RAG1-/- mice by intraperitoneal (i.p.) injection in 0.5 ml 
cRPMI. Immune and control anti-serum was obtained from either immunized or control 
mice, filtered (0.2µm), heat fixed for 30 min at 55ºC and stored for use.  Serum and mAbs 
were passively transferred into recipient mice i.p. 
Statistical methods. All data were analyzed using GraphPad Prism software (GraphPad 
Software, San Diego, CA). Viral titer data were analyzed with the nonparametric Mann-
Whitney test. All differences not specifically stated to be significant were insignificant (P> 
0.05). 
 
Results 
Construction of norovirus capsid protein-expressing VRPs.   
VEE based VRPs expressing MNV1.CW3 ORF1, ORF2 and ORF3 as well as ORF2 
of the human noroviruses Lordsdale (LV) and Chiba (CV) were produced for use in 
vaccination experiments. Western blots of ORF1 VRP infected cell lysates revealed 77 kDa 
and 19 kDa proteins, which correspond in size to MNV proteinase-polymerase precursor 
protein and cleaved 3C-like proteinase (Fig.5.1A) (239).  Culture supernatants contained a 57 
kDa protein, which corresponds in size to the MNV RNA-dependent RNA polymerase.  
ORF2 VRP infected cell lysates and supernatant both contained the 58 kDa capsid protein.  
ORF3 VRP infected cell lysates contained the 22 kDa ORF3 protein.  Denatured MNV, LV, 
or CV VLPs purified from cells infected with VRPs expressing each respective ORF2 were 
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used to examine the potential cross-reactivity of capsid proteins from different noroviruses 
by western blot.  Hyper-immune polyclonal rabbit antisera to MNV (277) cross-reacted at 
low levels with CV (GI.4) and LV (GII.4) VLPs.   
 
Short term live virus and subunit vaccination against MNV 
 We first determined whether we could detect short term immunity to homologous 
MNV challenge and if proteins encoded by specific MNV ORFs could elicit effective 
immunity. After oral inoculation with MNV1.CW3, wild type mice exhibit detectable viral 
titers in the ileum and the MLN three to five days post infection; virus is cleared by day 
seven. Wild type mice were therefore primed orally and boosted three weeks later with 
MNV1.CW3, the closely related strain MNV1.CW1, or reovirus Type I Lang as an unrelated 
virus control, in live-virus vaccines (275). Additional mice were vaccinated subcutaneously 
and boosted three weeks later in the footpad with VRPs expressing MNV ORF1, MNV 
ORF2, or MNV ORF3, either separately or in combination.  Controls for VRP vaccination 
included PBS or VRPs expressing hemagglutinin (HA) from a mouse adapted influenza A 
virus. Two weeks post-boost, mice were orally challenged with MNV1.CW3 and organs 
harvested three days later for titration of virus (Fig. 5.2A). Prior infection with either 
MNV1.CW1 (p=0.0002) or MNV1.CW3 (p=0.0009) significantly decreased MNV1.CW3 
replication in the ileum compared to mice infected with reovirus (Fig. 5.2B). Similar results 
were observed in the MLN following MNV.CW1 (p=0.0001) and MNV.CW3 (p=0.0003) 
vaccination (Fig. 5.2B). ORF2 VRP vaccines (alone or in combination with other VRPs) also 
protected against MNV1.CW3 in both distal ileum (p=0.005) and MLN (p=0.02) compared 
to the HA VRP control group. ORF1 VRPs alone or in combination with ORF3 VRPs had a 
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slight but statistically significant effect on MNV1.CW3 levels in the distal ileum and MLN 
(Fig. 5.2B).  ORF3 VRPs alone did not confer significant protection (Fig. 5.2B). Together 
these data show that vaccination with either live virus or ORF2 VRPs can confer short term 
protection against MNV challenge.  
We then compared efficacy of vaccination with homologous versus heterologous 
ORF2 proteins.  Mice were vaccinated with VRPs expressing ORF2 from CV (genogroup 
GI.4) or LV (genogroup GII.4) and challenged with MNV1.CW3.  Vaccination with LV 
capsid partially protected against MNV infection in the distal ileum (p=0.0007) but not the 
MLN (Fig. 5.2B). No significant reduction in MNV titers was seen after immunization with 
CV capsid (Fig. 2B). Protection after LV ORF2 VRP vaccination did not correlate with 
generation of cross-reactive serum IgG as measured by ELISA (Fig.5.1B), despite cross-
reactivity observed by western blot using hyper-immune rabbit antisera generated against the 
MNV capsid (Fig.5.1A).  Fecal extracts collected at 1-4 weeks post-immunization yielded no 
measurable homotypic or heterotypic IgG or IgA (data not shown). These data show that 
there is measurable immunologic cross protection between Lordsdale virus and MNV in the 
distal ileum, but that this does not correlate with the production of cross-reactive antisera. 
 
Vaccination can occur in aged mice 
 Because the elderly are more susceptible than younger adults to human norovirus 
infections (2), we determined whether increased age altered vaccine efficacy in mice.  Prior 
work has shown that mice older than 1 year of age have diminished vaccine responses to 
SARS virus antigens (46).  We therefore compared vaccine efficacy in eight week old (adult) 
and aged (14 month old) mice.  Adult and aged mice were vaccinated with MNV ORF2 
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VRPs or HA VRPs and challenged with MNV1.CW3 as outlined in Fig. 5.2A.  In contrast to 
studies using SARS virus antigens, aged mice responded as well as adult mice to MNV 
ORF2 vaccination as indicated by decreased MNV1.CW3 titers after challenge in both the 
distal ileum and MLN (Fig. 5.2C). Interestingly, despite this protective effect, sera from 
vaccinated aged mice had significantly lower anti-MNV ORF2 IgG compared to adult mice 
(Fig. 5.1C).  These data again indicate that protection against MNV infection does not always 
correlate with serologic responses, raising the possibility that T cells play a fundamentally 
important role in vaccination against MNV.   
 
Protective effect of live MNV vaccine does not wane over 6 months 
We next determined whether protection conferred by MNV1.CW3 or MNV ORF2 
VRPs was long lived. Wild type mice were primed and boosted as in Fig. 5.3A with 
MNV1.CW3 or MNV ORF2 VRPs. Control vaccinations included HA VRPs, reovirus TIL 
or PBS. Mice were then challenged with MNV1.CW3 two, four, 14, or 24 weeks later and 
tissues harvested three days post-challenge for MNV titration. We observed complete 
protection against ileal MNV1.CW3 infection two weeks post-boost after vaccination with 
either MNV1.CW3 (p=0.0001) or ORF2 VRPs (p<0.0001) compared to reovirus TIL or HA 
VRP controls (Fig. 5.3B). While vaccination with either MNV1.CW3 of ORF2 VRPs was 
effective at controlling MNV1.CW3 replication in MLN, live virus vaccination was more 
effective than ORF2 VRP vaccination (p=0.0003) (Fig. 5.3B).  Live virus vaccines conferred 
full protection against MNV1.CW3 replication in both the distal ileum and the MLN at 4, 14 
and 24 weeks after vaccination.  In contrast, vaccination with ORF2 VRPs, while statistically 
significant, was less effective than vaccination with MNV1.CW3 at these later time points 
 152 
(Fig. 3B). This data shows that both live virus and subunit vaccines induce long term 
protection against MNV infection. However, live virus may provide more complete 
protection against reinfection. 
 
Mechanisms responsible for vaccination by live virus and ORF2 VRPs  
We next determined the immunologic mechanism(s) responsible for effective vaccine 
responses.  We vaccinated B cell -/-, MHC Class I x β2M -/- (130), and MHC Class II -/- 
mice immunodeficient in B cells, CD8 T cells (154, 205), and CD4 T cells (79), respectively, 
with MNV1.CW3 or ORF2 VRPs (Fig. 5.4A).  PBS, HA VRPs, and reovirus TIL served as 
vaccination controls. Mice were challenged with MNV1.CW3 orally two weeks post-boost, 
and tissues were harvested and analyzed for viral titers three days later.  
Live MNV vaccination induced significant protection against MNV challenge in both 
the distal ileum and the MLN of B cell -/-, MHC Class II -/- and MHC Class I x β2M -/- 
mice (p< 0.05; Fig. 5.4B). However, there was considerable variation in the efficacy of 
vaccination in distal ileum and MLN among immunodeficient mice species.  In both B cell -
/- and MHC Class I x β2M -/- mice, vaccination with live virus resulted in complete 
protection in the distal ileum but only partial protection in the MLN (Fig. 5.4B). In MHC 
Class II -/- mice, partial protection was elicited in both tissues (Fig. 4B). In contrast, wild 
type mice were completely protected in both tissues. These data demonstrate that complete 
protection after vaccination with live virus requires the concerted action of B cells, MHC 
Class II, MHC Class I, and β2M, consistent with the tissue specific roles for B cells, CD4 T 
cells, and CD8 T cells in the development of complete protection against MNV infection.  
Less variation was observed after vaccination with ORF2 VRPs between the distal ileum and 
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MLN, which was partially protective in B cell -/- and MHC Class II -/- in both tissues (Fig. 
5.4B). There was no protection in either tissue after vaccination of MHC Class I x β2M -/- 
mice with ORF2 VRPs (Fig. 5.4B), suggesting that protection by VRPs critically depends on 
either classical or non-classical CD8 T cells.  We can conclude from these experiments that 
all major aspects of adaptive immunity are required for optimally effective responses to 
either live virus or ORF2 VRP vaccination.   
   
CD8 and CD4 T cells are important for clearance of primary MNV infection.  
The experiments above support the hypothesis that CD4 T cells, CD8 T cells, and B 
cells are important for optimal vaccine responses to MNV. We, therefore, asked if the same 
cell types are required for clearance of acute infection.  To determine the role of T cells in 
clearance of acute MNV infection, we inoculated wild type, MHC Class II-/-, and MHC 
Class I x β2-m−/− mice orally with MNV1.CW3 and measured viral titers in the distal ileum 
and MLN three, five, seven and 21 days post infection (Fig. 5.5B-C). We detected no 
significant difference in viral titer between MHC Class I x β2-m−/− mice and wild type mice 
three and five days post infection, indicating that MHC Class I was dispensable in MNV 
infection at early time points (Fig. 5.5B). However, at seven days post-infection, MHC Class 
I x β2-m−/− mice had significant levels of MNV titers in both the distal ileum (p=0.0002) and 
the MLN (p<0.0001) compared to wild type mice, which had completely cleared the 
infection (Fig. 5.5B). MHC Class I x β2-m−/− mice eventually cleared MNV infection, as 
demonstrated by a lack of detectable virus by 21 days post infection, suggesting CD8 T cells 
are important for efficient clearance of MNV, but are not required for eventual clearance of 
MNV infection. 
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In contrast to MHC Class I x β2-m−/− mice, MHC Class II-/- mice had higher MNV 
titers in the ileum than wild type mice both three (p=0.0002) and five (p=0.0058) days after 
infection (Fig. 5.5C). At seven days post infection, minimal viral titers remained, and at eight 
days post infection, both MHC Class II-/- and wild type mice had cleared the infection from 
the distal ileum. In MLN, viral titers in wild type and MHC Class II-/- were not significantly 
different at days three and five post-infection. However, there was a small, but statistically 
significant increase in titer in the MLN of MHC Class II-/- compared to wild type mice at 
seven days post infection (p=0.0402; Fig. 5.5C). By eight days post infection, MLN infection 
was cleared. Together these data indicate that CD4 T cells are necessary for control of acute 
MNV infection but, like CD8 cells, are not required for eventual clearance of MNV 
infection. 
The availability of persistently infected RAG1-/- mice allowed us to determine the 
role of CD4 and CD8 T cells in clearance of MNV infection using adoptive transfer. Both 
immune splenocytes and intraepithelial lymphocytes (IEL) can control murine rotavirus and 
reovirus enteric infection (48, 165, 184, 186). We therefore transferred splenocytes from 
MNV-immune wild type mice to persistently infected RAG1-/- mice and followed the 
clearance of MNV from ileum and duodenum/jejunum.  Transfer of 1x107 immune, but not 
non-immune, splenocytes into persistently infected RAG1-/- recipients significantly reduced 
MNV titer in the duodenum/jejunum (p<0.0001) and distal ileum (p<0.0001) six days post 
transfer (Fig. 5.6B) and was maintained through 16 days post-transfer (data not shown). 
These data show that adoptively transferred immune splenocytes are sufficient to clear 
persistent MNV infection in the intestine of RAG1-/- mice.  
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To define which cells in immune splenocytes were required for MNV clearance, CD4 
or CD8 T cells were depleted from splenocytes transferred into RAG1-/- recipients. To 
determine the extent of depletion in vivo, we monitored CD4 and CD8 T cell populations in 
the spleens of RAG1-/- recipients. Significant numbers of CD4 and CD8 T cells could be 
detected in spleens by flow cytometry analysis six days post transfer of undepleted 
splenocytes (Fig. 5.6A). Administration of depleting antibodies led to effective depletion of 
the appropriate T cell populations (Fig. 5.6A).  
Control antibody did not alter the capacity of immune splenocytes to decrease MNV 
titer in the duodenum/jejunum (p<0.0001) or distal ileum (p<0.0001) (Fig. 5.6B). Depletion 
of either CD4 (p=0.0042) or CD8 (p=0.0002) T cells individually led to a significant increase 
in MNV titers in duodenum/jejunum compared to control depletion (Figure 5.6B). Combined 
depletion of both CD4 and CD8 T cells from transferred immune splenocytes caused an 
additional significant increase in MNV titers when compared to CD4 depletion alone 
(p=0.02) or CD8 depletion alone (p=0.03). In the distal ileum, depletion of CD4 T cells 
(p=0.0003) or CD8 T cells (p<0.0001) led to a significant increase in MNV titers (Figure 
5.6B). However, the depletion of both CD4 and CD8 T cells from transferred immune 
splenocytes did not have an additive effect.  This data demonstrate that both immune CD4 
and CD8 T cells are necessary for clearance of persistent MNV infection from the intestine. 
 
Perforin has a role in clearance of MNV infection 
 Two major effector mechanisms for the antiviral effects of T cells are the production 
of IFNγ and perforin-mediated cytolysis (reviewed in (267)). To address which activity is 
important in viral clearance, we adoptively transferred immune splenocytes from IFNγ-/- or 
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perforin-/- mice into persistently infected RAG1-/- mice and determined their capacity to 
clear intestinal MNV infection.  Immune splenocytes from IFNγ-/- mice cleared MNV 
infection as effectively as splenocytes from wild type mice (Fig. 5.6B).  However, immune 
splenocytes from perforin-/- mice were significantly less effective at clearing intestinal MNV 
infection than cells from either wild type or IFNγ-/- mice in the duodenum/jejunum 
(p=0.0003) and distal ileum (p=0.0075; Fig. 5.6B).  Perforin-deficient immune splenocytes 
did, however, retain some capacity to clear MNV infection in the duodenum/jejunum 
(p=0.0086) and distal ileum (p=0.0001) compared to transfer of non-immune cells.  These 
data suggest that perforin is critical for efficient clearance of MNV infection from the 
intestine, but it is not likely to be the only mechanism driving viral clearance.   
 
B cells are required to control early mucosal MNV replication and long term clearance 
in mesenteric lymph nodes but not intestine.  
We have previously demonstrated that RAG1-/- mice, which are deficient in both T 
cells and B cells, develop a chronic persistent MNV infection (124), whereas wild type mice 
efficiently clear infection. This indicates that adaptive immunity is important for MNV 
clearance. To evaluate the role of B cells in the control of primary MNV infection we 
compared MNV titers in B cell deficient µMT mice and wild type B6 mice in the distal ileum 
and the mesenteric lymph nodes (MLN) after p.o. infection. At three and five days post 
infection µMT mice had significantly higher virus titers compared to the wild type controls 
in the distal ileum (p=0.002 and p=0.014, respectively) and also in the MLN (p=0.009 and 
p=0.0004, respectively; Fig. 5.7).  The majority of both wild type B6 and µMT mice cleared 
ileal infection by day seven post-infection, with only two of ten µMT mice having any 
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measurable ileal titer at this time point (Fig. 5.7). In the MLN, wild type mice cleared 
infection by day seven, while titers in µMT mice decreased approximately 100-fold from 
their peak at five days post-infection. However, MLN titers in µMT mice remained 
detectable at days seven (p=0.0004), ten (p=0.045), and 21 (p=0.045) post-infection, and 
were statistically significant compared to wild type mice (Fig. 5.7). These data show that B 
cells are important in the control of MNV infection at days three and five in both the distal 
ileum and MLN. However, while B cells were dispensable for clearance of MNV in the distal 
ileum, they were required for clearance of infection from MLN. 
 
MNV specific polyclonal sera and IgG are sufficient to limit MNV replication in the 
intestine and spleen 
To determine if the lack of antibodies in µMT mice are directly responsible for 
clearance of virus, we tested the ability of passively transferred anti-MNV antibody to limit 
viral replication. To obtain MNV specific polyclonal antibody we mock immunized or MNV 
immunized wild type mice and obtained non-immune and immune serum 35 to 42 days post 
infection. We transferred 500µl of serum via i.p. injection into persistently infected RAG1-/- 
mice and measured virus titers in the distal ileum and spleen six days post-transfer. In the 
distal ileum, transfer of immune serum led to a modest but significant decrease in the levels 
of MNV titer compared to non-immune serum transfers (p= 0.013; Fig. 5.8A). Similar results 
were obtained in the duodenum/jejunum (data not shown). In the spleen, the transfer of 
immune serum had a much more significant effect, where levels of MNV were reduced to 
below the level of detection in half of the mice examined (p<0.0001). This demonstrates that 
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MNV immune polyclonal serum is sufficient to reduce MNV titers in the intestine and 
spleen. 
Even though IgA is classically thought of as the main antibody isotype present at the 
mucosal surface (reviewed in (174)), there are reports of IgG antibody controlling mucosal 
viral infection (139, 183, 273). We therefore wanted to determine if IgG antibodies specific 
for MNV capsid could reduce MNV titers. We obtained the anti-MNV capsid monoclonal 
antibodies (mAb) A6.1, A6.2 and H6.1, all of IgG2a isotype, that had been previously shown 
to neutralize MNV in vitro ((127, 277) & unpublished data). We administered 500µg of each 
mAb via i.p. injection into persistently infected RAG1-/- mice.  In the distal ileum, each mAb 
significantly reduced MNV titers compared to the 9BG5 mAb control (p=0.0002; Fig. 5.8B). 
In the spleen, mAbs A6.1, A6.2 and H6.1 were also able to significantly reduce the levels of 
MNV titers (p=0.0002, p=0.0004 and p=0.0207, respectively; Fig. 5.8B). This demonstrates 
that mAbs of IgG isotype directed against MNV capsid are able to control MNV infection in 
the distal ileum and spleen. 
 
Discussion 
Noroviruses are a significant public health problem throughout the world; however, 
there is no licensed vaccine for human noroviruses.  The study of immunity to noroviruses 
has been limited by the lack of an immunologically manipulable small animal model in 
which to study protection and immunity to live noroviruses, as well as the mechanisms 
involved in clearing norovirus infection from the intestine. The discovery of MNV and the 
development of murine models present the opportunity to examine immunity to a norovirus 
and its individual components.  
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The two to three day time frame of resolution of clinical symptoms of human 
norovirus infection has been largely thought to be due to innate immune mechanisms, and 
indeed previous studies in STAT1 and IFNαβγ receptor deficient mice support this 
conclusion. However, the present study demonstrates that adaptive immune cells also had 
roles that were relevant in three to seven days post-infection. B cells and T cells may be 
important not only in clearing a primary norovirus infection, but also in preventing 
subsequent infections.  Given that cross-reactivity between noroviruses has been 
demonstrated for T cells and antibodies within the same genogroup (145), effector cells from 
a previous norovirus infection may be important in combating additional norovirus challenge. 
Our data convincingly showed both arms of the immune system as important in both the 
natural history and the generation of memory effector cells in norovirus infection. This 
demonstrates that vaccination strategies against noroviruses must develop mechanisms to 
target T cells and/or B cells and boost their ability to function more effectively. 
In this report, we demonstrated that protective short-term and long-term immunity 
were generated to MNV by vaccination with live virus or VRPs expressing ORF2, the viral 
capsid protein. This is also the first study to delineate the importance of ORF2 but not ORF1 
and ORF3 proteins in generating effective immunity to noroviruses. While protection 
associated with ORF2 vaccination was not complete in all experiments, it lead to significant 
reduction in viral loads even in long term vaccination studies. Our demonstration of long 
term immunity to MNV is the first demonstration of long term immunity to a norovirus. 
Previous challenge studies with the human Norwalk virus strain did not demonstrate long 
term immunity (203); therefore, immunity generated by vaccination against MNV in contrast 
to human noroviruses must be further dissected. In particular, in the continued absence of a 
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cell culture system for human noroviruses, VLPs derived from human strains from different 
genogroups will be instrumental in determining if cross-protection exists between MNV and 
other noroviruses. Furthermore, VLPs may allow us to determine if subunit or live-attenuated 
virus is a better vaccine strategy.  
In the distal ileum, B cells, MHC Class I, and β2M were not required for viral 
clearance following vaccination with live virus; however, partial clearance still occurred 
following vaccination in MHC Class II -/- mice (Fig. 5.4B). Furthermore, virus was 
consistently cleared from the distal ilea of both B cell -/-, MHC Class I -/-, and MHC Class II 
-/- immunodeficient mice following acute MNV infection (Fig. 5.5B and 5.7).  In contrast, 
vaccination in the MLN was sensitive to the loss of any subset of adaptive immune cells, and 
B cells were particularly important in generating protective immunity following vaccination 
(Fig. 5.4B) or in clearance of acute infection (Fig. 5.7). These findings suggest that each arm 
of the adaptive immune response is important in efficient clearance of MNV infection, and   
effective vaccination likely requires a full complement of T cells and B cells to confer 
complete protection from MNV infection in multiple tissues. 
Immune CD4 and CD8 T cells derived from MNV immune wild type mice were able 
to clear persistent MNV infection in the intestine of RAG1-/- mice in adoptive transfer 
experiments. Similar experiments with rotavirus and reovirus infections show that control of 
these viruses is also dependent on the presence of T cells (61, 66, 266). However, in contrast 
to the requirement for both CD4 and CD8 T cells that we observed in MNV infection, 
rotavirus and reovirus each rely more heavily on either CD4 or CD8 T cell responses.  In 
rotavirus, the predominant protective role of T cells is due to TCRαβ+ CD8 T cells (48, 60, 
61, 164, 185), though CD4 T cells appear to play a specific role in rotavirus VP6 protein 
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mediated immunity (165). In reovirus, immunodepletion experiments have shown that CD4 
T cells are more important than CD8 T cells in reovirus immunity, though part of the CD4 T 
cell effect is likely related to B cell activation (266).  
We have demonstrated that T cells are important in norovirus immunity and shown 
that the T cell effector molecule perforin, but not IFNγ, had a role in clearance of MNV 
infection (Fig. 5.6B). It is interesting that we did not observe a requirement for IFNγ in 
clearance of MNV infection. Data from human norovirus studies show that CD4 and CD8 T 
cells are able to proliferate and produce IFNγ (145, 207, 247).  However, our finding that 
perforin may be important in norovirus immunity appears consistent with data from reovirus 
infection studies, where lymphocyte populations in the intestine have been demonstrated to 
express perforin, in addition to other T cell effector molecules FasL and TRAIL post-reovirus 
infection (21, 82). Because the effector role of perforin is unequivocally linked to granzyme-
mediated pathways (reviewed in (143, 267)), it is likely that one or more of the known 
granzymes will be demonstrated as having a role in clearance of MNV infection in future 
studies as well.  Overall, the difference between MNV and other enteric viruses in the 
importance of CD4 and CD8 T cells highlights the fact that similar organ tropisms for viruses 
may not always predict the manner in which they are individually controlled by the immune 
system.  
 CD4 and CD8 T cell subsets as well as B cells had different tissue specific roles in 
vaccination and clearance of MNV replication. Following vaccination, MHC Class I x β2-
m−/− mice were completely protected from MNV challenge with live virus in the distal ileum, 
but not in the MLN (Fig. 5.4B). In genetically deficient mice, CD4 T cells were important in 
the distal ileum at early time points post infection, with no effect in the MLN (5.5C). The 
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distal ileum of B cell deficient mice was cleared of MNV infection by seven days after 
infection, but the MLN was not.  Thus clearance of ileal MNV infection appears to be more 
dependent on each individual immune cell subset than clearance of infection from intestinal 
lymphatic tissue.  The reason for this is not clear.  It is possible that MNV infection in the 
lymphatic system is inaccessible to specific cell subsets or antibodies.  Passive transfer of 
mAbs successfully limited MNV infection in the intestine of RAG -/- mice; however, as 
RAG1-/- mice do not have normal mesenteric lymph nodes, adoptive and passive transfer 
experiments shed no light on the role of antibodies or T cells in lymphatic infection.  
Alternatively, because viral loads in the MLN are typically higher per gram of tissue weight 
than in the ileum, individual immune cell subsets may be insufficient to clear infection and 
instead require the concerted effect of multiple cell types. 
The role of B cells in control of MNV infection appears to be primarily due to the 
production of anti-viral antibody.  Data supporting this conclusion include decreased mucosal 
MNV infection following passive transfer of polyclonal antisera into immunodeficient mice 
(Fig. 5.8A) and the lack of viral clearance in the MLN of B cell deficient µMT mice (Fig. 
5.7). We further found that IgG mAbs can significantly decrease MNV infection at mucosal 
sites (Fig. 5.8B). Together these data argue that systemic IgG has a significant effect on 
mucosal norovirus infection, although the specific types of IgG induced and epitopes targeted 
by vaccination to alter mucosal infection remains an open question.   
In conclusion, this report includes the first demonstration of short and long term 
protective immunity against norovirus infection using both live virus and VLP-based 
vaccines. We showed that B cells, CD4 and CD8 T cells are all required for generation of 
complete and efficient protective immunity against MNV challenge, although protective 
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immunity can still be generated in the absence of individual subsets.  Additionally, a 
combination of studies using immunodeficient mice, lymphocyte depletion, and passive and 
adoptive transfers revealed that antibody, CD4, and C8 T cells each had important and tissue 
specific roles in clearance of norovirus infection from the murine intestine and MLN, with 
the role of CD8 T cells partially dependent on the effector molecule perforin.  
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Figure 5.1 
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VRP protein expression and serum IgG responses in immunized mice. 
(A) MNV protein expression from culture supernatants and cell lysates of BHK cells infected 
with VRPs expressing MNV1.CW3 ORF1, ORF2, or ORF3.  Chiba virus (CV) and 
Lordsdale virus (LV) VLPs were analyzed for cross-reactivity with MNV rabbit polyclonal 
antisera by western blot. (B) Sera from mice immunized with VRPs expressing ORF2 from 
MNV1.CW3, CV, or LV tested for cross-reactivity to MNV1.CW3, CV, and LV VLPs by 
ELISA.  (C) Serum anti-MNV antibody measured by ELISA from 8 week old and 14 month 
old mice after MNV1.CW3 challenge.  
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Figure 5.2 
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Short term vaccination against MNV using live MNV strains and VRPs expressing 
ORF1, ORF2 and ORF3 from MNV and ORF2 from Chiba virus and Lordsdale virus. 
(A) Vaccination protocol used in short term vaccination. (B) Viral titers in distal ileum and 
MLN of wild type mice after MNV1.CW3 challenge following vaccination with the 
indicated vaccines. (C) Viral titers in distal ileum and MLN of 8 week old or 14 month old 
wild type mice immunized with MNV1.CW3 ORF2 VRP or HA VRP and challenged with 
MNV1.CW3. These data are pooled from 2 independent experiments with 3-5 mice per 
group in each experiment. (**) indicates p<0.0001, (*) indicates p<0.05. LD indicates the 
limit of detection. 
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Figure 5.3 
A. 
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Long term vaccination against MNV using a live MNV strain and ORF2 VRPs. 
(A) Vaccination protocol used in long term vaccination. (B) Viral titers in distal ileum and 
MLN of wild type mice after MNV1.CW3 challenge following vaccination with indicated 
vaccines. These data are pooled from 3 independent experiments with 5 mice per group in 
each experiment. (**) indicates p<0.0001, (*) indicates p<0.05. LD indicates the limit of 
detection. 
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Figure 5.4 
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Complete short term protection against MNV infection requires MHC Class II, MHC 
Class I, β2M and B cells.  (A) Vaccination protocol used in short term vaccination using 
immunodeficient mice. (B) Viral titers in distal ileum MLN of B cell -/-, MHC Class II -/- 
and MHC Class I x β2M -/- mice after MNV1.CW3 challenge following short term 
vaccination with the indicated vaccines. These data are pooled from 3 independent 
experiments with 3-5 mice per group in each experiment.  (**) indicates p<0.0001, (*) 
indicates p<0.05. LD indicates the limit of detection. 
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Figure 5.5 
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MHC Class II limits early MNV replication, and deficiency in MHC Class II or  MHC 
Class I & β2m delays MNV clearance.  (A) Protocol of challenge used in experiments in 
this figure. Viral titers in distal ileum and MLN of wild type and MHC Class I x β2-m−/− mice 
(B) and MHC Class II-/- mice (C) after infection with MNV1.CW3. These data are pooled 
from 3 independent experiments with 3-5 mice per group in each experiment. (**) indicates 
p<0.0001, (*) indicates p<0.05. LD indicates the limit of detection. 
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Figure 5.6 
A. 
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B. 
 
Immune CD4 and CD8 T cells are both required and perforin plays a role in clearance 
of persistent MNV infection in RAG1-/- recipients.  (A) Representative flow cytometric 
analysis of splenocytes harvested from RAG1-/- recipient mice 6 days post transfer of 
splenocytes.  (B) Viral titers in duodenum/jejunum and distal ileum 6 days after adoptive 
transfer of medium alone, wild type non-immune splenocytes, wild type immune 
splenocytes, wild type immune splenocytes with or without depleting antibodies or immune 
splenocytes from IFNγ -/- or perforin -/-     (Pfn -/-) mice . These data are pooled from 3 
independent experiments with 3-5 mice per group in each experiment. (**) indicates 
p<0.0001, (*) indicates p<0.05. LD indicates the limit of detection. 
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Figure 5.7 
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B cells limit MNV replication and are required for MNV clearance in the distal ileum 
and mesenteric lymph nodes.  Viral titers in distal ileum and MLN of B6 and µMT mice. 
These data are pooled from at least 2 independent experiments with 5 mice per group in each 
experiment and each symbol indicates a sample from an individual mouse. (*) indicates 
p<0.05. LD indicates the limit of detection.  
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Figure 5.8 
A. 
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B. 
 
 
Immune serum and neutralizing IgG monoclonal antibodies reduce MNV infection 
from intestine and spleen of RAG1-/- mice.  Viral titers in distal ileum and spleen of 
persistently infected RAG1-/- recipients 6 days after passive transfer of either immune serum 
(A) or neutralizing monoclonal antibodies specific for capsid protein (B). These data are 
pooled from 3 independent experiments with 3 mice per group in each experiment. (**) 
indicates p<0.0001, (*) indicates p<0.05. LD indicates the limit of detection. 
 
  
 
 
 
 
CHAPTER VI. 
 
Alphavirus adjuvanted norovirus VLP vaccines:  Heterologous, humoral and mucosal 
immune responses protect from murine norovirus challenge 
 
Abstract 
 
 The development of an effective norovirus vaccine likely requires the capacity to 
protect against infection with multiple norovirus strains. Advanced recombinant genetic 
systems and the recent discovery of a mouse-tropic norovirus strain provide robust model 
systems for vaccine efficacy studies.  We coadministered multivalent VLP vaccines with 
alphavirus adjuvant particles to mice and evaluated homotypic and heterotypic humoral and 
cellular protective immunity to human and murine norovirus strains.  Multivalent VLP 
vaccines induced robust IFN-γ and receptor-blocking antibody responses to heterologous 
human strains not included in the vaccine composition.  Furthermore, vaccination with or 
without MNV VLP resulted in significantly reduced viral loads following MNV challenge.  
Passive transfer of sera from mice monovalently vaccinated with MNV VLP to 
immunodeficient mice completely protected against MNV infection; however, adoptive 
transfer of purified CD4+ or CD8+ cells did not influence viral loads in murine tissues.  
Together, these data suggest humoral immunity induced by multivalent norovirus vaccines 
may protect against heterologous norovirus challenge. 
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Introduction 
 Noroviruses are responsible for at least 23 million global infections in the United 
States annually (166), although this number is likely under a drastic underestimate.  Effective 
vaccines are needed to control widespread norovirus outbreaks; however, immunity to 
noroviruses remains a controversial topic, as short-term but not long-term immunity could 
protect against re-infection in human challenge studies (119, 203).  Human norovirus vaccine 
research has been hampered by the lack of a small animal model or in vitro culture system 
for identifying key components of protective immunity. The manipulation of recombinant 
genetic systems, however, has allowed for in vitro production of norovirus antigens from 
multiple strains that can be delivered as norovirus vaccines to small animals to generate 
immune responses (10, 80, 93, 105, 178, 207, 284, 289).  Furthermore, the recent discoveries 
of murine norovirus strains that can replicate in vitro and in vivo provide alternative avenues 
for vaccine development (124, 277).   
 Previous studies with norovirus-like particle (VLP) vaccination have shown that 
humoral and cellular immune responses can be generated to human norovirus strains in both 
humans and mice (8, 9, 178, 246, 247).  Furthermore, antibody responses following infection 
with norovirus or immunization with VLP can block ABH histo-blood group antigen 
(HBGA) binding to VLPs in a strain specific manner (91).  HBGAs are carbohydrates 
ubiquitously expressed on mucosal tissues and red blood cells that have been implicated as 
natural receptors for norovirus binding and entry, suggesting blockade of HBGA interactions 
with VLPs may prevent norovirus infection (159).  Alternatively, CD4+ T cell responses 
following norovirus infection in humans or VLP vaccination in mice are also induced and 
have been characterized by secretion of Type II interferons (IFN-γ) upon stimulation with 
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VLPs (145, 178).  Presently, however, the components of protective immunity and the 
impact of multiple exposures in norovirus immunity are unknown.   
 The norovirus family consists of 40+ genetically diverse strains that can differ by up 
to 40% in capsid amino acid sequence between strains within a genogroup and by >50% 
between genogroups (75).  Most studies into norovirus immunity have focused on individual 
strains; however, a limited number have shown that antibody responses to one norovirus 
strain have little cross-reactivity to other strains both within and across genogroups (86, 145, 
180, 219, 259).  Not surprisingly, human challenge studies have shown that infection with 
one norovirus strain does not prevent infection with another strain (281).  Efficacy of 
norovirus vaccines, however, is dependent on protection from multiple circulating strains.  
Our group previously addressed this problem by showing that multivalent immunization with 
VEE replicon particles (VRPs) expressing norovirus VLPs from three genetically distinct 
strains induced antibody responses that blocked receptor binding to a heterologous VLP not 
included in the vaccine composition (149).  This is the first data suggesting that 
administration of multiple VLPs may be a successful vaccination strategy for protection 
against more than one norovirus strain, including those not incorporated in the vaccine.  
However, the key strains necessary for eliciting a broad-based immune response to multiple 
noroviruses still requires more detailed studies including homologous and heterologous 
cross-challenge in experimental animals. 
 To induce robust immune responses to noroviruses, some VLP vaccines have been 
coadministered with known biological adjuvants (8, 10, 80, 178, 207).  Previous studies from 
our group have alternatively used the VRP as a delivery vaccine vector for VLP expression 
in vivo (93).  We believe this model is advantageous because mammalian cells are permissive 
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to VRP infection and VLPs are assembled in vivo in large quantities, with the caveat that 
different vaccine formulations are needed for each norovirus strain.  However, a recent 
finding from Thompson et al. showed that VRPs have inherent adjuvant activity when 
uncoupled from transgene expression function (256).  This approach has enhanced safety 
features associated with uncoupling VRP infectivity from transgene protein expression 
function and the ability to administer multiple VLPs simultaneously with a common adjuvant 
However, it is not clear if this approach provides for protective immune responses.  
 The concurrent discovery of murine noroviruses (MNV) provides a workable model 
in which to test the efficacy of multivalent vaccine formulations as well as the mechanism of 
protection (124, 277).  Upon peroral inoculation, MNV infects the murine intestine as the 
primary site of replication followed by establishment in multiple peripheral tissues as 
secondary sites.  In this study, we evaluate in detail the immune responses elicited to human 
and murine norovirus strains within and across genogroups following multivalent vaccination 
with norovirus VLPs coadministered with null VRP adjuvants.  These experiments establish 
the null VRP adjuvant as a robust strategy for eliciting high levels of protective humoral and 
cellular immunity against noroviruses. 
 
Materials and methods 
VLPs and VRPs.  VRPs expressing norovirus ORF 2 were cloned and produced as described 
in (11).  Null VRP were kindly provided by the Carolina Vaccine Institute (UNC).  
Norovirus VLPs were produced and purified as described in (149) and visualized by EM to 
insure appropriate particle size and structure.  VLPs used in vaccination experiments were 
further concentrated by centrifugation at 3000 x g in Centricon tubes (Millipore) O/N at 4º C.  
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VLPs used in ELISpots were produced by direct electroporation of pVR21-NoV ORF2 RNA 
to avoid potential structural VEE protein contamination. 
Vaccination.  6 week old BALB/c mice (Charles River) were vaccinated via footpad 
inoculation with monovalent or multivalent norovirus VLP vaccines containing 2 µg of each 
VLP alone or in conjunction with 105 null VRP or 1 µg CpG DNA (Invivogen).  Mice used 
in VLP titration experiments received VLP doses of 0.02 µg, 0.2 µg, 2 µg, or 10 µg  Norwalk 
virus (NV) VLP coadministered with null VRP.  Other monovalent vaccination groups 
received NV (GI.1), , Lordsdale-like (LV; GII.4), or MNV-1 (GV) VLPs.  Multivalent 
groups received genogroup I (GI)-specific VLPs representing Southampton (SH; GI.2), 
Desert Shield (DS; GI.3), and Chiba (CV; GI.4) strains with or without NV VLPs; GII-
specific VLPs representing Hawaii (HV; GII.1), Toronto (TV; GII.3), and M7 (GII.13) 
strains with or without LV VLPs; or complete VLP cocktails containing all GI and GII VLPs 
with or without NV and LV VLPs or all GI and GII VLPs with or without MNV VLPs (GV) 
(Table 6.1).  Mice were vaccinated and boosted at days 0 and 28.  Donor mice for adoptive 
transfers were vaccinated a third time on day 52.   
MNV infection.  MNV-1 CW.3 was kindly provided by Dr. H.W. Virgin (Washington 
University School of Medicine).  To generate virus stocks, murine macrophage-like Raw 
264.7 cells (UNC TCF) cultured in complete DMEM (Gibco) were infected with MNV at an 
MOI of 0.1 and incubated for 36 hours.  Supernatant was then collected, clarified by 
centrifugation at 13,000 x g for 15 min (Beckman), and ultracentrifuged for 3 h at 100,000 x 
g over a 5% sucrose cushion to pellet purified virus.  Pellets were resuspended in PBS, 
aliquotted, and stored at -80º C until use.  Virus stocks were titered by plaque assay as 
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previously described (277).  Mice used in MNV challenge experiments were infected with 3 
x 107 pfu MNV-1 CW.3 in 30 µl total volume per orally on d 42.   
Sera, feces, and tissue samples.  Animals were euthanized and distal ileum, spleen, 
mesenteric lymph node (MLN), and sera were harvested from mice used in MNV challenge 
experiments on d 45 and stored at -80º C.  Tissues were resuspended in 1 ml complete 
DMEM and disrupted with silica/zirconia beads (Biospec Products) using the MagnaLyser 
homogenizer (Roche) at 6000 rpm for 30 s.   Sera and fecal samples from all other mice were 
collected on d 42.  Ten fecal pellets per mouse were resuspended in 1 ml PBS containing 
10% goat serum and 0.01% Kathon fecal inactivator (Supeleco) and homogenized by 
vortexing for 20 min.  Solid material was then removed by centrifugation for 20 min, and 
fecal extracts stored at -20º C. 
ELISA and HBGA binding blockade assays.  ELISAs for serum IgG antibody cross-reactivity 
to NoV VLPs and binding assays for serum antibody blockade of HBGA binding were 
performed as previously described (149).  IgG subtype ELISAs were performed as described 
using purified IgG1 (Sigma) or IgG2a (Sigma) as standard controls and anti-IgG1-AP 
(Southern Biotech) and anti-IgG2a-AP (Southern Biotech) as secondary antibodies, 
respectively.  To quantitate specific antibody in fecal extracts, 96-well high binding plates 
(Costar) were coated with 2 µg VLP or serially diluted mouse IgG or IgA standard for 4 h at 
RT and blocked overnight in blocking buffer (Sigma) at 4° C.  Fecal extracts diluted 1:2 in 
blocking buffer were 2-fold serially diluted and incubated in wells containing VLP for 2 h at 
RT.  Wells were then incubated with anti-mouse IgG-HRP or IgA-HRP (Southern Biotech) 
for 2 h and developed with OPD tablets (Sigma) dissolved in 1:1 0.1 M sodium citrate and 
0.1 M citric acid and 0.02% hydrogen peroxide for 30 min in the dark.  Reactions were 
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stopped with 0.1 M sodium fluoride and read at OD450 (Biorad Model 680).  IFN-γ EIA (BD 
Pharmingen) was performed per manufacturer’s instructions.  Splenocyte culture was 
conducted as described for ELISpots.  Culture supernatants were clarified by centrifugation, 
diluted 1:2 in assay diluent, followed by two-fold serial dilutions for use in the assay.   
ELISpots.  Prewetted multiscreen 96-well filtration plates (Millipore) were coated overnight 
with rat anti-mouse IFN-γ antibody AN18 (Mabtech) at a concentration of 5µg/ml in 100 µl 
PBS at 4°C.  Plates were then blocked for >1 h with complete RPMI 1640 media (10% FBS, 
1mM non-essential amino acids, 1mM sodium pyruvate, 100 ug/ml penicillin-streptomicin) 
at 37°C.  Spleens from vaccinated mice were harvested and individual splenocyte 
suspensions obtained by manual disruption, filtration with a 100 µm cell strainer, and lysis of 
red blood cells.  5 x 105 splenocytes were seeded onto plates and stimulated with NV VLPs 
or LV VLPs at 1 µg/ml or Concanavalin A at 5 µg/ml (MP Biomedicals) in duplicate in 100 
µl media for 48 h at 37°C under 5% CO2.  Plates were then washed with PBS/0.05% Tween, 
incubated with 100 µl biotinylated anti-mouse IFN-γ antibody at 1ug/ml (Mabtech) in PBS-
0.5% FBS for 2 h at 37°C, washed, and incubated with 100 µl streptavidin-alkaline 
phosphatase (Mabtech) diluted 1:1000 in PBS-0.5% FBS for 1 h.  Plates were washed and 
developed with 100 µl BCIP/NBT (Promega) as substrate in AP Buffer (0.5 M Tris, 0.5 M 
NaCl, 0.025 M MgCl 2).  Spots counts were analyzed by Zellnet Consulting (Fort Lee, New 
Jersey).  Wells containing confluent areas were assigned compensatory values using the 
equation [total spot number = spot count + 2 x (spot count x %confluence /[100% - 
%confluence])]. 
Passive and adoptive transfers.  Eight wild-type mice were immunized as described above, 
and unimmunized controls were treated in parallel.  Sera and spleens from immune and 
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control groups were harvested on d 56.  Spleens from respective immunization groups were 
pooled and single-cell splenocyte suspensions obtained by manual disruption through a 100 
µm cell-strainer.  Splenocyte suspensions were resuspended in MACS buffer (PBS pH 7.2, 
0.5% BSA, 2 mM EDTA), divided in half, and CD4+ or CD8+ cells purified, respectively, by 
magnetic bead sorting using the QuadroMACS purification system (Miltenyi) per 
manufacturer’s protocol.  For adoptive transfers, 5 x 106 CD4+ or CD8+ cells from immune or 
non-immune mice were administered in a total volume of 500 µl i.p. to Scid C.B.17 mice 
(Jackson Laboratories) (N=6/recipient group).  For passive transfer of sera, immune or non-
immune serum samples were equivalently pooled, diluted 1:2 in PBS, and administered i.p. 
to Scid mice at 200 µl per mouse.  Scid mice were challenged with 3 x 107 pfu MNV.CW3 
twenty-four hours post-transfer, and tissues were harvested three days post-infection.  Tissue 
samples were processed as described above.   
FACS.  Whole and purified splenocyte suspensions from adoptive transfer groups were set 
aside for FACS analysis.  5 x 105 cells per tube were blocked with anti-FcκII/III (1:500; 
eBioscience) in 100 µl FACS buffer (HBSS + 2% FBS) for 20 min on ice.  Cells were then 
pelleted, resuspended in 100 ul FACS buffer, and stained with anti-B220 conjugated to FITC 
(1:400), APC (1:400), or biotin (1:800) as single color controls for staining or cocktails 
containing anti-CD3-FITC (1:200), anti-CD4-Biotin (1:1000), and anti-CD8-APC (1:800).  
Cells were incubated for 45 min on ice, pelleted, and resuspended in 100 µl FACS buffer 
with avidin-PerCP (1:400) for 45 min on ice.  Samples were then washed and resuspended in 
500 µl PBS.  All antibodies were obtained from eBioscience (San Diego, CA).  FACS 
analysis was performed by the UNC Flow Cytometry Core Facility.   
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Real-time PCR.  RNA was Trizol-extracted from VLPs and subjected to RT-PCR using 
random hexamers for amplification.  Real-time PCR was performed using non-structural 
VEE-specific primers provided by Ande West (Carolina Vaccine Institute, UNC).     
Statistics.  All statistics comparing two groups were performed using the two-tailed t-test; all 
statistics comparing multiple groups were performed using One-way ANOVA and Tukey’s 
post-test in GraphPad software. Single asterisks (*) are representative of P values <0.05, 
double asterisks (**) are representative of P<0.01, and triple asterisks (***) are 
representative of P<0.001. 
 
Results 
Null VRP adjuvants induce robust systemic and mucosal antibody responses in 
monovalent VLP vaccines. 
 To determine effective VLP concentrations for subsequent vaccinations, mice were 
immunized twice with a VLP titration series consisting of 10 µg, 2 µg, 0.2 µg, or 0.02 µg NV 
VLP coadministered with 105 IU null VRP.  Fecal IgA, fecal IgG, serum IgG, and serum 
blockade of receptor binding were evaluated (Fig. 6.1).  Measurable IgA and IgG were 
detected in fecal extracts of all mice receiving 0.2-10 µg VLP (Fig. 6.1a).  Antibody titers 
increased in correlation with increasing amounts of VLP administered, and IgG titers were 
consistently higher than IgA.  Serum antibody was also significantly higher following 
vaccination with all VLP concentration >0.02 µg (P<0.05; Fig. 6.1b) and blocked H type 3 
receptor binding increasingly effectively with increased VLP concentration (Fig. 6.1c).  From 
these data, we concluded that 2 µg VLP elicited a robust humoral immune response in 
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rodents, and as such, all subsequent multivalent vaccine experiments were performed at this 
dose.   
 To compare the effect of null VRP adjuvant activity to that of an FDA-approved 
adjuvant for human vaccination, we immunized mice with 2 µg NV VLP or LV VLP alone 
or in conjunction with either 105 IU null VRP or 1 µg CpG DNA.  Serum antibody responses 
to NV or LV VLPs, respectively, were significantly higher following null VRP vaccination 
than CpG vaccination (P<0.01 and P<0.001, respectively), and both adjuvant groups induced 
significantly higher responses than VLP alone (P<0.001; Fig. 6.2a).  Sera from groups 
vaccinated with NV VLP but not LV VLP blocked NV VLP binding to H type 3, and 
adjuvanted groups blocked binding with lower sera concentrations than groups receiving 
VLP alone (6.2b).  Parallel results were obtained for blockade of LV VLP binding to H type 
3 following LV VLP vaccination, respectively (Fig. 6.2c).  Percentage of sera necessary for 
blockade of 50% (BT50) and 90% (BT90) H type 3 binding are shown in Table 6.2.  BT50 
and BT90 values were significantly lower in adjuvanted than non-adjuvanted sera (P<0.05).   
 
Multivalent vaccines induce enhanced cross-reactive and receptor-blocking antibody 
responses. 
 To determine the effect of multivalent VLP vaccination coadministered with null 
VRP or CpG adjuvants on homotypic and heterotypic antibody responses and receptor 
blockade, we vaccinated mice with pools of VLPs (2 µg/VLP) alone or coadministered with 
null VRP or CpG adjuvants.  Mice received multivalent immunizations consisting of 
genogroup I (GI) VLPs, GII VLPs, or both GI and GII VLPs.  GI VLPs are derived from the 
NV (GI.1), SoV (GI.2), DS (GI.3), and Chiba (GI.4) strains, and the GII VLPs are derived 
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from the LV (GII.4), HV (GII.1), TV (GII.3), and M7 (GII.13) strains. VLP vaccine 
formulations and acronyms are summarized in Table 6.1.  NV VLPs were excluded from GI-
specific (GI-) and complete GI/GII (GI-/GII-) multivalent vaccine formulations to allow 
determination of heterotypic antibody blockade of receptor binding to NV VLPs compared to 
vaccines containing the NV antigen.  LV VLPs were likewise excluded GII-specific (GII-) 
and complete (GI-/GII-) vaccine formulations  Serum IgG responses following vaccination 
with the complete cocktail of GI/GII VLPs (GI+/GII+) coadministered with null VRP 
adjuvants resulted in robust antibody responses to NV and LV VLPs, respectively, that were 
significantly higher than in groups lacking adjuvant (P<0.001; Fig. 6.3a).  Furthermore, 
antisera following GI-/GII- vaccination still mounted strong cross-reactive IgG responses to 
NV and LV VLPs, supporting our previous findings (149).  GI-/GII- VLP pools 
coadministered with null VRP induced significantly higher heterotypic responses to NV and 
LV VLPs than GI-/GII- VLP vaccination without adjuvant (P<0.05).  However, GI-/GII- 
heterotypic antisera reactivity to NV and LV VLPs was significantly less than homotypic 
GI+/GII+ antisera (P<0.05).  Evaluation of antisera blockade of H type 3 binding to VLPs 
revealed that GI+/GII+ antisera completely blocked H type 3 binding to both NV and LV 
VLPs with increased blockade in groups receiving adjuvant (Fig. 6.3b-c).  Significantly less 
sera was required to attain BT90 values following GI+/GII+ vaccination with adjuvant than 
without adjuvant (Table 6.2).  Furthermore, GI-/GII- antisera following null VRP vaccination 
contained cross-reactive antibodies that partially ablated H type 3 binding to both NV and 
LV VLPs.  BT50 serum concentrations were significantly higher following GI-/GII- null 
VRP vaccination than GI+/GII+ null VRP vaccination in NV VLP-H type 3 blockade 
(P<0.05); however, they were not significantly different in LV VLP-H type 3 blockade.  
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Also, BT50 concentrations were significantly lower following GI-/GII- null VRP vaccination 
than GI-/GII- VLP vaccination without adjuvant (P<0.001 in NV blockade and P<0.05 in LV 
blockade).  These data suggest that multivalent vaccines coadministered with null VRP 
adjuvants efficiently induce cross-reactive and receptor-blocking IgG responses to 
heterologous strains that cannot be attained following monovalent vaccination. 
 We performed an additional study where mice were vaccinated with genogroup-
specific VLP pools in conjunction with null VRP adjuvant.  Groups of mice received 
immunizations of all four GI VLPs (GI+), all four GII VLPs (GII+) or three genogroup-
specific VLPs lacking NV or LV VLPs, respectively (GI- and GII-; Table 6.1).  Serum IgG 
responses comparing genogroup-specific vaccination to monovalent or multi-genogroup VLP 
vaccines are shown in Fig. 6.4a.  Cross-reactive responses of monovalent NV antisera to LV 
VLP and vice versa are shown as controls.  All monovalent or multivalent vaccines 
containing NV or LV VLPs, respectively, induced highly reactive IgG responses to NV or 
LV VLPs that were not significantly different from one another.  Genogroup-specific or 
multi-genogroup VLP pools lacking NV and/or LV, respectively, mounted cross-reactive 
responses that were not significantly different from one another and were only significantly 
less than homotypic monovalent responses (P<0.01) but not homotypic multivalent 
responses.  Blockade profiles from each genogroup-specific vaccination group uphold 
findings discussed above whereby multivalent genogroup-specific vaccines lacking target 
antigens mount intermediate blockade responses (Fig. 6.4 b & c) with BT50 values 
significantly higher than homotypic values (P<0.05) but significantly lower than heterotypic 
monovalent values (P<0.01; Table 6.2).  Furthermore, increasing the number of VLPs in the 
vaccine composition did not significantly change homotypic antibody titers or blockade of 
 193 
receptor binding.  Increasing genogroup-specific VLP vaccines to include VLPs from both 
genogroups appeared to moderately increase cross-reactive responses to both NV and LV 
VLPs, respectively.  Increasing the amount of null VRP administered from 105 IU to 106 IU 
per vaccine did not enhance cross-reactive receptor-blockade responses (data not shown). 
 Complete cross-reactivity profiles from all null VRP antisera groups to the entire 
panel of VLPs is shown in Fig. 6.5.  Obvious trends that emerge are significantly low cross-
reactivity to additional VLPs following monovalent vaccination with NV or LV (P<0.001), 
although slightly increased cross-reactivity exists to VLPs within a genogroup; low cross-
reactivity to strains in opposite genogroups following GI and GII vaccination (P<0.05); 
enhanced cross-reactivity to heterologous NV or  LV strains within a genogroup following 
GI- and GII- vaccination, respectively; and cumulative cross-reactivity to heterologous NV 
and LV strains following complete VLP vaccination.  These results suggest cross-reactivity 
induced by multivalent vaccination is likely genogroup-specific; therefore, vaccines must 
contain both GI and GII strains to induce a cumulative cross-reactivity to the majority of 
human norovirus strains. 
 Because noroviruses are enteric pathogens and the likely site of neutralization is the 
gastrointestinal tract, we also analyzed NV-specific IgG and IgA content in fecal extracts 
from monovalent and multivalent vaccination groups coadministered with no adjuvant, CpG 
or null VRP (Table 6.3).  NV-reactive and total IgG and IgA content were determined, and 
percentages of NV-specific subtype antibody were calculated.  Significantly more total IgA 
than IgG was present in fecal extracts (P<0.001); however, significantly more IgG than IgA 
was specific for NV VLPs as a percentage of total IgG than total IgA (P<0.001).  Vaccination 
with null VRP adjuvant induced significantly more total IgG but not IgA compared to CpG 
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(P<0.05) or VLP alone (P<0.01).  A similar trend was seen by increasing the number of 
VLPs administered, although values were not significant.  Monovalent vaccination with null 
VRP induced significantly higher homotypic NV-specific IgA responses than multivalent 
vaccination (P<0.05); multivalent vaccination induced higher homotypic IgG responses than 
monovalent vaccination, although not significantly.  Multivalent GI-/GII- null VRP 
vaccination induced significantly lower NV-specific IgG (P<0.05) but not NV-specific IgA 
than GI+/GII+ vaccination.  Percentages of NV-specific IgG were equivalent in monovalent 
and GI+/GII+ groups receiving adjuvant and contributed a substantial amount to total 
measurable IgG; percentages of NV-specific IgA were miniscule.  LV-specific responses 
following monovalent and multivalent LV VLP vaccination were lower and more variable 
(data not shown).  These data suggest multivalent null VRP vaccination induces a 
predominantly IgG subtype response in feces.  Fecal extracts from unimmunized controls 
were able to block receptor binding equally as well as from vaccinated samples; therefore, 
neutralization capacity of these antibodies could not be determined (data not shown). 
 
Null VRP vaccines induce stimulation of T helper 1 cells. 
 Previous literature has reported that CD4+ T helper 1 (TH1) cells are activated 
following norovirus infection and IFN-γ produced (145).  To evaluate activation of TH1 
responses following monovalent and multivalent null VRP vaccination, we harvested 
splenocytes from vaccinated mice and stimulated cultures with NV or LV VLPs.  We 
performed IFN-γ ELISpots on splenocytes from unimmunized mice or mice immunized with 
NV or LV VLPs without adjuvant; NV VLPs, LV VLPs, GI+/GII+ VLP pools, or GI-/GII- 
VLP pools coadministered with null VRP; or null VRP alone (Fig. 6.6a).  Splenocytes from 
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mice immunized with VLP alone did not secrete IFN-γ upon stimulation with NV or LV 
VLPs.  In contrast, splenocyte cultures from all mice immunized with null VRP contained 
significantly higher numbers of IFN-γ-secreting cells following stimulation with NV or LV 
VLP (P<0.01) than VLP alone or unimmunized controls.  Furthermore, the numbers of IFN-
γ-secreting cells following NV or LV VLP stimulation were not different from one another in 
any null VRP vaccine group, regardless of presence or number of VLPs in the vaccine 
composition.  Unstimulated cultures did not secrete IFN-γ, ruling out non-specific 
stimulation.  To exclude the possibility of VLP contamination during production with 
structural VRP particles, which have similar densities as VLPs and may cosediment during 
purification, we produced all VLPs used in stimulations by direct electroporation of VEE 
non-structural vector RNA containing the norovirus capsid sequence without VEE helper 
RNAs.  Conversely, reverse-transcription PCR followed by real-time PCR of NV and LV 
VLP preparations with non-structural VEE-specific primers were positive, revealing that 
VLPs encapsidate VEE non-structural RNA upon assembly (data not shown).  This finding 
explains the high number of IFN-γ secreting cells upon VLP stimulation in cultures from 
mice vaccinated with null VRP alone.  Furthermore, we cannot determine from our ELISpot 
data if cross-stimulation with NV and LV VLP exists in null VRP vaccinated mice.  Because 
ELISpots measure the number of IFN-γ secreting cells and not total amounts of IFN-γ 
produced, we stimulated parallel splenocyte cultures with NV or LV VLPs and harvested 
culture supernatants to circumvent this issue.  EIA of culture supernatants from each group 
again showed high IFN-γ secretion in all groups vaccinated with null VRP; however, 
coadministration of NV VLP or LV VLP induced secretion of significantly more IFN-γ upon 
stimulation with homologous NV or LV VLPs, respectively, than vice versa (P<0.05; Fig. 
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6.6b).  This data suggests that norovirus strain-specific stimulation is in fact induced; 
however, the variability between groups in this experiment does not allow for null VRP 
background compensation or analysis of cross-reactivity to norovirus VLPs.   
 Because TH1 responses correlate with serum IgG2a subclass responses, we used this 
alternative evaluation to determine induction of TH1 cell responses by multivalent VLP 
vaccination.  Serum samples from mice vaccinated with monovalent or multivalent VLP 
vaccines alone or in conjunction with CpG or null VRP adjuvants were analyzed for IgG1 
and IgG2a subclass specificity to NV and/or LV VLPs (Fig. 6.7).  Monovalent and 
multivalent vaccination with NV and/or LV VLPs induced IgG2a titers that were slightly 
increased when coadministered with CpG and significantly increased when coadministered 
with null VRP compared to VLP alone (P<0.05).  Heterotypic IgG2a responses to NV and 
LV VLPs following GI-/GII- vaccination were lower than homotypic responses, and titers 
were not different in CpG and null VRP recipient groups.  IgG1 titers were not significantly 
different in VLP versus adjuvant groups but maintained uniform levels of reactivity to NV 
and LV VLPs that were significantly lower than IgG2a titers in null VRP recipient groups 
(P<0.05), although a spike in NV-specific IgG1 levels appeared to occur following 
monovalent and multivalent VLP vaccination with CpG.  Increasing the number of VLPs in 
NV or LV null VRP vaccines from one to four to eight VLPs did not change specific IgG1 or 
IgG2a responses to NV or LV VLPs, respectively.  Together, these data suggest null VRP 
vaccines induce IgG2a responses specific for NV and/or LV antigens, which may correlate to 
a TH1-type response.  Furthermore, CpG and null VRP adjuvants induced cross-reactive 
IgG2a to NV and LV VLPs in the GI-/GII- vaccine group, implying TH1 cross-reactivity to 
additional strains may also occur. 
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Multivalent VLP vaccines coadministered with null VRP result in decreased viral load 
following MNV challenge. 
 To determine if monovalent and multivalent vaccines can protect against norovirus 
challenge, we utilized the MNV infection model.  Mice were immunized with monovalent 
MNV VLP vaccines or multivalent VLP vaccines consisting of eight human VLPs with 
MNV VLPs (Hu+/MNV+) or without MNV VLPs (Hu+/MNV-; Table 6.1).  Each was 
administered alone or in conjunction with CpG or null VRP adjuvants, similar to the human 
strain vaccines described previously in this paper.  Mice were then challenged with MNV 
three weeks after secondary immunization, and spleens, mesenteric lymph nodes (MLN), and 
distal ileums were harvested three days later.  Tissue homogenates were analyzed for viral 
titers by plaque assay.  Monovalent and MNV+/Hu+ vaccination with or without adjuvant 
induced complete protection from MNV infection in the spleen, with significantly lower viral 
titers than vaccination with null VRP alone (P<0.001; Fig. 6.8a).  Hu+/MNV- vaccination did 
not completely protect against MNV infection in the spleen; however, viral loads were 
significantly lower in Hu+/MNV- groups coadministered with null VRP adjuvant compared 
to those vaccinated with null VRP alone (P<0.05).  Viral loads in MLN and distal ileum were 
not significantly reduced following monovalent or multivalent VLP or CpG vaccination 
compared to unvaccinated controls.  Null VRP administration, however, significantly 
reduced viral loads compared to controls following monovalent and Hu+/MNV+ vaccination 
in both MLN (P<0.001) and distal ileum (P<0.05).  Hu+/MNV- vaccination coadministered 
with null VRP significantly reduced viral loads in the distal ileum as well (P<0.05).  MNV, 
Hu+/MNV+, and Hu+/MNV- antisera all contained MNV-reactive serum IgG following null 
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VRP vaccination, where MNV and Hu+/MNV+ responses were equivalent and significantly 
higher than the cross-reactive response in Hu+/MNV- groups (P<0.001; Fig. 6.8b). These 
findings show that multivalent VRP vaccines can successfully protect against spread of 
norovirus infection to some peripheral tissues and can reduce viral loads in primary and 
additional secondary sites of replication even without the presence of homologous MNV 
antigen in the vaccine composition using the MNV infection model.  These results lend 
strong support for the development of multivalent human norovirus vaccines. 
 
Humoral immunity protects against acute MNV infection. 
 To determine the mechanism of protection induced by null VRP vaccines, we 
vaccinated immunocompetent wild-type mice monovalently with MNV VLPs 
coadministered with null VRP and passively transferred antisera or adoptively transferred 
purified CD4+ or CD8+ splenocytes into immunodeficient Scid mice.  Unimmunized mice 
were treated in parallel as controls.  CD4+/CD3+ and CD8+/CD3+ T cells from immune and 
non-immune spleens were each found to be ≥90% pure by FACS analysis (Fig. 6.9a-d).  
After 24 h, Scid mice were infected with MNV, and tissues were harvested three days later.  
Because Scid mice do not support a competent adaptive immune system and have 
underdeveloped immune organs, MLNs were not analyzed.  Adoptive transfers of immune 
CD4+ or CD8+ did not prevent establishment of MNV infection in the spleen compared to 
transfer of non-immune cells, as determined by plaque assay (Fig. 6.10a).  Passive transfer of 
antisera, however, was able to completely protect immunodeficient mice from MNV 
infection in the spleen in all mice tested, whereas transfer of non-immune sera had no effect 
on viral titers (P<0.001).  Significant MNV-specific antibodies were found to be circulating 
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in both donor wild-type mice and recipient Scid mice compared to non-immune controls 
(P<0.001; Fig. 6.10b).  Plaque assays on distal ileum of immune and non-immune mice did 
not result in measurable viral titers, indicating immunodeficient mice may support 
differential infection than wild-type mice.  Additional studies must be conducted to 
determine if viral titers are present in duodenum, jejunum, and proximal ileum following 
MNV infection in Scid mice.  Nonetheless, these data clearly indicate that humoral immunity 
induced by monovalent null VRP vaccination can prevent establishment of acute MNV 
infection and provide further support for the development of null VRP vaccines in humans. 
 
Discussion 
 Multivalent vaccination has become a popular tool in generating cross-reactive 
immunity to heterologous strains of bacterial and viral pathogens.  Cattle immunized with 
bivalent adjuvanted vaccines containing two viral subtypes of killed bovine viral diarrheal 
virus produced neutralizing antibody and IFN-γ responses to both strains (210).  Mice 
vaccinated simultaneously with VEE replicon particles (VRPs) expressing three different 
cowpox proteins survived infection and were protected from clinical symptoms better than 
monovalently vaccinated mice (257).  In humans, adjuvanted multivalent streptococcal 
peptide vaccines from six serotypes are in phase I clinical trials (136), and multivalent 
vaccines containing 26 serotypes are in development (101).  Of particular significance, 
effective quadrivalent human papilloma virus (HPV) VLP vaccines are currently available 
(reviewed in (233)), which are as effective as monovalent vaccines at inducing 
seroconversion (65).  Multivalent vaccination is not without its drawbacks, however.  
Immune interference was reported in one study where diphtheria and tetanus toxoids had 
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reduced immunogenicity when coadministered with pertussis toxoid (260).  Furthermore, 
multivalent vaccines do not necessarily elicit cross-reactive immunity to additional 
heterologous strains (36).  This is the first study to address the efficacy of multivalent 
norovirus VLP vaccines using a codelivered adjuvant as well as the first study to address the 
efficacy of null VRP adjuvants as vaccine components in a small animal infection model.  In 
this study, null VRPs represent a novel vaccine adjuvant that should not only be safe for use 
in human vaccine trials (45) but also generates higher immune induction to coadministered 
antigens than the human-approved CpG DNA adjuvant.     
We have systematically designed and tested the efficacy of monovalent and 
multivalent norovirus VLP vaccines coadministered with null VRP adjuvants in generating 
cross-reactive and receptor-blocking antibody responses, T cell responses, and protection 
from heterologous MNV challenge.  These findings are supported by evidence showing that:  
1) Immunodeficient mice were completely protected against MNV infection following 
transfer of antisera from wild-type mice following monovalent MNV VLP vaccination 
coadministered with null VRP adjuvant, most likely by antibody-mediated neutralization.  2) 
Increasing the number of antigens in the vaccine composition did not significantly blunt the 
immune response to the original antigens.  3) VLP vaccines lacking target antigens induced 
strong cross-reactive antibody responses to heterologous strains that partially blocked 
receptor binding to these strains.  4) VLP vaccines lacking target antigens significantly 
reduced viral loads in murine tissues following heterologous viral challenge.  Although 
multivalent vaccination did not provide protection from heterologous MNV infection, a 
significant reduction in viral load may be tightly correlated with reduction of clinical disease, 
as seen with HIV, respiratory syncytial virus, or human papilloma virus infections (1, 24, 
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67), or transmission following infection.  However, one study recently showed no differences 
in viral load in symptomatic and unsymptomatic norovirus infected individuals (194). 
Overall, our data provides strong support and justification for development of multivalent 
VLP/null VRP vaccines against highly heterogeneous noroviruses.   
 Alphavirus replicon particles (VRP) are single hit vectors which traditionally express 
high concentrations of transgene in infected tissues, and the dogma has argued that co-
expression is essential for vaccine efficacy (214).  Alternatively, the adjuvant activity of 
VRPs lacking a transgene has been clearly documented (256).  Our data clearly show that co-
administration of VLPs with null VRP adjuvants induces significant systemic, mucosal, and 
cellular immune responses.  The mechanism by which null VRPs function as adjuvants is not 
known, but stimulation of immune cells by the single round of viral RNA replication these 
replicons undergo in mammalian cells is a likely possibility.  Of importance, the safety of 
VRPs as vaccine vectors has long been questioned due to the presence of functional 
Venezuelan equine encephalitis genes and BL3 requirements for safety testing (215).  
Despite this, the safety record for VRPs and other alphavirus replicon vectors is robust, and 
VRPs have been approved for use in human clinical trials for HIV gene expression (45).  One 
potential new concern, however, is evidence that VLP preparations expressed using this 
system may efficiently package VEE replicon RNAs.  By uncoupling VLP transgene 
expression from VRPs in vaccines, additional safety benefits are realized that prevent the 
inadvertent design of new chimeric pathogens capable of self-replication, packaging and 
release.   While helper virus contamination has been recognized in Epstein-Barr virus and 
adeno-associated virus vector systems, for example (40, 268), no evidence of chimeric virus 
generation has been reported.  Although extensive safety trials have not been published for 
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null VRPs, these adjuvants retain safety features of the original vector but are a more likely 
candidate for extensive use in clinical trials due to these encouraging features.   
 Previous work from our lab has shown that antibodies from both infected humans and 
VRP vaccinated mice can block HBGA binding to homologous norovirus strains (91, 149).  
We also published an original study showing that VRP vaccination can generate intermediate 
cross-reactive receptor-blocking antibodies to heterologous norovirus strains when multiple 
vectors are administered simultaneously (149).  While this study laid the groundwork for the 
research presented here, only four VLPs were available to us at that time.  This work utilizes 
a representative panel of eight human VLPs that together account for ≥95% of all norovirus 
infections, including the predominantly circulating GII.4 strains.  Furthermore, we are now 
able to address inter-genogroup versus intra-genogroup cross-reactivity following multivalent 
vaccination, which was not possible with the single GI VLP previously available to us.  Our 
findings obviate a clear discrepancy in cross-reactivity between genogroups.  Monovalent 
vaccines generated very low cross-reactive antibody responses to all heterologous strains, 
although strains within a genogroup elicited a slightly higher cross-reactive response.  
However, multivalent genogroup-specific vaccination elicited strong cross-reactive and 
intermediate receptor blocking antibody responses to other genogroup-specific strains but in 
no way enhanced cross-reactivity to strains between genogroups.  This result is most likely 
caused by a cross-reactive epitope repertoire that is greater when multiple, closely related but 
distinct antigens are included in the vaccine composition compared to a single antigen.  The 
addition of strains from both genogroups in our cumulative VLP vaccines did not detract 
from either genogroup-specific response but rather accentuated cross-reactivity and receptor 
blockade to inter-genogroup strains.  Antisera from multivalent vaccination groups could also 
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block receptor binding of evolutionarily distinct GI.1 (NV genocluster) and GII.4 (LV 
genocluster) VLPs (data not shown), suggesting blockade responses may be genocluster 
rather than strain specific and may be of particular importance when applied to GII.4 
norovirus vaccine design.  Previous studies in multivalent vaccination to Neisseria and 
Streptococcus species induced cross-reactive antibodies that could neutralize heterologous 
serotypes (7, 106); however, multivalent HIV envelope vaccines failed to induce cross-
reactive neutralizing antibody responses (36).  Together, these data support the rationale for 
including multiple norovirus strains from different genogroups in a comprehensive norovirus 
vaccine.   
   Multivalent human VLP vaccines coadministered with null VRP and lacking the NV 
and LV components elicited intermediate receptor blockade responses to NV and LV VLPs 
in vitro in our surrogate neutralization assay.  No receptor for MNV has been identified to 
date; however, multivalent mouse VLP vaccines coadministered with null VRP lacking the 
MNV VLP component lent intermediate protection from MNV challenge in vivo.  We can 
speculate that these two findings are reflective of one another and intermediate protection is 
conferred to heterologous strains following multivalent vaccination.  However, several 
additional factors must be considered when evaluating the vaccine design of this study that 
may impact protective outcomes.  VLP vaccination lacking adjuvant imparted specific but 
significantly lower receptor blocking responses in vitro and elicited no protection from MNV 
challenge in the ileum and MLN of infected mice, which can be explained by poor immune 
responses against unadjuvanted VLP vaccines (8, 10).  In contrast, CpG adjuvanted vaccines 
resulted in significant antibody induction to homologous and heterologous antigen; however, 
null VRP adjuvants imparted significantly more protection following MNV challenge.  While 
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serum antibody reactivity and blockade were not significantly different following CpG and 
null VRP adjuvanted vaccination, fecal IgG and IgA as well as the serum IgG2a subtype 
were significantly higher in null VRP vaccinated mice, which may explain this discrepancy.  
Unmethylated CpG DNA adjuvant activity is the result of innate immune activation through 
Toll-like receptor (TLR)-9, which promotes antigen-specific adaptive immune responses 
(137, 223).  The mechanism of null VRP adjuvant activity is not known but may be linked to 
RNA replication.  The protective effects of null VRP adjuvant vaccination may, therefore, be 
linked to differential mechanisms of immune induction or a higher activation of antibody and 
T cell responses in selective tissues that may not be represented by serum IgG responses.   
   Preparation of VLP reagents may be a caveat to our vaccine design. We surmise that 
concentration by centrifugation causes some VLPs to lose particle structure  A previous 
study by Harrington et al. showed that antisera following vaccination with norovirus capsid 
proteins containing a mutation that does not allow for particle assembly only partially 
blocked receptor binding (91).  Because we achieve complete blockade in our receptor 
binding assays, significant structure is not lost; however, it may determine complete 
protection versus partial protection in the MNV infection model.  Because we observed only 
partial protection in some tissues in monovalent and multivalent MNV vaccination 
experiments adjuvanted with null VRP (Fig. 6.8), we boosted wild-type donor mice a third 
time with unconcentrated VLPs prior to performing passive transfer experiments.  The use of 
unconcentrated VLP, an additional immune boost by a third immunization, or both likely 
resulted in complete protection from challenge following passive transfer of antisera (Fig. 
6.10) but not in the original vaccination experiment.  We also showed in our original VLP 
titration experiments that vaccination with 10 µg of VLP induces better receptor blockade 
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than the 2 µg administered in the experiments presented here.  We were unable to increase 
this concentration in multivalent vaccines due to the finite volume that can be administered to 
a mouse footpad and the concentrations we can achieve with individual VLP preparations; 
however, higher concentrations of VLP may be required to induce an entirely protective 
state.  We can test these hypotheses by vaccinating monovalently with higher VLP 
concentrations or multivalently by considering different routes of administration. 
 We chose to use Scid mice for our transfer experiment as they are the most 
commercially available immunodeficient mouse crossed on the BALB/c background.  We 
observed that Scid mice did not maintain MNV infection in the same tissues that have been 
documented for multiple strains of wild-type and immunodeficient mice crossed on the 
C57BL/6 (discussed in Chapter V).  While the MLN is underdeveloped in immunodeficient 
strains, and therefore, does not support MNV infection like immunocompetent mice, we were 
surprised to find the distal ileum did not contain significant MNV titers following infection 
of non-immune recipient mice in our transfer experiment.  Additional sites of MNV 
replication in this strain need to be determined for future experiments.  We have observed 
from our work with the MNV infection model in wild-type mice that the MLN typically 
maintains the highest levels of infection, followed by the distal ileum.  The spleen 
consistently maintains the lowest level of infection (unpublished observations).  Although the 
spleen was the only tissue in which we could observe viral loads in our transfer experiment, 
the high viral titers found in non-immune sera-recipient mice compared to the complete lack 
of viral titers found in the immune sera-recipient mice lend strong support that pre-existing 
antibody can prevent acute MNV infection, although we would have preferred to observe this 
finding in additional tissues.  Both donor and recipient mice had robust circulating anti-MNV 
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IgG titers.  While Scid mice can exhibit T and B cell “leakiness” at 12+ weeks of age that can 
confound transfer data, we used mice 6 weeks of age to avoid this problem.  Therefore, we 
can conclude that humoral immunity is the likely mechanism of protection following MNV 
VLP vaccination. 
 Overall, our data suggest that increased antibody cross-reactivity to heterologous 
norovirus strains following multivalent VLP vaccination coadministered with null VRP 
adjuvant can significantly decrease viral loads upon challenge.  Unfortunately, mice don’t 
develop clinical disease making it impossible to determine if this reduction in viral load 
corresponds to reduced morbidity.  Homologous vaccination induced antibodies that 
completely blocked receptor binding and were able to completely protect against infection in 
transfer experiments.  Human VLP vaccines containing GII.4 components are widely needed 
to prevent frequent norovirus outbreaks; however, multivalent vaccines containing multiple 
GI and GII components may be crucial in preventing other isolated outbreaks and emergence 
of new predominant strains. 
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Table 6.1 
 
VLP vaccination chart. 
 
Name   Genogroup(s) Type VLP(s) in vaccine composition  
 
NV     GI Monovalent NV 
GI+  Multivalent NV, SoV, DSV, Chiba 
GI-  Multivalent SoV, DSV, Chiba (-) NV 
   
LV     GII Monovalent LV 
GII+  Multivalent LV, HV, TV, M7 
GII-  Multivalent HV, TV, M7 (-) LV 
 
GI+/GII+     GI/GII Multivalent all GI/GII  
GI-/GII-  Multivalent all GI/GII (-) NV/LV 
 
MNV     GV Monovalent MNV 
Hu+/MNV+     GI/GII/GV Multivalent all GI/GII, MNV  
Hu+/MNV-     GI/GII Multivalent all GI/GII (-) MNV   
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Figure 6.1 
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VLP titration.   Mice were immunized with NV VLP at doses of 0.02 µg, 0.2 µg, 2 µg, and 
10 µg.  Sera and feces were harvested and anti-NV antibody quantitated by ELISA (A-B).  
Sera were also tested for interference of H type 3 binding to NV VLPs (C).   
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Figure 6.2 
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Homotypic antibody responses following monovalent vaccination with and without 
adjuvant.  Sera from mice immunized with NV or LV VLP alone or in conjunction with 
CpG or null VRP adjuvants were analyzed for anti-NV or anti-LV IgG, respectively, by 
ELISA (A).  Serially diluted antisera were also tested for blockade of H type 3 binding to NV 
VLPs (B) and LV VLPs (C). 
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Figure 6.3 
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C. 
Antisera blockade of LV VLP-H type 3 binding
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Antibody responses following multivalent vaccination with or without adjuvant.  Sera 
from animals immunized with multivalent VLP vaccines either alone or in conjunction with 
CpG or null VRP adjuvant were analyzed for IgG reactivity to NV or LV VLPs (A).  
GI+/GII+ groups received NV and LV VLPs as a vaccine component; GI-/GII- groups did 
not.  Serially diluted sera were also tested for interference of H type 3 binding to NV VLPs 
(B) and LV VLPs (C).  Significance between null VRP groups are noted with (*) (A).   
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Figure 6.4 
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C. 
Antisera blockade of LV VLP-H type 3 binding
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Null VRP adjuvant coadministered with monovalent, genogroup-specific, and 
cumulative VLP cocktail vaccines.  Sera from animals immunized with null VRP and 
monovalent, genogroup-specific multivalent, cumulative multivalent, or heterotypic 
monovalent VLP vaccines with or without NV or LV VLPs as a vaccine component were 
analyzed for IgG reactivity to NV or LV VLPs (A).  Serially diluted sera were also tested for 
interference of H type 3 binding to NV VLPs (B) and LV VLPs (C). 
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Table 6.2 
 
Average percent sera for blockade of 50% (BT50) and 90% (BT90) H type 3 binding.† 
 
                NV VLP-H type 3                      LV VLP-H type 3 
Vaccine  BT50 (range) BT90 (range)  BT50 (range) BT90 (range) 
NV VLP 2.2 (0.6-5) 6.9 (1.3-20)  N/A  N/A 
NV CpG  0.5 (0.2-0.6) 1.4 (0.6-2.5)  N/A  N/A 
NV null  0.2 (0.2-0.6) 0.4 (0.2-1.3)  N/A  N/A 
LV VLP  N/A  N/A   6.3 (2.5-10) 12.5 (5-20) 
LV CpG  N/A  N/A   1.0 (0.2-2.5) 2.0 (0.6-5) 
LV null  N/A  N/A   0.2 (--)   0.4 (0.2-1.3) 
GI+ null  0.8 (0.6-1.3) 1.7 (1.3-2.5)  N/A  N/A 
GI- null  12.5 (10-20) N/A   N/A  N/A 
GII+ null  N/A  N/A   0.2 (--)  0.3 (0.2-0.6) 
GII- null  N/A  N/A   N/A  N/A 
GI+/GII+ VLP 2.9 (1.3-5) 7.7 (1.3-10)  1.5 (0.2-5) 17.5 (10-20) 
GI+/GII+ CpG 0.6 (0.2-1.3) 1.8 (0.6-2.5)  0.2 (--)  0.3 (0.2-0.6) 
GI+/GII+ null  0.8 (0.6-1.3) 1.7 (1.3-2.5)  0.2 (--)  0.2 (--) 
GI-/GII- VLP  N/A  N/A   N/A  N/A 
GI-/GII- CpG  8.0 (0.2-20) 18 (10-20)  17.5 (10-20) N/A 
GI-/GII- null  7.1 (2.5-10) N/A   8.8 (2.5-20) N/A 
 
†
 Sera that blocked H type 3 binding at the lowest concentration tested were assigned a BT 
value half the lowest serum concentration tested (0.2).  Sera that could not block H type 3 
binding at the highest concentration tested were assigned a BT value twice the highest serum 
concentration tested (20).  Antisera groups with no BT values within the range of detection 
were designated N/A. 
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Figure 6.5 
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Serum IgG cross-reactivity profile.  Antisera from mice immunized with each monovalent 
or multivalent VLP vaccine coadministered with null VRP adjuvant were analyzed for cross-
reactivity to the VLP panel.   
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Table 6.3 
 
Anti-NV IgG and IgA in fecal extracts. 
 
  Anti-NV IgG  Total IgG Anti-NV/       Anti-NV IgA      Total IgA    Anti-NV/ 
  ± SEM    ± SEM    total IgG       ± SEM         ± SEM     total IgA 
Vaccine  (ng/ml)  (ng/ml)   (%)         (ng/ml)        (µg/ml)    (%) 
_________________________________________________________________________________________ 
VLP 
     NV  0.5 ± 0.3 62.3 ± 12.6 0.8        2.5 ± 1.2        47.3 ± 10    5.3E-03 
     GI/GII+ 2.4 ± 0.7 174.6 ± 79.1 1.4        0.7 ± 0.1        25.7 ± 4.6    2.7E-03 
     GI/GII- 0.5 ± 0.2 110.7 ± 30.6 0.5        1.1 ± 0.7        30.6 ± 2.6    3.6E-03 
CpG 
     NV  12.2 ± 6.7 94.5 ± 9.7 12.9        7.2 ± 2.2        56.5 ± 2.0    1.3E-02 
     GI/GII+ 34.9 ± 8.0 316.0 ± 203.8 11.0        3.2 ± 1.9        30.6 ± 8.1    1.0E-02 
     GI/GII- 10.4 ± 6.6 315.8 ± 6.0 3.3        1.8 ± 0.8        31.3 ± 1.5    5.8E-03 
null VRP 
     NV  44.1 ± 9.3 254.0 ± 54.9 17.4        68.1 ± 32.2        44.0 ± 4.7    1.5E-01 
     GI/GII+ 88.1 ± 47.9 504.6 ± 267.4 17.5        10.4 ± 8.7        27.5 ± 1.6    3.8E-02 
     GI/GII- 9.1 ± 4.2 318.3 ± 50.6 2.9        7.7 ± 2.4        31.5 ± 7.6    2.4E-02 
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Figure 6.6 
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IFN-γ secretion following VLP stimulation.  Splenocytes from mice immunized with 
monovalent or multivalent VLP vaccines with or without null VRP adjuvant, with null VRP 
alone, or with no antigen were stimulated with NV VLPs, LV VLPs, or media alone and 
tested for IFN-γ secreting cells by ELISpot (A) or IFN-γ secretion in supernatant by EIA (B). 
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Figure 6.7 
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IgG subtypes.  Mice immunized with monovalent (A-B) and multivalent vaccines with (C-
D) or without (E-F) NV or LV VLPs were analyzed for IgG1 and IgG2a serum antibody 
subtype responses.  Subtype responses to increasing amounts of VLPs are shown in (D).   
 
223
 
Figu
re
 6.8 
 A
.
 
M
LN
MNV VLP
Hu+/MNV+ VLP
Hu+/MNV- VLP
MNV CpG
Hu+/MNV+ CpG
Hu+/MNV- CpG
MNV null
Hu+/MNV+ null
Hu+/MNV- null
null only
mock
0 1 2 3 4
*
*
*
 
 
*
*
*
V
accin
e
Log titer (pfu/ml)
D
istal
 ile
u
m
MNV VLP
Hu+/MNV+ VLP
Hu+/MNV- VLP
MNV CpG
Hu+/MNV+ CpG
Hu+/MNV- CpG
MNV null
Hu+/MNV+ null
Hu+/MNV- null
null only
mock
0 1 2 3 4 5
*
*
*
 
 
 
*
 
 
 
*
V
accin
e
Log titer (pfu/ml)
 
  
Sple
e
n
MNV VLP
Hu+/MNV+ VLP
Hu+/MNV- VLP
MNV CpG
Hu+/MNV+ CpG
Hu+/MNV- CpG
MNV null
Hu+/MNV+ null
Hu+/MNV- null
null only
mock
0 1 2 3 4
*
*
*
 
 
*
*
*
 
 
 
 
 
 
*
*
*
 
 
*
*
*
 
 
 
 
 
 
*
*
*
 
 
*
*
*
 
 
 
*
V
accin
e
Log titer (pfu/ml)
 
     
 224 
B. 
Serum IgG
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MNV vaccination and challenge.  Mice immunized with monovalent MNV VLP or 
multivalent VLPs +/- MNV VLP were challenged with MNV and tissues harvested three 
days post-infection.  Plaque assays were performed on homogenized spleen, MLN, and distal 
ileum (B).  Serum IgG reactivity to MNV VLPs was determined by ELISA (B). 
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Figure 6.9 
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C. 
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FACS analysis.  CD4+ and CD8+ cells purified from non-immune (A,C) and immune (B,D) 
splenocytes were verified for CD3+ and CD4+ (A-B) or CD8+ (C-D) expression by FACS (A-
D).   
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Figure 6.10 
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Adoptive transfers.  Wild-type mice were immunized three times with MNV VLP 
coadministered with null VRP.  Unimmunized controls were treated in parallel.  Two weeks 
after final boost, sera, CD4+ and CD8+ splenocytes were harvested and purified.  Sera, CD4+, 
or CD8+ were passively or adoptively transferred to Scid knockout mice.  Twenty-four hours 
post-transfer, mice were infected with MNV1 and tissues harvested 3 days post-infection.  
Spleens were evaluated for MNV titers by plaque assay (A).  Distal ilea did not support 
MNV infection in any transfer recipients (data not shown).  MNV-specific serum IgG in 
serum donor and recipient mice were measured by ELISA (B).  Non-immune mice had no 
detectable MNV antibody and were assigned values half the lower limit of detection per 
assay. 
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CHAPTER VII. 
 
Conclusions 
 
 This dissertation thoroughly characterizes B cell and T cell immunity induced by 
vaccination with norovirus VLPs expressed by or coadministered with VEE replicon 
particles in the mouse.  Experiments conducted in vitro correspond with findings from in vivo 
studies, painting a well-defined picture of the shared impact of both antibody and T cell 
mechanisms in homotypic and cross-reactive immune responses following vaccination.  
Importantly, VLP vaccines are also able to protect against mouse norovirus challenge, 
providing the first proven effective vaccine against norovirus infection. 
 The work presented here began as a small research project investigating the cross-
reactive responses of antibodies following monovalent or multivalent VRP vaccination with 
four human norovirus strains.  Thanks to the cloning work of Lisa Lindesmith, our VRP and 
VLP panel grew to include 18 strains from 10 genoclusters in 3 genogroups over the last four 
years, which allowed the detailed characterization of cross-reactive antibody responses from 
very closely genetically related strains within a genocluster to inter-genogroup inter-species 
strains.  The discovery of the adjuvant activity of the VRP by Joseph M. Thompson (256) 
allowed us to study the effects of multivalent vaccines comprising VLPs representing all 10 
genoclusters in the VLP panel with ease and efficiency.  The concurrent discovery of the 
mouse norovirus by Skip Virgin’s group at Washington University and the optimization of 
techniques to study adaptive immunity by Karen Chachu lead to a beautiful collaboration 
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testing the efficacy of these vaccines in a mouse model.  Each of these contributions was 
instrumental in bringing my dissertation project to its mature status, and I recognize them 
accordingly. 
 The immune response following norovirus infection is highly undercharacterized.  
Antibody and T cell responses have been documented following norovirus infection in 
humans and following norovirus VLP vaccination in humans and mice (10, 145, 247).  
Induction of immune responses following VLP vaccination suggests the capsid protein is 
immunogenic, and antibody specificity for norovirus VLPs and T cell stimulation with VLPs 
following infection suggests the capsid is antigenic as well (145, 247).  Because the capsid 
composes the outer surface of the norovirus virion that is exposed to the internal environment 
during infection, we can hypothesize that the capsid is the primary target of the humoral 
immune response for antibody neutralization.  However, previous studies into the immune 
response to ORF1 and ORF3 had not been undertaken heretofore.  Our studies into the 
protective effect of vaccination with VRP expressing norovirus ORF1, ORF2, and ORF3 
solidified our hypothesis where ORF1 and ORF3 offered little to no protection against MNV 
challenge in the mouse model.  In contrast, ORF2 conferred significant protection against 
MNV infection.  These important findings support ongoing research into VLP subunit 
vaccines for protection against noroviruses. 
 Effective vaccines must also activate the branch of the adaptive immune system 
responsible for virus neutralization.  Extensive studies into the mechanisms of the immune 
response elicited following MNV infection have been carried out in knockout mice by Karen 
Chachu at Washington University.  These findings, summarized in Chapter V, clearly 
indicate that both B cells and T cells are instrumental in controlling MNV infection.  Mice 
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immunodeficient for B cells (µMT mice) did not clear MNV from the mesenteric lymph 
nodes (MLN) at all time points tested through 21 days post-infection (Fig. 5.7), and passive 
transfer of immune antisera from wild-type mice or monoclonal antibodies to MNV both 
significantly reduced MNV titers in persistently infected RAG-/- mice (Fig. 5.8).  Together 
these data support anti-MNV antibody responses as critical for controlling MNV infection.  
Parallel studies in mice deficient in CD4+ or CD8+ T cell production were also tested for 
clearance of MNV infection.  Both cell subsets were also clearly important in clearance of 
MNV, as immunodeficient mice cleared virus more slowly than wild-type mice (Fig. 5.5), 
and in vitro depletion of CD4+ and/or CD8+ cells from immune wild-type splenocyte 
suspensions prior to adoptive transfer into persistently infected RAG1-/- mice also resulted in 
significantly higher viral loads compared to transfer of undepleted control preparations (Fig. 
5.6).  Although T cells were not required for eventual clearance of MNV, they played a 
significant role in controlling viral replication at early time points post-infection.  
Furthermore, infection of IFN-γ and perforin knockout mice revealed that MNV may be 
cleared by T cells using a perforin-mediated mechanism (Fig. 5.6).  These data conclude that 
both B cells and T cells are involved in the adaptive immune response following MNV 
infection.  Cell subsets likely act in a coordinated fashion in viral clearance and can 
compensate for one another if one subset is compromised.   
 We have shown that MNV ORF2 expressed from VRP protect against MNV 
infection.  However, the mechanism of adaptive immunity induced by vaccination may be 
different than the mechanism induced following natural infection.  To characterize the 
efficacy of MNV ORF2 vaccines and their mechanism of action, we conducted vaccination 
experiments over prolonged periods of time and in knockout mice.  Results conclusively 
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showed that vaccination of wild-type mice significantly protects against MNV infection 
through 24 weeks post-vaccination (Fig. 5.3).  Vaccination of B cell-/-, MHC class I-/-, and 
MHC class II-/- knockout mice with VRP-MNV ORF2 additionally induced significantly 
reduced viral loads in all three immunodeficient groups post-infection; however, no knockout 
group was able to completely protect against MNV infection as well as wild-type mice (Fig. 
5.4), suggesting B cells and T cells may use a combined mechanism following vaccination.  
In contrast, a separate experiment described in Chapter VI showed that antisera from wild-
type mice vaccinated with MNV VLPs coadministered with null VRP and passively 
transferred to immunodeficient Scid mice completely protected against acute MNV infection, 
whereas adoptively transferred purified CD4+ or CD8+ splenocytes did not protect.  This 
finding suggests humoral immunity is integral in preventing MNV infection.  It is possible 
that VRP used as a vaccine vector to express VLPs induces a different immune mechanism 
than VRP coadministered with VLP as an adjuvant or that knockout mice bred on different 
genetic backgrounds respond differently.  However, because both antibodies and T cells 
appear to be associated with viral clearance following norovirus infection, an ideal norovirus 
vaccine would activate both arms of the immune system. 
 We recognize that the immune response induced following MNV infection or 
vaccination may not entirely mirror that seen following norovirus infection in humans, 
although human infection studies have also revealed activation of both humoral and cellular 
immunity (145, 247).  Studying human immunity, however, is much less straightforward 
because humans can be infected with multiple norovirus strains that are extremely genetically 
diverse, and understanding how one norovirus infection impacts subsequent norovirus 
infections is additionally important.  In Chapter II and Appendix 1 we showed 
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comprehensive antibody cross-reactivity profiles among norovirus strains where strains in 
different genogroups exhibit very low cross-reactivity and more genetically related strains in 
the same genogroup exhibit slightly heightened (but still quite low) cross-reactivity.  
Additional findings that no antisera can block receptor binding to heterologous VLPs in in 
vitro assays may explain why individuals can have multiple norovirus infections with 
different strains even after previous exposure (203, 281).  Cross-reactivity between limited 
numbers of norovirus strains and homotypic antibody blockade of receptor binding has been 
documented repeatedly (86, 91, 145, 180, 219, 259); however, our data shows the most 
comprehensive antibody cross-reactivity and blockade profile to date.   
 We are also the first group to compare cross-reactive antibody responses to strains 
within the same genocluster.  The GII.4 noroviruses currently cause approximately 80% of 
all norovirus outbreaks worldwide (55, 264).  To attempt to explain their continued 
circulation over the last decade, we created a time-ordered panel of GII.4 VLPs spanning 
three decades.  Multiple alignments of published sequences revealed clusters of mutations 
that coincided with circulating strains during established outbreak periods, and bioinformatic 
analysis showed that evolution of the capsid sequence was occurring at specific sites 
structurally important for receptor binding (Fig. 3.1).  VLPs representing each evolutionarily 
distinct strain and expressed by VRPs to generate antisera were tested for cross-reactive and 
receptor blocking antibody responses.  Our results indicated that strains were in fact 
antigenically distinct: Antisera responses were strain-specific with limited cross-reactivity, 
binding profiles to HBGAs expanded and contracted with inclusion of specific mutations in 
the P2 binding domain and peripheral sites, and blockade of receptor binding was variable 
and attributable to identifiable mutations by bioinformatics prediction.  Assuming blocking 
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receptor binding yields a virus noninfectious, we were able to conclude that antibodies 
generated in humans or mice against earlier strains were likely not protective to later 
circulating GII.4 strains as they did not prevent HBGA binding to contemporary VLPs (Fig. 
3.3 and 3.5).  The continued evolution of GII.4 norovirus capsids mirrors that seen with 
influenza where new antigenically distinct strains emerge every 2-3 years and could explain 
escape from herd immunity one would expect to see with a continually circulating virus.  
Additional studies with time-ordered VLPs from the GI.1 and GII.2 genoclusters described in 
Appendix 2 revealed that not all genoclusters exhibit continued evolution.  GI.1 VLPs 
isolated more than three decades apart exhibited identical antibody cross-reactivity and 
receptor blockade profiles (Fig. A2.1), suggesting this genocluster is not evolving and may 
explain the low prevalence of GI outbreaks.  GII.2 VLPs, on the contrary, showed an 
intermediate evolutionary pattern where an archaic strain cross-reacted with one of two 
contemporary strains, one contemporary strain cross-reacted with the other, and one 
contemporary strain was altogether antigenically distinct (Fig. A2.2).  This data supports 
evolution within the GII genogroup and may explain their increased prevalence compared to 
GI strains.  Overall, evolution within norovirus clusters likely dictate emergence of new 
predominant strains into populations naïve to the selected mutations. 
 Cross-reactive T cell responses to noroviruses are ambiguous.  While several reports 
have stated that IFN-γ is secreted in response to VLP stimulation of T cells following 
norovirus infection or VLP vaccination in humans and mice (145, 178, 247), only a single 
study broached the subject of cross-reactivity (145).  Lindesmith et al. observed that CD4+ 
PBMCs from individuals infected with Snow Mountain virus (SMV) mounted significant 
IFN-γ responses upon stimulation with homologous SMV VLPs or heterologous 
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intragenogroup Hawaii VLPs (145).  Norwalk VLPs, derived from a different genogroup, did 
not stimulate PBMCs.  In contrast, we reported in Chapter V that IFN-γ knockout mice were 
still able to combat MNV infection whereas perforin -/- mice were less able to do so, 
indicating that perforin but not IFN-γ may be involved in the anti-norovirus immune 
mechanism.  While these findings in the mouse are appealing, studies with human strains 
remain the focus of cross-reactivity studies.  Unfortunately, we learned that using the VRP 
expression system for production of VLPs lead to VEE non-structural RNA contamination of 
the particles, which in turn lead to VEE-specific T cell activation following VLP stimulation 
of cells from VRP vaccinated mice (Fig. 4.3 and 6.6).  This finding makes identification of 
cross-reactive VLPs nearly impossible using our system, although our experiments clearly 
show that IFN-γ is abundantly produced following VLP stimulation.  To circumvent this 
problem, we turned to peptide stimulation using overlapping 15-mer pools reconstituting the 
complete Norwalk and Farmington Hills capsid sequences synthesized independently of 
VRP.  This approach will not only allow us to identify cross-reactivity between strains but 
also to identify specific epitopes within the capsid sequence for T cell stimulation.  Our 
results show that the NV sequence FDLSLGPHLNPFLLH in the shell domain contains one 
potential NV-specific epitope, and the FH sequence 
CLLPQEWVQHFYQEAAPAQSDVALL in the P1 domain contains 1-2 potential FH-
specific epitopes based on IFN-γ secretion following peptide stimulation of splenocytes (Fig. 
4.X).  We additionally found that these stimulatory sequences to NV- or FH-immune cells 
were not cross-reactive to one another.  Additional studies to identify the exact epitope 
within these stimulatory sequences and multiple alignments to determine conservation of 
epitopes across strains within genoclusters and genogroups must be performed.  Furthermore, 
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peptide stimulation of human immune cells must also be conducted as epitopes may not be 
conserved across species.  However, using a small animal model to mimic immune responses 
likely seen in humans suggests that norovirus capsid peptides will also induce IFN-γ 
secretion following human immune cell stimulation and that specific epitopes can be 
identified.  These findings could be instrumental in vaccine design for anti-norovirus T cell 
activation and will teach us how antigenically conserved genetically related strains are in 
cellular immunity. 
 Identifying strains that generate cross-reactive immune responses to other strains is 
very important for formulation of cumulative vaccines.  Our original finding in Chapter II 
showed that administering a VRP cocktail expressing three heterologous VLPs to mice 
induced enhanced antibody cross-reactivity as well as enhanced cross-reactive receptor 
blockade to strains not included in the vaccine composition.  We followed up on these results 
by designing a comprehensive study into the effects of monovalent versus multivalent 
vaccination with our expanded panel of VLPs with particular emphasis on cross-reactive and 
receptor blockade responses within and across genogroups and the protective effect of these 
vaccines in the mouse model.  We substituted VRP expression vectors with non-coding VRP 
adjuvants, which we coadministered with VLPs, to capitalize on the availability of a single 
common adjuvant for vaccine formulation.  Our results described in Chapter VI showed that 
multivalent genogroup specific vaccines induce cross-reactive and receptor blocking 
antibody responses to strains within the common genogroup but not across genogroups (Fig. 
6.4).  Inclusion of VLPs from both genogroups expands cross-reactivity to additional GI and 
GII strains and enhances the cross-blockade response (Fig. 6.4).  Furthermore, splenocytes 
were also activated to produce IFN-γ upon homologous and heterologous stimulation with 
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VLP in both monovalent and multivalent vaccine recipients, although specific cross-
reactivity could not be determined due to background stimulation induced by VRP (Fig. 6.6).  
These in vitro data support use of multivalent vaccines for enhanced protection against 
cumulative norovirus challenge.  To test the efficacy of multivalent vaccines in an in vivo 
infection model, we vaccinated mice with multivalent human VLP vaccines with or without 
the MNV VLP component.  Our results showed that MNV VLP coadministered with VRP 
adjuvant in monovalent or multivalent vaccines significantly reduced viral loads post-MNV 
challenge in all tissues tested (Fig. 6.8).  Furthermore, multivalent vaccines lacking MNV 
VLP also reduced viral loads in all tissues (Fig. 6.8), suggesting cross-reactive protection.  
Because protection was not absolute, additional studies using increased VLP concentrations 
must be performed to optimize vaccine formulation.  We performed an additional experiment 
where antisera, purified CD4+ cells, or purified CD8+ cells were adoptively transferred from 
monovalently vaccinated wild-type mice into immunodeficient Scid mice prior to MNV 
challenge.  Mice receiving antisera were completely protected from MNV infection whereas 
those receiving purified T cells were not (Fig. 6.10).  Our results not only revealed that the 
mechanism of protection induced by monovalent null VRP vaccines is likely antibody-
mediated but also that complete protection can be attained with these vaccines.  Passive 
transfer of antisera from multivalently vaccinated mice must be performed to determine if 
this mechanism is upheld and if cross-reactive antibody can elicit a protective effect in 
immunodeficient mice. 
 The data presented in this dissertation provide insight into the mechanisms of 
adaptive immunity induced by norovirus infection and norovirus VRP vaccination.  
Norovirus infection and VRP vaccination induce both B cell- and T cell-mediated responses; 
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however, null VRP vaccines may mediate protection in a T cell independent manner.  We 
have shown that low levels of cross-reactive antibody are induced following monovalent 
vaccination and are not likely to protect against heterologous norovirus challenge.  However, 
multivalent vaccination induced antibody responses that are cross-reactive and potentially 
cross-protective against heterologous norovirus strains.  Further characterization of 
multivalent norovirus vaccines in the mouse model and subsequent clinical trials in humans 
will reveal the efficacy of these novel norovirus vaccine candidates. 
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APPENDIX 1 
Chapter II. 
 
 
Materials and methods.   
 Southampton virus (SoV; GI.2), Desert Shield virus (DSV; GI.3), Chiba virus (CV; 
GI.4), Toronto virus (TV; GII.3), M7 virus (GII.13), mouse norovirus-1, (MNV-1; GV), GI.1 
Westchester, and GII.2 Buds and Ina capsid genes were cloned into pVR21 and VRPs 
produced as described (11).  Mice were primed and boosted with each individual strain, and 
sera were collected on day 35 for use in ELISA and receptor binding blockade assays as 
described in Chapter II.  Additional groups of mice received heterologous monovalent and/or 
multivalent VRP prime-boost regimens on day 1 and 42.  Prime-boost VRP vaccination 
groups included HV-HV, HV-SM, HV-NV, HV-cocktail (NV, SM, and HV), cocktail-
cocktail, cocktail-HV, cocktail-SM, and cocktail-NV.  Sera were collected on day 0, 14, 28, 
pre-boost, and day 3, 7, 14, and 21 post-boost and ELISAs performed to determine strain-
specific antibody responses. 
 Statistics were performed using One-way ANOVA and Tukey’s post-test in 
GraphPad Prism software.  Significance is designated with * (P<0.05), ** (P<0.01), or *** 
(P<0.001). 
 
Results. 
Intermediate heterotypic antibody responses are induced to additional norovirus 
strains within a genogroup but not across genogroups. 
 Following immunization with our panel of VRPs expressing norovirus VLPs, antisera 
to each individual strain were tested for antibody cross-reactivity to our panel of VLPs.  Our 
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results supported previous findings from Chapter II.  Homotypic antibody responses in mice 
were significantly more robust to the immunizing VLP than to heterologous VLPs (P<0.001); 
however, clear heterotypic trends emerged whereby cross-reactive antibodies recognize 
VLPs within a genogroup better than VLPs in different genogroups that were significant in 
many cases (Fig. A1.1a-b).  Antisera cross-reactivity to our panel of VLPs following 
immunization with GI strains is shown in Fig. A1.1a (Beachfront Avenue!); antisera cross-
reactivity following GII immunization is shown in Fig. A1.1b.  Antisera blockade of NV 
VLP or LV VLP binding to H type 3 was also tested (Fig. A1.1c-d).  As previously noted, no 
heterologous antisera group could block binding, regardless of cross-reactive IgG titers.   
 An additional group of mice were immunized with MNV VLPs, which constitute the 
murine-specific GV cluster.  MNV antisera were tested for cross-reactivity to our panel of 
human VLPs (Fig. A1.2a), and our panel of human antisera were tested for cross-reactivity to 
MNV VLPs (Fig. A1.2b).  Not surprisingly, very low cross-reactivity existed between these 
intergenogroup strains, although MNV antisera reacted significantly more to M7 VLPs than 
the rest of the panel (Fig. A1.2a).  Furthermore, MNV antisera could not block NV VLP or 
LV VLP binding to its H type 3 receptor (Fig. A1.2c-d). 
 
Multivalent vaccination but not heterologous monovalent vaccination elicits enhanced 
antibody responses. 
 In Chapter II, we analyzed cross-reactivity of human antisera to heterologous VLPs.  
Overall cross-reactivity to heterologous VLPs was lower than to the infecting strain; 
however, a single sample from an individual infected with SM cross-reacted more strongly to 
HV VLPs than to SM VLPs.  To investigate if previous exposure to one strain can lead to a 
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higher cross-reactive response to that strain following subsequent heterologous exposure, we 
primed mice with one strain, boosted with a heterologous strain, and analyzed antisera cross-
reactivity to both VLPs pre- and post-boost compared to mice primed and boosted with 
homologous antigen.  In analyzing homologous prime and boost with HV VRP, antisera IgG 
specific for HV VLPs peaks and plateaus at approximately 1 mg/ml 14 days post-prime (Fig. 
A1.3a).  After HV VRP boost, specific IgG levels increased to >2 mg/ml, plateaued, and 
began to drop by day 21 post-boost.  In contrast, mice primed with HV VRP followed by 
boost with SM or NV VRPs (Fig. A1.3b-c) lead to weaker serum IgG responses to HV, SM, 
and/or NV VLPs post-boost (400-800 µg/ml IgG) compared to homologous boost with HV. 
Responses to both priming and boosting strains were equivalent at day 21 post-boost.  
However, reactivity to SM or NV VLPs at day 14 post-boost was not significantly different 
from reactivity to SM or NV VLPs 14 days post-prime with each antigen, respectively (data 
not shown), suggesting heterologous immunization may affect IgG responses to the 
immunizing antigen independent of previous exposures although pre-existing antibody titers 
are also boosted. 
 Our results in Chapter II described strongly-reactive antibody responses to each 
vaccine component following multivalent vaccination in mice.  Because heterologous prime 
and boost regimens did not induce substantial antibody responses to either immunizing 
strain, we primed mice with HV VRP or multivalent VRP vaccines and boosted with 
multivalent VRP vaccines or individual VRP components, respectively, to determine the 
effect of multivalent vaccination on IgG responses to individual strains (Fig. A1.4).  Mice 
immunized with HV VRP and boosted with multivalent vaccines composed of NV, SM, and 
HV VRPs mounted a strong serum IgG response to HV VLPs but not to NV or SM VLPs 
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(Fig. A1.4a).  However, priming with multivalent VRPs followed by boosting with identical 
multivalent VRPs or one of the three VRP components lead to very strong serum IgG 
responses to the boosting strain(s) (Fig. A1.4b-e).  Boosting with identical multivalent 
vaccines (Fig. A1.4b) resulted in specific IgG responses to each strain to levels mirroring that 
following homologous monovalent vaccination (Fig. A1.3a).  Boosting with individual VRPs 
resulted in specific IgG levels of 3.5-4.5 mg/ml to the boosting strain (Fig. A1.4c-e), which 
are nearly twice that seen following homologous monovalent vaccination (Fig. A1.3a).  
These data reveal that multivalent vaccination results in very robust antibody responses upon 
re-exposure with any vaccine component.  Boosting with heterologous VRP not included in 
the multivalent VRP prime did not mount strong cross-reactive responses to the boosting 
strain (data not shown), suggesting that one immunization with multivalent VRPs is not 
sufficient to induce heightened cross-reactivity to heterologous strains. 
 
Discussion. 
 Chapter II discussed the levels of antibody cross-reactivity induced among four 
norovirus strains following VRP vaccination in the mouse.  Our increased panel of VRPs and 
VLPs has allowed further characterization of cross-reactivity among genetically distinct 
noroviruses, and our results support our original findings that more antisera cross-reactivity 
exists between strains within a genogroup than between genogroups following monovalent 
VRP immunization.  Analysis of nine human strains in separate genoclusters within GI and 
GII showed a more delineated pattern in cross-reactivity within a genogroup as well as more 
statistical significance in cross-reactive responses compared to inter-genogroup cross-
reactivity.  These results are not surprising, as one would expect more genetically related 
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strains to induce more cross-reactive antibodies.  The low cross-reactivity of GI and GII 
antisera to the GV MNV VLP and vice versa corroborate our findings.  Nonetheless, no 
additional antisera contained cross-reactive antibodies that could block NV VLP or LV VLP 
binding to the H type 3 receptor, regardless of genogroup origin of the vaccinating strain, 
reiterating that strains are in fact antigenically distinct.   
 In our studies in human antisera cross-reactivity in Chapter II, one human antisera 
sample reacted more strongly to heterologous HV VLPs than to homologous SM VLPs, 
representing the infecting strain.  We were curious if pre-exposure history to heterologous 
strains can change specific antibody responses following exposure to a different strain.  
Original antigenic sin (OAS) is defined as a state in B cell immunology where memory cells 
recognize epitopes on a related but genetically distinct strain following a previous infection 
and become activated to produce antibodies against the original strain, which may or may not 
be protective against the current strain.  We hypothesized that OAS could explain the 
continued circulation of noroviruses through repeatedly exposed populations, the 
predominance of the GII.4 strains, and the capacity for individuals to have multiple norovirus 
infections within a short time period.  To address this issue, we immunized mice sequentially 
with two heterologous strains.  Compared to homologous immunization, heterologous prime-
boost lead to low serum IgG to both the priming and boosting strains at all time points 
following the boost.  While the IgG reactive for the priming strain was in fact boosted by the 
heterologous immunization, levels of IgG reactive for the boosting strain resembled IgG 
levels following primary immunization, suggesting the IgG response to the heterologous 
boost may be independent of the prime.  Because VRP induced robust IgG levels to the 
immunizing strain only following homologous prime and boost, additional studies into the 
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potential for OAS would likely need to use an immunization schedule composed of a prime 
and boost with the same homologous strain, followed by a secondary booster with a 
heterologous strain to conclusively determine the effect of multiple exposures. 
 In Chapter II, multivalent norovirus vaccination was shown to induce strong antibody 
responses to each component of the vaccine composition that were not different from 
antibody responses following monovalent vaccination with each individual strain.  We 
performed an additional study to determine the effect of re-exposure to individual antigens 
on antibody responses.  Mice primed with HV VRP and boosted with a multivalent pool 
including HV VRP mounted a strong serum IgG response to HV VLPs but not to the other 
pool antigens, mirroring our results above suggesting a prime and boost with homologous 
antigen are required to attain high specific antibody levels.  Interestingly, boosting with a 
multivalent vaccine following monovalent priming increased the HV-specific response to 
levels nearly twice that of homologous monovalent or multivalent vaccination.  Additional 
experiments replicated this finding, where multivalent VRP prime followed by monovalent 
boost with each of the vaccine components resulted in stronger IgG responses to the boosting 
antigen than homologous prime-boost.  Together, these findings suggest that multivalent 
vaccination leads to very strong antibody responses following re-exposure to a vaccinating 
strain, even after primary immunization. 
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Figure A1.1. 
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C. 
Antisera blockade of NV VLP-H type 3 binding
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D. 
Antisera blockade of LV VLP-H type 3 binding
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Cross-reactive antibody responses to human strains within and across genogroups.  
Antisera from mice vaccinated with each human norovirus strain from our panel of VRPs 
were tested for cross-reactivity to our panel of VLPs by ELISA (A-B) and blockade of NV 
VLP-H type 3 and LV VLP-H type 3 binding (C-D). 
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Figure A1.2 
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C. 
MNV antisera blockade of NV VLP-H type 3 binding
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D. 
MNV antisera blockade of LV VLP-H type 3 binding
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Mouse norovirus cross-reactive antibody response.  Mice immunized with VRP-MNV (A) 
or our panel of human strain VRPs (B) were tested for cross-reactive serum IgG to our panel 
of human VLPs or MNV VLPs, respectively.  MNV antisera were also tested for blockade of 
H type 3 binding to NV (C) or LV (D) VLPs. 
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Figure A1.3 
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C. 
Prime: HV; Boost: NV
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Heterologous prime-boost regimens elicit lower specific serum IgG to priming or 
boosting antigens than homologous prime-boost regimens.  Mice were primed with HV 
VRP and boosted with HV VRP (A), SM VRP (B), or NV VRP (C) and antisera measured 
for reactivity to HV VLPs (A-C), SM VLPs (B), and/or NV VLPs (C) over a series of time 
points indicated on the x-axis. 
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Figure A1.4 
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C. 
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E. 
Prime: cocktail; Boost: NV
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Multivalent prime and/or boost regimens induce robust serum IgG responses to specific 
antigens in the vaccine composition.  Mice were primed with HV VRP and boosted with 
multivalent VRPs (A), primed and boosted with multivalent VRPs (B), or primed with 
multivalent VRPs and boosted with HV VRP (C), SM VRP (D), or NV VRP (E).  Antisera 
were tested for specific IgG reactivity to HV, SM, and/or NV VLPs. 
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APPENDIX 2 
Chapter III. 
 
Materials and methods. 
 
G1.1 Westchester (WC) and GII.2 Ina and Buds capsid genes were cloned into VRP, VRPs 
were administered to mice to generate antisera, and VLPs were produced.  Antibody 
blockade assays were performed as described in (149). 
 
Results. 
Heterotypic antibody responses to strains within norovirus genoclusters are robust but 
variable. 
 We cloned evolutionarily distinct capsid genes from the GI.1 WC strain in the 
Norwalk genocluster and the GII.2 Ina and Buds strains in the Snow Mountain genocluster 
into VRPs.  Antisera generated in mice following VRP immunization were tested for cross-
reactivity to our prototype NV and SM VLPs and vice versa.  WC and NV antisera reacted 
strongly and equivalently to WC and NV VLPs, suggesting these strains are very closely 
related antigenically (Fig. A2.1a).   Furthermore, NV and WC antisera both equally and 
completely blocked NV VLP and WC VLP binding to H type 3 (Fig. A2.1c-d).  In contrast, 
antisera from the GII.2 strains had variable cross-reactivity to one another (Fig. A2.2).  
Antisera cross-reactive responses to Ina VLPs were equivalent to homotypic responses 
following SM or Buds immunization.  However, Ina antisera did not cross-react nearly as 
well to heterologous VLPs.  Furthermore, neither Ina or SM cross-reacted significantly to 
Buds VLPs.  No receptor for SM VLP binding has been identified; therefore, antisera 
blockade assays were not done. 
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Discussion. 
In Chapter III, we discussed the evolution of GII.4 norovirus strains over time.  The question 
remained whether other GI and GII genoclusters exhibit similar evolutionary patterns.  We 
tested the GI.1 strains NV and WC, isolated in 1968 and 2001, respectively, for antisera 
cross-reactivity and receptor blockade and discovered these antisera were not significantly 
different from one another in either category.  Equivalent cross-reactivity and blockade to 
both strains indicate that the GI.1 genocluster did not evolve between isolation of each strain.  
As these evolutionary patterns were different than that observed among the time-ordered 
GII.4 strains,  the GI.1 genocluster may be static or evolving very slowly.  In contrast, the 
GII.2 strains exhibited differential cross-reactivity among strains.  Antisera to SM, originally 
isolated in 1976, and to Ina and Buds, both isolated in 2002, all cross-reacted equivalently to 
Ina VLPs; however, neither heterologous strain cross-reacted well to Buds VLPs.  In 
addition, Ina antisera did not cross-react to SM VLPs although SM antisera reacted to Ina 
VLPs.  The cross-reactivity profiles of these antisera suggest that some strains within the 
GII.2 genocluster retain common antigenic sties over a long period of time while others have 
evolved rapidly.  Like the GII.4 strains, some GII.2 strains appear to be more antigenically 
related than others, and antisera cross-reactivity to one VLP does not warrant reciprocal 
antisera cross-reactivity to the other VLP.  This research supports our hypothesis that 
plasticity exists within the capsid sequence and antigenic drift may occur to avoid antibody 
recognition.  Antibody blockade of receptor binding could not be tested as no receptor for 
GII.2 strains has been identified.  Together, our data show that another GII genocluster may 
exhibit evolution over time, similar to the GII.4 cluster, while the GI genocluster tested did 
not change.  These findings may explain the continued prevalence of GII outbreaks overall 
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compared to those reported for GI; however, additional studies with time-ordered VLPs from 
multiple GI and GII clusters must be conducted to confirm these patterns. 
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Figure A2.1 
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C. 
GI.1 antisera blockade of WC-H type 3 binding
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Strains within the GI.1 genocluster are antigenically equivalent.  Antisera from mice 
immunized with the NV and WC strains were analyzed for specific IgG cross-reactivity to 
NV and WC VLPs (A), blockade of NV-H type 3 binding (B), and blockade of WC-H type 3 
binding (C). 
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Figure A2.2 
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Strains within the GII.2 genocluster are antigenically distinct.  Antisera from mice 
immunized with GII.2 strains SM, Ina, and Buds were tested for specific IgG cross-reactivity 
to SM, Ina, and Buds VLPs. 
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